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Abstract 
etaining b-glycosidases are a ubiquitous family of enzymes found in all 
kingdoms of life. They are produced by living organisms to catalyze the 
hydrolysis of carbohydrates b-glycosidic links in a highly sophisticated 
manner, thus they are involved in a plethora of biological processes. In fungi 
and bacteria, they are used to process organic biomass as source of energy and also to 
metabolize carbohydrate conjugates for structural and host infection purposes. In 
mankind, their functions or dysfunctions are correlated with multiple metabolic disorders, 
such as lysosomal storage disorders and lactose intolerance. Among the largest families of 
retaining b-glycosidases are GH5, GH30 and GH11. These hydrolase families include 
most of the known b-glycosidases in nature with different substrate specificities and 
structural topologies. GH5 and GH30 belong to Clan A hydrolases with a (b/a)8 TIM 
barrel catalytic domain, while GH11 belongs to Clan C with a b-jelly roll fold. All of the 
three families have found multiple biotechnological applications and the quest for 
discovering new inhibitors against them has been an intense research area. In this 
introduction, the aim is to discuss the general characteristics of GH5, GH30 and GH11 
fold topologies and classification, in addition to the dynamics and stability of their 
catalytic domains. Besides, it is aimed to introduce the most important inhibitors and 
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Introduction 
 
arbohydrates in their diverse forms in conjunction to their glycoconjugates are 
cornerstone components of life in all organisms. Besides their structural and 
energy storage roles, they are involved in a myriad of biological processes, 
including -but not limited to- cell communication, host-pathogen interactions1, 
signal transduction, inflammation2, intracellular trafficking and multiple diseases3. In 
nature, plant cell walls represents the largest reservoir of carbohydrates, forming about 
75% of the biomass on earth4. The functional and structural diversity of carbohydrates is 
a consequence of the astronomic number of possible combinations of their 
monosaccharides building blocks5, therefore it is not surprising that the genomes of most 
organism include about 1-3% genes that code for carbohydrate-active enzymes6. 
Polysaccharides are very stable compounds in nature; their spontaneous hydrolysis occurs 
at a rate in the range of 10-15 s-1, corresponding to a half-life of 4.7 million years7! 
Organisms have evolved to produce highly efficient catalysts that hydrolyze carbohydrate 
glycosidic bonds and enhance the hydrolysis rate by a factor of more than 1017 7. This 
superfamily of sophisticated enzymes is called glycoside hydrolases (GHs), and its 
members exert their function in a specific manner on various glycosidic bonds depending 
on the number, position, or configuration of the hydroxyl groups in the sugar molecule. 
Therefore, glycoside hydrolases have found multiple biotechnology applications, such as 
in biofuel production8, paper pulp bleaching and the food industry9. In humankind, 
deficiency of GHs leads to multiple metabolic disorders such lysosomal storage disorders10 
and lactose intolerance11. Hence, glycosidases inhibition has been an attractive subject of 
research, and the identified inhibitors have found extensive use as agrochemicals and 
therapeutic agents12, such as antifungal agents, insecticides, antidiabetics, anti-obesity 
compounds, antivirals and compounds to correct lysosomal storage disorders13, 14. To 
discover novel glycosidases from genomic sequences, an enormous effort was dedicated 
to classify this historically important family of enzymes using several classification systems, 
including those based on the substrate or product specificity, mode of attack (exo-
glycosidic versus endo-glycosidic enzymes) and the stereochemical mechanism. In 1991, 
a classification of glycoside hydrolases based upon amino acid sequence similarities was 
introduced, which is now provides more than 140 sequence-based families of glycoside 
hydrolases, and structures of members of at least 120 families have been solved 
(www.cazy.org)15. Among the largest GH families are the retaining b-glycosidases GH5, 
GH30 and GH11. Although these three families differ in terms of structures and 
sequences, all of them include members with the same substrate specificity, such as b-
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B-glycosidases have variable structures and substrate specificities, therefore, each GH
family has been classified into different Clans18. The GH5 and GH30 b-glycosidases
classify as the GH Clan A, which consists of proteins with an (b/a)8-barrel catalytic
domain fold, while GH11 is in the GH Clan C, with a b-jelly roll catalytic domain fold.
Due to their industrial and therapeutic importance, the focus here is to discuss the general
features of their fold topology, dynamics, conformational stability and inhibition, with the
aim to provide the reader with a general overview of the structural and biophysical
characteristics of these three families of enzymes.
b-glycosidases catalytic mechanism
Retaining b-glycosidases perform their catalytic reaction in two steps first described by 
Koshland, using a catalytic dyad functioning as a nucleophile and acid/base19. The first 
step is a glycosylation of the enzyme by nucleophilic attack of the anomeric carbon of the 
substrate, which induces an electronic rearrangement and a hydrolysis of the glycosidic 
linkage. The nucleophilic attack is concomitant with a proton transfer from the acid/base 
residue and the departure of the leaving group from the aglycon site. In the second step, 
an activated water molecule acts as a nucleophile with the assistance of the general 
acid/base to deglycosylate the nucleophile residue. The product is released from the 
glycon pocket and a new catalytic cycle could take place (Figure 1.1.a). It is proposed 
that the two steps of the reaction pass through a transient oxocarbenium like state and 
depending on the sugar ring configuration the substrate could adopt different itineraries 
pathway during catalysis19. In the case of GH5 and GH30, the substrate itinerary is 
supposed to pass by the 3S1 à 3H4‡ à 1C4 pathway for the Michaelis complex à TS à 
intermediate enzymatic half reaction20 (Figure 1.1.b). On the other hand, the substrate 
itinerary for GH11 xylanases has been proposed to follow a path of 4C1 à OE à OS2‡ à 
B2,5 for the xylose residue at -1 subsite21. However, this issue remains as yet unresolved. 
Early structures of intermediate complexes trapped with 2-fluoro sugars were interpreted 
as 2,5B conformations22, suggesting a 2SO à 2,5B à 5S1 itinerary. The Michaelis complex 
of xylohexaose bound to the xylanase XynII from T. reesi revealed a slightly distorted 4C1 
conformation21. Thus, the sugar ring itinerary of GH11 families number is still under 
debate. 
Retaining b-glycosidases can also perform a transglycosylation reaction by simply 
changing the temperature23 or the pH24 of the enzymatic assay or by providing the 
enzyme with a suitable aglycon acceptor25 (Figure 1.1a). This reaction has been 
successfully applied to synthesize oligosaccharides and glycoconjugates. The 
transglycosylation capacity of (mutant) β-glycosidases, in combination with their high 
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Figure 1.1. (a) General hydrolysis and transglycosylation mechanism and (b) Koshland double displacement 
mechanism and substrate itinerary of retaining β-glucosidases. 
GH5 and GH30 fold topology 
All GH5 and GH30 glycosidases have a (a/b)8-TIM barrel catalytic domain with two 
conserved carboxylic acid residues located in b-strands 4 and 7, serving as nucleophile 
and acid/base catalytic dyad. The distance between these two catalytic residues is highly 
conserved, often between 5 and 5.5 Å between the Oe1 and Oe2 atoms of the nucleophile 
and acid/base glutamic acid residues, respectively26. GH5 and GH30 glycosidases 
comprise fungal, bacterial and eukaryotic b-1-4 glucanases, b-1-4 mannases, b-1-4 
xylanases, cellulases and glucosylceramidases16,17. GH5 glycosidases have been further 
classified into 53 subfamilies providing a more accurate prediction of function of yet 
uncharacterized proteins17. A new classification approach has led to the transfer of five 
GH5 protein subgroups to GH30 group 2, including the lysosomal enzyme GBA (Figure 
1.2c). The GH5 and GH30 glycosidases resemble each other regarding protein structure 
and substrate specificities, but show differences in topology16,27. For instance, one 
characteristic of the GH30 enzymes is the fusion of the (a/b)8-barrel catalytic domain 
with a b-structure consisting of an immunoglobulin like fold (Figure 1.2f). This b-
structure, poorly conserved in GH30 glycosidases, is absent in GH5 enzymes (Figure 
1.2d). Characteristically, the TIM barrel of most GH5 enzymes is sealed with a cap like 
structure, which does not occur in GH30 enzymes (Figure 1.2d). A special case is 
endoglycoceramidase II (EGCII) from Rhodococcus sp. that removes the entire 
oligosaccharide from gangliosides like GM3 and GM1 (Figure 1.2d)28. EGCII has two-
fold domains, a catalytic TIM barrel adjoined to a b-sandwich domain, like in GH30 
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enzymes, being composed of only 8 b-strands in a barrel geometry (Figure 1.2e). 
Exceptionally, the TIM barrel of EGCII is not capped by the small b-strand sheet 
observed in most other GH5 family members29. Unlike EGCII, EGCI (another 
endoglycoceramidase from Rhodococcus equi with broader substrate specificity than EGCII) 
displays a typical GH5 TIM barrel fold sealed with two b-strands at the non-catalytic face 
of the domain. However, in addition, the TIM barrel of this enzyme is also fused to a b-
sandwich structure30 (Figure 1.2a). Thus, EGCI is a typical GH5 enzyme while EGCII 
shows structural features of members of both GH5 and GH30 families. The evolutionary 
relationship between these enzymes remains unclear.  
In humans, no endoglycoceramidase is characterized yet, although an endo hydrolysis 
activity towards gangliosides has been noted for human cancer cells and tissues of other 
mammals31,32.  
Figure 1.2. GH5 and GH30 general fold and secondary structure arrangement. (a) EGCI 3D structure (PDB 
ID: 5j7z)30. (b) EGCII 3D structure (PDB ID: 2osx)29. (c) GBA 3D structure (PDB ID:2v3e)33. (d) Diagram of 
the GH5 family members secondary structure organization adopted from (16). (e) EGCII secondary structure 
arrangement (PDB: 2osx). (f) GBA (PDB: 1ogs) secondary structure elements of GH30 members16. b# refers to 
TIM barrel domain b-strand number and bs# refers to a b-strand number of the b-side domain. 
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GH11 fold topology 
GH11 is one of the best characterized GH families, which is reflected by the 31 structures 
deposited in the PDB and CAZyme databases. This family includes bacterial and fungal 
enzymes considered to be true xylanases, due to their high substrate specificity toward 
non-decorated xylan polymers and their high catalytic efficiency34. GH11 enzymes 
display unique biophysical properties such as a low molecular weight (20 kDa) and 
variable pH and temperature optima, making them attractive candidates for several 
industrial and biotechnological applications35. For instance, xylanases are widely used in 
paper pulp bleaching36 biofuel production8, and food industries9. This class of enzymes 
has a globular catalytic domain with an approximate gyration radius of 17 Å and a β-
jelly-roll fold composed of antiparallel b-sheets A and B that shape a long (~25 Å), deep 
(~9 Å) and wide (4 Å) catalytic cleft37 (Figure 1.3a). The overall shape of this fold is often 
compared to a right-hand fist37. The b-strands A are nearly planar and distorted at the 
end to form a hand palm and fingers, and the B strands are in a perpendicular position 
to  the A strands sculpting the binding cleft including, the thumb region. The two sides of 
the cleft are connected by a long loop called the cord38. The fold includes a single a-helix, 
sitting under the b-strands B structure. Around 20 % of the amino acids comprizes serines 
and threonines, providing an extensive hydrogen bond network that rigidifies the fold. A 
sequence alignment of the GH11 family members, using 236 unique sequences out of 456 
PSI-BLAST hits (the 220 excluded sequences where found to be more than 95% 
conserved) revealed a high conservation, (Figure 1.3b) most variability is observed for 
the surrounding residues located on the protein surface. The residues lining the catalytic 
cleft are highly conserved, both in space and in sequence, and a “backbone” like pattern 
is formed by multiple aromatic side chains at the bottom of the cleft (Figure 1.3a). 
Among the aromatic residues (residue numbering refers to 1BCX), many are highly (more 
than 80%) conserved regarding the type of the aromatic side chain (Trp9, Tyr69, Trp71 
and Tyr80) while other positions seem to be more flexible (Trp129 and Tyr174 can be 
substituted by Phe and Trp, respectively). Tyr165 is more variable (less than 50% 
conserved) and can sometimes be substituted by Glu, which could mean that a polar 
group is more important than an aromatic residue at this position.  
The PSIXG sequence motif of the thumb region is highly conserved, suggesting the 
importance of this hairpin loop for the protein function (Figure 1.3a). The amino acid 
sequence that harbours the nucleophilic glutamic residue is also conserved (ATEG) with 
one exception, where a glutamine is present instead of a glutamic acid. The sequence in 
which the acid/base residue (Glu) is located is more variable, and in some cases, the 
acid/base residue is substituted by either a glutamine or an arginine. These type changes 
of the catalytic dyad could reflect a different mode of action of these enzymes or a change 
of their pH optima. Overall, the strong sequence conservation of the GH11 family is 
remarkable because generally, proteins structures are better conserved than sequences39. 
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GH11 family members exhibit a wide variability of their biochemical properties with 
different pH and temperature optima. These variabilities seem to be caused by only minor 
sequence differences.  
Figure 1.3. (a) GH11 β-jelly-roll fold. (b) GH11 amino acid conservation based on sequence alignment using 
the ConSurf Server. 
b-glycosidases dynamics and stability
GH5 and GH30 TIM barrel dynamics and stability 
Enzymes are very dynamic entities, exerting their function by sampling multiple 
conformational substates during catalysis40. Thus, it is insufficient to describe only the 
ground state structure of the resting state if a complete understanding of the catalytic 
function is to be achieved. Although there are numerous b-glycosidases structures 
available, few efforts were dedicated to investigating their molecular dynamics. The 
scarcity in dynamics studies could stem from the robust understanding of the chemistry 
that governs b-glycosidases catalytic reactions and also from the challenges of studying 
protein dynamics experimentally. The biophysical and theoretical techniques that have 
been employed to study the global dynamics of retaining b-glycosidases include molecular 
dynamic simulations (MD), frequency decay fluorometry that exploit tryptophan 
emission, hydrogen/deuterium exchange (HDX) mass spectrometry and the versatile 
technique NMR spectroscopy, which can cover a broad spectrum of protein time scale 
motions from ps to hours with an atomic resolution.  
Clan A b-glycosidases have a TIM barrel catalytic domain fold, so studying the dynamics 
of a particular member could provide a general trend for the dynamics of this recurrent 
topology. For instance, David et al. have studied the dynamics of the catalytic domain of 
the β-(1,4)-glycosidase Cex (or CfXyn10A) from the soil bacterium Cellulomonas fimi from 
ns to ms time scale using NMR spectroscopy41. The conclusion from this study was that 
the TIM barrel domain is uniformly rigid on the different probed time scales. Few 
dynamic changes were observed for the glycosyl-enzyme intermediate state complex, 
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although an enhancement of the thermal stability and proteolysis resistance of the domain 
was observed. A lower resolution technique was also employed to follow the 
conformational dynamics of a thermophilic and a mesophilic Clan A b-glycosidase form 
extremophilic archaeon Sulfolobus solfataricus (Sbgly) and from Escherichia coli (Cbgal), using 
multitryptophan emission decay42. The thermophilic variant harbours twelve tryptophans 
distributed over the core of the protein TIM barrel domain and some of them are located 
on flexible loops. The study showed that there are two groups of tryptophan fluorescence 
decay: A short-lived and a long-lived tryptophan life time decay, reflecting the well packed 
and rigid TIM barrel core and the flexibility of the protein surface loops, respectively. 
However, when incubated with the irreversible inhibitor cyclophellitol (see below), a 
quenching of tryptophan short lived residues fluorescence was observed, pointing toward 
a structural rigidification of the TIM barrel flexible loops. In contrast, the mesophilic b-
galactosidase variant exhibits a uniform distribution of tryptophan fluorescence decay, an 
indication of a looser structure of the TIM barrel domain. The same trend was also 
observed in case of b-glucosylceramidase (GBA) where HDX mass spectrometry was 
employed. The study showed that the residues that reside within the core of TIM barrel 
domain are highly protected against the H/D exchange process, and loops that connect 
the a-helices and b-sheet of the catalytic domain are the ones with the lowest protection 
factor43. All of these observations lead to the conclusion that the TIM barrel domain is 
globally rigid, yet includes flexible loops that might have a determinant role in protein 
function. It is proposed that the rigid TIM barrel fold provides the correct frame for 
favourable interactions with carbohydrate substrates and this rigidity could be necessary 
to bind, distort, and subsequently hydrolyze the glycosidic linkage within the enzyme 
active site41.  
GH11 b-jelly roll dynamics and stability 
The b-jelly roll fold is common among a variety of proteins with no functional 
correlation31. To interrogate GH11 b-jelly roll fold dynamics and the contribution of the 
protein motion in its catalytic reaction b-1-4xylanase form Bacillus circulans (BCX) was 
selected to be studied by NMR due to its well-characterized structure and suitable 
biophysical properties44. BCX comprizes 185 residues with a molecular weight of 20 kDa 
and a stokes radius of ~17 Å37. Its small size and well-dispersed NMR spectra facilitated 
a thorough study of its dynamics. A survey carried out by Connelly et al. has revealed that 
the protein in its substrate-free form displays a high average order relaxation parameter 
(S2 =0.86+/-0.04), indicative of restricted motion on the pico-nanosecond time scale, 
which is in agreement with the very compact and globular fold observed with 
crystallographic and hydrodynamic experiments45. The dynamics uniformity of BCX is 
in line with the extensive intramolecular hydrogen bond network. By examining the BCX 
crystal structure, 146 backbone amides out of 185 participate in this network. The same 
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dynamic behaviour on the fast timescale was observed when studying the complex of the 
protein with 2-deoxy-2-fluoro-β-xylobioside. However, these findings do not exclude the 
possibility of slower dynamics on the millisecond time scale, which is more relevant for 
catalysis as it covers the rate of the substrate turnover (20 s-1 against 2,5-DNPX2 
substrate)46.  
A unique feature of GH11 is the presence of a thumb loop region that is believed to play 
a determinant role in selective substrate binding and product release47. Multiple 
molecular dynamics simulations have suggested the opening of the thumb loop to induce 
the product dissociation48-50. The thumb region displays a well-structured classical 
hairpin, containing a type I b-turn (residues 117-120 in BCX) with six internal hydrogen 
bonds. The only evidence of a full opening of the thumb was observed in the case of a 
specific xylanase mutant from B. subtilis in the crystalline state51. A recently published 
study of xylanase millisecond time scale dynamics, using the relaxation dispersion CPMG 
technique52, showed that the protein in its free form experiences a millisecond motion for 
multiple residues localized within the binding site53. Residues of the thumb regions were 
not detected due to peak broadening. In the presence of its substrate, an enhancement of 
the millisecond (ms) time scale motion was observed. This study has provided the first 
evidence of such motion in GH11 family enzyme. It is difficult to interpret relaxation 
dispersion effects in structural terms. These ms dynamics might reflect a chemical 
exchange of the backbone amides that could be due to side chain reorientations and not 
due to conformational changes in the protein backbone.  
A thorough MD investigation on GH11 family enzymes was undertaken for XYNII from 
Trichoderma reesei54. By combining the different crystal structures, it was proposed that the 
protein samples three sequential substates during its catalytic reaction. First, the protein 
adopts an open state to allow substrate accommodation within the cleft. Substrate binding 
induces a closed conformation necessary for positioning the substrate into the correct 
configuration for glycosidic bond hydrolysis. The last state is a loose structure from which 
the product is released. The study provided a model for the enzyme catalytic cycle based 
on the available crystal structures that still needs to be validated with studies in solution.  
Overall, the conclusion that could be deduced from these studies is that the b-jelly roll 
catalytic domain of GH11 has an inherent structural rigidity emerging from the strong 
hydrogen network between its secondary structure elements. Most of the GH11 family 
members are secreted enzymes55. Thus, the lack of their conformational flexibility might 
be an adaption mechanism to function in harsh extracellular conditions. Besides, no 
allosteric regulation was identified for GH11 xylanases so far. Therefore, it is speculated 
that they do not need to contain flexible regions to facilitate effector binding. Additionally, 
this structural rigidity could also be required for sugar ring distortion necessary for the 
hydrolysis of the glycosylic link. To this point, all of the experimental observations point 
toward a globular and rigid fold of GH11 during its reaction pathway with minor 
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conformational changes of the protein structure and a plausible local opening of the 
thumb region.  
b-glycosidases inhibitors and their applications
The high abundance of b-glycosidases encoding genes in all organisms is reflecting their
pivotal roles in multiple biological processes. In humankind, b-glycosidases function or
dysfunction is related to different pathological states, leading to an increased interest in
the therapeutic application of inhibitors. Cognate b-glycosides inhibitors can be divided
in different classes based on their mode of action and covalency. In the following section,
the focus is on the most frequently used b-glycosidases inhibitors.
Covalent mechanism-based inhibitors: Mechanism-based inhibitors are covalent 
inhibitors (or inactivators) that obliterate the enzyme activity by forming a covalent bond 
between the enzyme and a functional group of the inactivator56. The bond is typically 
formed by a nucleophilic attack of an activated center on the inactivator leading to the 
formation of a covalent complex. Inactivation can be caused by blocking the substrate 
accessibility to the enzyme active site or by modifying one of the enzyme catalytic 
residues. This class of inhibitors has attracted interest to probe b-glycosidases structure 
and function and to identify catalytic residues57. 
Epoxide- and aziridine-based inactivators: This type of inactivators has found successful 
applications due to their high inactivation efficiency and stability. Aziridine and epoxide 
are widely utilized to identify glycosidases nucleophile catalytic residues as they exploit 
the first step of the catalytic enzyme mechanism. The inactivation mechanism involves 
the attack of the epoxide or aziridine by the enzyme nucleophile, resulting in ring opening 
and the formation of an adduct bond between the enzyme and the inhibitor, which 
emulates the intermediate state of the natural substrate hydrolysis reaction. The process 
is facilitated by protonation of the inactivator by the general acid/base residue (Figure 
1.4a)57.  In 1974 Quaroni et al. have used conduritol B-epoxide (CBE) 1 (Figure 1.4a) 
to identify the catalytic carboxylate in both sucrase and isomaltase58. Radioactive CBE 
derivatives were also used to identify catalytic active site residues in different glycosidases59 
before bioinformatics emerged as a predictive method. The structural symmetry of CBE 
allows it to label both a and b-glycosidases60,61. Moreover, CBE has been shown to 
interact not only with nucleophile residues involved in catalysis but in some cases also 
with other active site residues. For instance, identification of the b-lac Z, b-
glucosylceramidase and almond b-glucosidase nucleophile residues by CBE was initially 
mistaken due to the inhibitor promiscuity, and it was later corrected62,63. Epoxide 
derivatives, such as exo-alkyl epoxide glycosides 2 (Figure 1.4a), a type of molecule that 
contains an epoxide moiety linked to a glucoside by an alkyl chain, were also effectively 
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used to label the nucleophile catalytic residue for a variety of enzymes and X-ray 
crystallography was used to solve the 3D structure of their complexes64. It was observed 
that the linked residue depends on the alkyl chain length, such as in retaining b-1-4-
xylanase from T. reesi, in which 2,3-epoxypropyl β-D-xyloside and 3,4-epoxybutyl β-D-
xyloside labelled the nucleophile and the acid/base residues, respectively65. It was 
speculated that these results are mainly due to the alkyl chain flexibility and the different 
inactivator orientations adopted within the enzyme active site. The aza-analogue of CBE 
(aziridine) 3 (Figure 1.4a) was found to be a moderate inactivator for both Abg b-
glycosidase and yeast a-glucosidase, with slightly higher activity against the latter66. 
Aziridine based inactivators exhibit a positive charge, thus, they are specifically directed 
toward the negative active site of the enzyme, precluding non-specific interactions with 
other parts of the protein. These compounds have been shown to be more reactive than 
their epoxide counterpart due to the lower stability of the aziridine cycle66.  
CBE was extensively used to study and characterize human b-glucosylceramidase (GBA) 
structure/function relationships68,69. Aerts and co-workers have used CBE in the 
discovery of a novel cytosolic human GBA70. Irreversible binding of CBE to GBA was 
exploited to knock out GBA activity in both cell cultures and animals, allowing the study 
of GBA roles in maintaining cellular homeostasis and to establish the role of 
glucosylceramides accumulation in cancer cell71,72. CBE was also used to produce cellular 
and animal models for Gaucher disease and to study the morphology of Gaucher disease 
macrophages and its neurological manifestations73,74. Injection of CBE into healthy mice 
has helped to evaluate the minimum GCase activity (12-16%) required for maintaining a 
correct cellular functioning75. 
Although CBE has proven to be an effective b-glycosidases inactivator, its inherent 
symmetry limits its specificity toward different b-glycosidases. Thus, it has been proposed 
that the addition of a hydroxymethylene group on the C5 of CBE pyranose ring would 
enhance its potency and selectivity toward b-glycosidases65. Indeed, a natural compound 
identical to the proposed CBE derivative has been extracted from the mushroom Phellinus 
sp. by Atsumi et al.76, and it showed to be selective exclusively toward b-glycosidases. The 
compound was called cyclophellitol 4 (Figure 1.4a) and it has been used in the same 
manner as CBE against human GCase to induce a Gaucher disease-like state in cell 
cultures and in animal model77,78. The crystal structure of cyclophellitol covalently bound 
to a b-glycosidase has given clear insight into the intermediate state sugar ring distortion 
of this family of enzymes. The compound has been shown to adopt a 4C1 chair 
conformation79. These new structural insights have guided Witte et al. to rationally design 
selective activity-based probes (ABPs) toward GBA by incorporating a reporter group 
(biotin or BODIPY) attached via an alkyl or acyl linker to the cyclophellitol scaffold or its 
aziridine analogue80. The ABPs have found various biological applications and further b 
and a-glycosidases ABPs have been synthesized based on this principle81,82. 
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Figure 1.4. Retaining b-glycosidases mechanism-based inhibitors. (a) Epoxide- and aziridine-based 
inactivators. (b) CBE inactivation mechanism. 
Activated fluorinated glycosides inhibitors: The activated 2-deoxy-2-fluoro glycosides 5 
(Figure 1.4a) are one of the most selective retaining b-glycosidases inactivators. These 
inactivators mimic the natural substrate of the enzyme by incorporating an activated 
aglycon leaving group linked to a glycoside with a fluoride at the position C2. Thus, they 
are usually considered as slow substrates. The occupancy of C2 position by a fluoride 
helps to stabilize the intermediate state by destabilizing the oxocarbenium ion like 
transition states (Figure 1.5)83. The spontaneous hydrolysis of the enzyme-glycosyl 
intermediate has variable rates and its lifetime can vary from seconds to months. The 
enzyme catalytic activity could be rescued by using a suitable acceptor to transfer the 
fluorinated glycoside and liberate the nucleophile residue83. Like CBE and cyclophellitol, 
activated fluorinated glycosides have been extensively used to investigate the 
structure/activity relationship of a variety of retaining b-glycosidase enzymes using 
various biophysical techniques84. Additionally, NMR spectroscopy has been employed to 
generate a model of the oxocarbenium ion-like transition state itinerary and to investigate 
the dynamic aspects of b-glycosidases during the catalytic pathway, using this class of 
inactivators as a tool41,85. 
Fluorinated glycosides have also found multiple biological applications. They were used 
to identify novel mammalian retaining β-glucosidases86 and to characterize the 
mammalian lactase phlorizin hydrolase binding pocket87. The ability to trap b-
glycosidases in their intermediate state has also been used to explore the role of their 
aglycon binding site and its specificity. The kinetics of recovery of the enzyme activity, 
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after complex formation with fluorinated glycosides, was shown to be related to the 
binding affinity of the acceptor to the aglycon site88. This class of “slow substrates” was 
also used as a warhead to generate ABPs by linking the compounds to a fluorogenic 
reporter89. These ABPs were successfully used to selectively label b-glycosidases in 
complex biological samples and to discover novel b-glycosidases enzymes in Cellulomonas 
fimi90.  
Figure 1.5. The inactivation mechanism of activated fluorinated glycoside inhibitors for retaining b-
glycosidases. 
Non-covalent inhibitors: Non-covalent b-glycosidases inhibitors are more therapeutically 
attractive as they can reversibly inhibit the enzyme activity in a dose-dependent manner. 
Therefore, several b-glycosidases inhibitors comprising disaccharides, iminosugars, 
cabasugars, thiosugars and non-glycosidic inhibitors were either synthesized or extracted 
from natural sources91. In the following section, the focus is mainly on the iminosugars 
inhibitors because of their successful therapeutic application in a variety of human 
lysosomal storage disorders. 
Iminosugars are low molecular weight compounds also called polyhydroxylated alkaloids 
that exhibit at least two hydroxyl groups and one heterocyclic nitrogen atom. These 
compounds are abundant in plants and microorganisms92. The substitution of the oxygen 
or anomeric carbon of the pyranose ring by a protonated nitrogen has been proposed to 
mimic the positive charge generated in these positions upon partial cleavage of the 
glycosidic bond, thus emulating the transition state, which triggers a high inhibition 
potency93 (Figure 1.6b).  
One of the first iminosugars described was nojirimycin (NJ) 6 (Figure 1.6a), isolated 
from several strains of Bacillus and Streptomyces as well as mulberry tree leave. It contains 
an endocycle nitrogen in the place of the oxygen pyranosidic atom, and it was shown to 
be a potent inhibitor of both a and b-glycosidases inhibitors91 However, the presence of 
C1 hydroxylic group renders this compound unstable, hindering utilisation. 1-
Deoxynojirimycin (DNJ) 7 (Figure 1.6a) is a reduced version of nojirimycin that lacks 
the hydroxyl group from the anomic carbon enhancing the stability and inhibition 
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potency of the compound91. This compound also acts on both b and a-glycosidases. 
Changing the position of the heterocycle nitrogen atom to the anomeric carbon position 
of the DNJ pyranosidic ring led to a 440-fold inhibition enhancement toward b-
glycosidases with a moderate inhibition toward a-glycosidases94. It has been proposed 
that this enhancement of the inhibition potency is due to the better ability of the new 
compound in mimicking the b-glycosidases transition state. The new analogues are 
named 1-azasugars, represented by isofagomine (IFG) 8 (Figure 1.6a). IFG has the 
anomeric carbon and the ring oxygen of glucose replaced by nitrogen and carbon, 
respectively, and the C2 hydroxylic group is absent. The remaining hydroxyl groups are 
maintained, preserving a D-glucose like configuration. However, it was suggested that by 
keeping the hydroxyl group at C2 a stronger b-glycosidases inhibition would be observed, 
presumably due the addition of a hydrogen bond interaction with the enzyme active site. 
The compound having these characteristics is named noeuromycin 9, and it showed high 
inhibition specificity toward b-glycosidases95.  
The superior specificity of azasugars toward b-glycosidases has prompted their use as 
potential therapeutic substances, especially in the case of the lysosomal storage disorder 
such as Gaucher disease96. GBA is the enzyme responsible for cleaving the glucosidic 
bonds between the glucose and ceramide moieties of glucosylceramides in the lysosomal 
compartment of the cell. Reported single point mutations in GBA have been shown to 
decrease the half-life of the protein by destabilizing its native fold or by leading to the 
production of a misfolded protein. The deleterious GBA mutants are degraded by the cell 
control machinery, thus hampering the enzyme from reaching its lysosomal destination 
and leading to the accumulation of its glucosylceramide substrate96. IFG is one of the best 
structurally characterized azasugars, and due its high specificity and potency toward 
GBA, it was proposed to be used as a pharmacological chaperone to rescue GBA 
proteostasis in GD patients. In vitro and in vivo studies provided evidence for its stabilization 
effects on multiple GBA variants97. For instance, IFG was found to have a higher binding 
affinity to GBA at neutral pH (as found in the ER compartment) compared to acid pH 
(as found in the lysosomal compartment)43. This pH binding dependency is a pivotal 
property in assisting the folding of GBA mutants in the ER compartment to escape the 
cellular quality control machinery and to be released in the lysosome. IFG increases the 
thermal stability of the enzyme at neutral pH and raises the cellular level of GBA N370S 
and L444P mutants in GD patients tissues98. IFG is supposed to cross the blood-brain 
barrier and correct GD manifestation in the nervous system due its small size. Despite 
these promising results, IFG has failed in clinical trials, presumably due to its 
hydrophilicity, resulting in poor biodistribution. Thus, N-alkylated derivatives were 
produced and demonstrated to have a superior chaperone performance98. One of the 
successful compounds is N-butyl-deoxynojirimycin (NB-DNJ, Miglustat) 10 (Figure 
1.6b), which has dual beneficial effects on glucosylceramide depletion and on the 
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stabilization of GBA mutants99. Another derivative is N-nonyl-deoxynojirimycin (NN-
DNJ) 11 (Figure 1.6b), which showed an enhanced binding affinity toward GCase when 
tested in vivo, presumably due to its longer alkyl chain length100. Tuning of the alkyl chain 
length of these compounds and elucidating the stabilization mechanism toward GBA 
might provide valuable information that could pave the way for the development of a 
new generation of pharmacological chaperones.  
Figure 1.6. Retaining b-glycosidases iminosugar inhibitors. (a) Different type of iminosugars used against 
retaining b-glycosidases as reversible inhibitors. (a) Isofagomine inhibition mechanism. 
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Conclusion and perspective 
The structure/function relationship studies of b-glycosidases have provided an 
enormous amount of information about their physical characteristics. Uncovering the 
substrate itinerary during catalysis has helped to produce more potent and efficient 
inhibitors, although the full potential of this information has yet to be explored for a large 
number of retaining b-glycosidases, and, besides, the inhibitory stabilization mechanism 
is still poorly understood. 
Despite these tremendous insights, understanding of retaining b-glycosidases dynamics in 
relation to substrate binding and distortion as well as product release is still limited. 
Studies of the dynamics could address the paradox between the high structural 
conservation and wide variety of functions. The unique characteristic of b-glycosidases to 
shift the equilibrium of their hydrolysis reaction toward polymer synthesis under specific 
conditions has encouraged their use to produce relevant carbohydrates with a wide 
spectrum of therapeutic, industrial and research applications. Enzymatic synthesis of 
carbohydrates offers a one-step reaction under mild conditions with stereospecificity and 
without by-product generation and less environmental pollution, compared to classical 
chemical methods, which still require several protection, activation, coupling and 
deprotection steps.  
Depletion of fossil fuels at an enhanced rate and the effect of its utilization on the global 
economy and environment have pressed the quest for a renewable and clean source of 
energy. Bioethanol has been considered as a potential alternative fuel as its raw material 
(cellulose) is highly abundant101. b-glycosidases hold a promising future regarding their 
use in cellulose bioconversion process and biofuel production102. Fundamental studies of 
this family of enzymes will help to compose the right cocktail of enzymes for maximum 
cellulose bioconversion and to guide their re-engineering for optimal function under large 
scale industrial conditions.  
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THESIS OUTLINE 
The work presented in this thesis is devoted to deepening our understanding of the 
functional dynamics and conformational stability of retaining b-glycosidases. Over the 
years, tremendous efforts were dedicated to elucidate the structure/function relationship 
of this ubiquitous family of enzymes and to discern their substrate itineraries during 
catalysis. Nevertheless, the mechanism of stabilization of b-glycosidases by active site 
binders and the contribution of dynamics in catalysis remains poorly explored. Therefore, 
in this thesis it is aimed to address these aspects, relying on activity-based probes 
technology in conjunction with standard biochemistry and advanced NMR techniques. 
CHAPTER 1 gives a general introduction of the biophysical properties of GH5, GH11 
and GH30 b-glycosidase families and the inhibitors used to modulate their functions, both 
in fundamental research and in therapy. CHAPTER 2 describes the application of ABPs 
to characterize the conformational stability of endo-glycoceramidase EGCII, a bacterial 
homologue of GBA that holds promise as a therapeutic application against a number of 
inherited glycosphingolipidoses caused by deficiency in lysosomal exoglycosidases. 
CHAPTER 3 describes the application of ABPs and reversible b-glycosidase inhibitors 
to dissect the stabilization mechanism of GBA by active site occupancy in vitro and in vivo, 
as a proof of the principal for the pharmacological chaperone treatment against Gaucher 
disease. CHAPTER 4 describes the conformational landscape and dynamics of b-
glycosidases and their possible roles in the catalytic mechanism, using GH11 xylanase as 
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Abstract 
mall compound active site interactors receive considerable attention for their 
ability to positively influence the fold of glycosidases. Endoglycoceramidase II 
(EGCII) from Rhodococcus sp. is an endo-β-glucosidase releasing the complete 
glycan from ceramide in glycosphingolipids. Cleavage of the β-glycosidic linkage between 
glucose and ceramide is also catalysed by glucocerebrosidase (GBA), the exo-β-
glucosidase deficient in Gaucher disease. In this work, it is demonstrated that established 
β-glucoside-configured cyclophellitol-type activity-based probes (ABPs) for GBA also are 
effective, mechanism-based, and irreversible inhibitors of EGCII. The stability of EGCII 
is markedly enhanced by formation of covalent complexes with cyclophellitol ABPs 
substituted with hydrophobic moieties, as evidenced by an increased melting 
temperature, resistance against tryptic digestion, changes in 15N-1H transverse relaxation 
optimized spectroscopy spectra of the [15N]-Leu-labeled enzyme, and relative 
hydrophobicity as determined by 8-anilino-1-naphthalenesulfonic acid fluorescence. The 
stabilization of the EGCII conformation correlates with the shape and hydrophobicity of 
the substituents of the ABPs. It is concluded that the amphipathic active site binders with 
aliphatic moieties act as a “hydrophobic zipper” on the flexible EGCII protein structure. 
This work was published as: Ben Bdira, F., et al., Hydrophobic Interactions Contribute to Conformational 
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Introduction 
 
lycosphingolipids, an important class of cellular membrane lipids, contain a 
ceramide, and its primary hydroxyl is glycosylated with either a glucose or 
galactose residue to which further sugars may be attached. Two pathways for 
degradation of glycosphingolipids are known to exist in nature. Non-mammalian 
endoglycoceramidases are able to remove in one step the entire oligosaccharide chain 
from the ceramide moiety. Endoglycoceramidase II (EGCII) from Rhodococcus sp.1 was the 
first endoglycoceramidase identified (grouped in glucosyl-hydrolase family 5). Later, other 
non-homologous endoglycosidases degrading glycosphingolipids from leeches2 and 
earthworms3 were discovered. No mammalian endoglycoceramidase has been identified 
so far, although a similar enzymatic activity has been reported for rat and rabbit 
mammary glands4 and human cancer cells5. In mammalian cells, the degradation of 
glycosphingolipids takes place via a very different pathway. Inside lysosomes, the 
subcellular compartments that specialize in the breakdown of macromolecules, terminal 
sugars of glycosphingolipids are removed stepwise by specific exoglycosidases, ultimately 
generating the free lipid, ceramide. The physiological relevance of lysosomal degradation 
of glycosphingolipids is illustrated by associated pathologies. Inherited defects in 
glycosphingolipid degrading exoglycosidases cause a number of storage diseases in 
humans, collectively named glycosphingolipidoses. Most prevalent among these disorders 
is Gaucher disease, in which deficiency of the lysosomal β-glucosidase, named 
glucocerebrosidase (EC 3.2.1.45, GBA), a member of glycosidase family 30 
(www.cazy.org), causes accumulation of the substrate glucosylceramide. A number of 
GBA active site binders, called pharmacological chaperones, are being investigated as 
enzyme stabilizers with envisioned therapeutic application in Gaucher disease patients. 
One of the best studied compounds in this respect is the iminosugar isofagomine (IFG), a 
competitive GBA inhibitor6,7. The retaining β-glucosidase GBA employs a Koshland 
double-displacement mechanism following a 1S3→ 4H3 →4C1 reaction itinerary8. In the 
first displacement event, a covalent a-enzyme glucosyl intermediate is formed, with the 
glucopyranose moiety adopting a 4C1 conformation. After binding of the substrate β-
glucoside, a transition state emerges with high oxocarbenium ion character with a 
concomitant conformational change of the substrate in the Michaelis complex (1S3) to a 
4H3 half-chair9. It is the enzyme glucosyl intermediate state of the hydrolysis reaction that 
is emulated by cyclophellitol 1 (see Figure 2.1a for the compounds used in this study). 
Thus, cyclophellitol binds with high specificity to the β-glucosidase active site. 
Cyclophellitol 1, first isolated from a Phellinus sp. culture by Atsumi and co-workers10, 
irreversibly inhibits GBA by forming a stable, covalent adduct to residue Glu34011. The 
cyclophellitol epoxide is ideally positioned for acid-catalyzed nucleophilic opening 
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formed (with the inhibitor now also adopting a 4C1 conformation), with the ester bond 
much more stable and thereby irreversible compared to the acylal linkage that 
characterizes the enzyme-substrate covalent intermediate (Figure 2.1b)9. Substitution of 
the epoxide oxygen with nitrogen yields cyclophellitol aziridine 2, an equally strong 
inhibitor12. Cyclophellitol 1 and cyclophellitol aziridine 2 functionalized to contain a 
fluorophore have been applied as activity-based glycosidase probes for sensitive in vitro 
and in situ detection of GBA molecules11,13. Conduritol B epoxide (CBE) 10, an analogue 
of cyclophellitol lacking the C8 methylene, likewise irreversibly inhibits GBA but with 
lower affinity and specificity14. Freezing of the enzyme midway through its catalytic 
reaction through covalent inhibition offers an important tool for investigating the 
characteristics of the formed complex and elucidating which parts of the inhibitors are 
important for efficient stabilization activity. Despite the significant differences in their 
amino acid sequences, as they belong to different families of glycoside hydrolases (Figure 
A1.1), GBA and EGCII share a similar folding topology of their polypeptide chains. Both 
of them display a TIM barrel (triose-phosphate isomerase barrel) catalytic domain formed 
by (a/b)8, which makes them both members of GH-A clan (www.cazy.org). The 
superposition of the three-dimensional (3D) structure of the TIM barrels has a root-mean-
square deviation (rmsd) of 3.1 Å for the Ca atoms [Protein Data Bank (PDB) entry 2v3e 
for GBA and PDB entry 2osx for EGCII] yet shows a remarkable superposition of the 
acid/base and the nucleophile catalytic residues, which are separated by an average 
distance of ∼5.2 Å, consistent with their role in a double displacement mechanism with 
net retention of stereochemistry (see Figure 2.2a,c). The two proteins also have the 
aglycan sites in the same position relative to the active site. The analysis of the GBA crystal 
structure in the presence of nonyl-deoxynojirimycin (NN-DNJ), a potent inhibitor of 
GBA, shows that the aliphatic tail of the substrate is accommodated within a narrow 
hydrophobic channel where it interacts with residues Leu241, Phe246, Tyr313, Leu314, 
and Tyr244. Similarly, the ceramide moiety of GM3 ganglioside, the natural substrate 
for EGCII, makes several hydrophobic interactions with residues Leu180, Tyr182, 
Ile183, Phe235, Ala275, Ile276, Tyr306, and Leu308 (Figure 2.2b,c). In view of the 
similarities between the two protein binding sites, it is not surprising that NN-DNJ can 
also inhibit EGCII and fits well in the active site of the EGCII crystal structure (PDB 
entry 2OSX)15 (Figure 2.2c). The GBA glycan binding site is much narrower than that 
of EGCII, which allows GBA to accommodate only a single glucose ring, precluding the 
binding of longer saccharide moieties and suggesting an explanation for the different exo 
and endo hydrolysis specificities for GBA and EGCII, respectively. The location of the 
reactive residues and primary sugar is, however, essentially the same in both active sites, 
suggesting that the mechanism of cleavage of the β-glycosidic linkage connecting glucose 
and ceramide is the same. The analogies between the two retaining β-glucosidases 
stimulated us to test the impact of a series of mechanism-based irreversible inhibitors 
known to bind covalently in the active site of GBA on EGCII conformational stability. 
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Here, it is demonstrated that in its free state in solution EGCII is thermolabile and highly 
flexible. An equilibrium between monomeric and dimeric states is observed for the resting 
state enzyme, because of the large solvent-exposed hydrophobic surface area of EGCII. 
Upon formation of the complex with the amphiphilic cyclophellitol analogues (4-8), 
marked stabilization and rigidification are observed, correlating with the lipophilic 
potential of the compounds. No changes are observed in the protein stability or rigidity 
after incubation with non-hydrophobic compounds (1 and 2). These findings demonstrate 
the importance of the length and shape of the non-glycan moiety of substituted 
cyclophellitols for the enzyme stabilization. 
Figure 2.1. (a) Structures of β-glucoside-configured cyclophellitols used and (b) Mechanism-based inactivation 
of β-glucosidases by covalent binding to a catalytic nucleophile. 
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Figure 2.2. Comparison of the folding topology and aglycan binding sites of GBA and EGCII. (a) Structural 
alignment of the TIM barrel catalytic domain of EGCII (orange cartoon) and GBA (cyan cartoon) using the 
jFATCAT algorithm59 (RCSB comparison tool). The acid/base and nucleophile catalytic residues are shown 
as sticks and colored red for EGCII and blue for GBA. For the sake of clarity, non-overlapping loops were 
hidden. (b) Aglycan binding site cavities of EGCII (orange) and GBA (cyan) as observed in the superposition 
shown in panel a. The surface of the residues interacting with the aliphatic tail of the ligands is shown; β-D-
glucose-ceramide (in EGCII) is colored red and NN-DNJ (in GBA) blue. (c) Primary sequences of EGCII and 
GBA with the structurally homologous parts highlighted in orange and cyan, respectively. Acid/base catalytic 
residues are marked with stars and a black box. Hydrophobic residues interacting with the NN-DNJ alkyl chain 
and the ceramide moiety of GM3 are marked with cyan and orange circles, respectively. Non-hydrophobic 
interacting residues within the aglycan binding sites are marked by black triangles. 
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Results 
Readouts for Active EGCII Molecules. It is first identified convenient readouts for active 
EGCII molecules. It is determined whether 4-methylumbelliferyl lactoside (4MU-Lac) is 
a suitable fluorogenic substrate for recombinant EGCII. This proves to be the case. The 
enzyme exhibits an optimal activity at pH 5.5 (Figure 2.3a), with hydrolysis occurring 
in a time-dependent manner (Figure 2.3b). Next, it is demonstrated that EGCII can be 
labeled in a mechanism-based manner by a b-glucoside-configured cyclophellitol 10 and 
cyclophellitol-aziridine substituted with a BODIPY fluorophore 9 (Figure 2.3c).  
Figure 2.3. Read-outs of active EGCII molecules. (a) Hydrolysis of 4MU-Lac by EGCII across a pH 
range, at 17 °C in 150 mM McIlvaine’s buffer. (b) Time-dependent liberation of 4MU from 4MU-Lac by 
EGCII at 17 °C and in 150 mM McIlvaine’s buffer pH 5.5 (c) Labeling of EGCII with cyclophellitol-aziridine 
ABP 9 at pH 5.5 and 17 °C and its competition by pre-incubation with CBE 10 in 150 mM McIlvaine’s buffer 
pH 5.5. The main EGCII protein band is marked with an arrow. 
Thermal stability of EGCII 
Under optimal conditions for enzymatic activity [150 mM McIlvaine’s buffer (pH 5.5)]16 
was monitored by recording the temperature dependence of the dichroic signal at 222 
nm and applying a range of heating rates from 1 to 5 °C/min (Figure 2.4a). The 
obtained unfolding curve at a heating rate of 1 °C/min shows an apparent Tm of 42 °C, 
close to the enzyme optimal catalytic temperature (37 °C) (Figure 2.4b)1. The apparent 
Tm value depends on the scanning rate, suggesting an irreversible denaturation process 
toward aggregation, which is visible by eye due to the turbidity of the protein solution. 
The unfolding kinetics of EGCII at 37 °C (pH 5.5) were determined by recording a CD 
spectrum every 10 min for 50 min. EGCII shows an exponential decay of its ellipticity 
signal at 222 nm with a half- life of ∼10 min and forms a visible aggregate. The enzymatic 
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activity was also tested with 4MU-Lac as a substrate. A parallel decay was observed 
(Figure 2.4c), correlating unfolding kinetics with loss of activity. During the kinetic 
unfolding, the amount of residual active protein was also followed by labeling with the 
activity-based probe compound 9 (Figure 2.4c, bottom panel). A similar decay of the 
fluorescently labeled EGCII over the incubation time was observed. EGCII denaturation 
was also followed at 25 °C by CD (Figure 2.4d). At this temperature, the enzyme’s 
activity is close to optimal (Figure 2.4b). At 25 °C [150 mM McIlvaine’s buffer (pH 
5.5)], EGCII is stable with no changes in its secondary structure and its active state as 
monitored by ABP (Figure 2.4d, bottom panel). These results show that EGCII is a 
thermolabile protein with an apparent Tm of 42 °C at a heating rate of 1 °C/min and 
tends to form an aggregate as a final step in the irreversible unfolding process. Therefore, 
for experiments requiring prolonged incubations, it is practical to work at 25 °C. 
Figure 2.4. Thermodynamic stability of EGCII. (a) Thermal denaturation curves of EGCII at varying 
scanning rates (1-5 °C/min), at a protein concentration of 5 μM. (b) Temperature dependence of EGCII activity 
toward 4MU-Lac in 150 mM McIlvaine’s buffer (pH 5.5), with an incubation time of 1 h. The activity at 25 °C 
is highlighted by the green rectangle; the error bars represent the standard deviations of a duplicate experiment. 
(c) Decays over time of the ellipticity at 222 nm (red empty circle and curve), the specific activity (blue filled
circle and curve), and SDS-PAGE of ABP labeling of EGCII samples at 37 °C in 150 mM McIlvaine’s buffer
(pH 5.5) (bottom panel). The red and blue curves are exponential decay fits of the ellipticity and enzymatic
activity (EA), respectively. The half-life decays are 12 min (ellipticity) and 7 min (enzymatic activity). The error
bars represent standard deviations of a duplicate experiment. (d) EGCII kinetic stability at 25 °C monitored by
circular dichroism spectra (blue lines), recorded every 10 min for 90 min, and SDS-PAGE of ABP selective
labeling of EGCII (bottom panel).
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EGCII flexibility and conformations in solution 
Limited proteolysis with trypsin at a trypsin: EGCII ratio of 1:100 was employed to 
investigate the flexibility of EGCII in solution. Proteolysis under different conditions and 
as a function of incubation time was analyzed via SDS-PAGE. At 25 °C, directly after 
trypsin addition, an additional band rapidly appears on the gel close to the intact protein. 
This could result from cleavage of one of the flexible ends of the protein. After incubation 
for 10 min, approximately 50% of the protein has been digested with the appearance of 
two major protein fragments with apparent molecular weight of 34 and 25 kDa (Figure 
2.6a). These fragment species remain relatively resistant to °C, the protein was fully 
digested into these two bands within 10 min, the digestion already being observed 
immediately upon addition of the protease (time zero) (Figure 2.6c). The peptic 
fragment pattern is similar at 37 and 25 °C, suggesting that digestion occurs at the same 
position in the polypeptide. To correct for the difference in trypsin activity at 25 and 37 
°C, the digestion at 25 °C was conducted by adding 3 and 10 times more trypsin. The 
tryptic pattern of EGCII was not affected by the additional trypsin activity (Figure 2.5). 
The subsequent rapid disappearance of the tryptic fragments at 37 °C, as compared to 
that at 25 °C, suggests that at the lower temperature the nicked polypeptide remains 
folded, whereas at higher temperature it unfolds, allowing further proteolysis of the two 
fragments. We tried to identify the site of digestion by mass spectrometry. 
The in-gel digestion and analysis by LC/MS of the produced tryptic fragments suggested 
that the major digestion occurs after Arg332. However, LC/MS of the intact fragments 
(that is, without further digestion into smaller peptides) suggested that the major digestion 
site is located after the preceding arginine residue at position 321 (observed mass for C-
terminal fragment 18622 Da, expected 18624 Da). It is concluded that either or both of 
these arginines represent the primary cutting site. Interestingly, in the EGCII crystal 
structure, both arginines are located in a long, well-structured a-helix (Figure 2.6e). In 
a modeling study, Hubbard et al. concluded that a local disorder or unfolding of the 
protein polypeptide chain of at least 12 residues is required to allow access into a protease 
active site17. Therefore, those results suggest that this part of the protein is less structured 
in solution than in the crystalline state. In the presence of the detergent lauryl glucoside 
(Figure 2.6b) or Triton X-100 (Figure 2.6d), the protein is strikingly resistant to tryptic 
digestion. It has been reported that the used surfactants have no inhibitory effects on 
trypsin18. This tryptic resistance of the protein in the presence of detergents could be due 
to interaction with the micelles, shielding the protein surface, leading to a more rigid and 
compact structure. Moreover, lauryl glucoside has an amphiphilic structure quite similar 
to that of EGCII natural substrates 11 (Figure 2.1a), and thus, it might interact with the 
binding pocket of the protein, stabilizing it in a rigid conformation (see below). Crystals 
of ECGII were obtained in the presence of 1% (v/v) Triton X-100, 10% (v/v) glycerol, 
and 25% (w/v) PEG19. The possibility that under these conditions, and because of crystal 
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packing effects, the protein could adopt a rigid conformation that is not representative of 
the lowest-energy state present in solution cannot be excluded.  
Next, EGCII in solution was studied by size exclusion chromatography (SEC) to monitor 
changes in the hydro- dynamic dimensions accompanying unfolding, dimerization, or 
conformational changes of globular proteins in solution20,21. It is observed that EGCII 
elutes as two fractions from the SEC column (P1 and P2) with elution volumes of 8.5 and 
9.5 mL, respectively. The integration of the chromatogram peaks area yields percentages 
of 30 and 70% for peaks 1 and 2, respectively (Figure 2.7a). The re-injection of the 
extremity of the collected fractions of the two peaks shows an exchange between the two 
states of the protein even at low concentrations (Figure 2.7c). The enzymatic activity of 
both peak fractions was the same within error (Figure 2.7b). They also exhibit the same 
molecular weight on SDS-PAGE. Therefore, both fractions represent a native and active 
state of EGCII. Native PAGE analysis of EGCII shows two bands, and staining of the gel 
with ABP 9 confirms that the enzyme in both of the bands is active (Figure 2.7d). The 
analysis of the molecular weight of the eluted peaks with SEC-MALLS yields an Mw of 
100 kDa for P1 and an Mw of 50 kDa for P2 (Figure A1.2), providing more evidence of 
a monomeric state and a dimeric state of the protein. Thus, it is concluded that EGCII is 
in equilibrium between monomeric and dimeric states in solution. 
Figure 2.5: Tryptic digestion of EGCII at different ratios: Tryptic digestion of EGCII with trypsin 
from bovine pancreas (Sigma) with Trypsin: EGCII ratios 1:100, 3:100, 10:100 (by weight) in 150 mM 
McIlvaine's(citrate/phosphate) buffer pH 5.5 at 25°C.  
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Figure 2.6. Time course of tryptic proteolysis of EGCII analyzed by SDS−PAGE. Tryptic proteolysis was 
performed at an E:S ratio of 1:100 (by weight) in 150 mM McIlvaine’s buffer (pH 5.5) at 25 °C (a), at 25 °C in 
the presence of 1% lauryl glucoside (b), at 37 °C (c), and at 25 °C in the presence of 1% Triton X-100 (d). 
Samples (5 μg) were taken from the reaction mixture every 10 min and analyzed via 10% SDS−PAGE followed 
by protein staining. (e) Major trypsin cleavage sites (Arg321 and Arg332 in the red helix) identified by mass 
spectrometry and depicted in EGCII 3D structure (PDB entry 2osw)19. N-Terminal and C-terminal protein 
fragments are colored blue and green, respectively. 
Figure 2.7. EGCII solution state analysis by size exclusion chromatography and native PAGE. (a) EGCII size 
exclusion chromatogram in 20 mM Tris-HCl and 150 mM NaCl (pH 7.6). The elution volumes of the peaks 
are indicated. (b) Enzymatic activity of eluted fractions P1 and P2 using 4MU-Lac as a substrate. The error 
bars represent the standard deviations of two experiments. (c) Size exclusion chromatograms of eluted fractions 
P1 (blue) and P2 (red). (d) Native gel analysis of the EGCII sample in Tris buffer, stained with Coomassie 
Brilliant Blue (CBB) and the activity-based probe (ABP) 9. 
CHAPTER 2 
CHAPTER 2
- 42 - 
EGCII complexed with N-alkyl azide-substituted cyclophellitol aziridine 
(compound 6) 
Because EGCII was found to irreversibly react with cyclophellitol aziridines, the impact 
of cyclophellitol derivatives on the biophysical properties of EGCII was studied. For this, 
compound 6 was used, an N-alkylated cyclophellitol aziridine functionalized with an 
azide. The effects of compound 6 on the thermodynamic properties of EGCII were 
investigated by measuring the apparent Tm of the complex. A pronounced increase in the 
apparent Tm of 12 °C was observed (Figure 2.8a). Such an increase is usually 
accompanied by changes in the protein structure and rigidity22,23. The occurrence of 
conformational changes of EGCII upon complex formation was probed by comparing 
15N-1H TROSY spectra of the free and bound states. EGCII contains 38 leucine residues 
that were used as probes to detect conformational changes. In the free form, only a few 
resonances are observed (Figure 2.8b), which are very intense, suggesting that some 
leucine residues are in highly flexible regions whereas many others experience slower 
mobility, on the millisecond to microsecond time scale, which results in broadening of 
their resonances due to chemical exchange processes. For the EGCII-6 complex, 
additional peaks with more spectral dispersion are observed, suggesting rigidification of 
regions of the enzyme. The effect of these conformational changes on the solvent-
accessible hydrophobic surface of EGCII was monitored by ANSA, as an extrinsic 
fluorescence probe, which interacts with the exposed hydrophobic areas of the protein. 
The results show an 8-fold decrease in exposed protein hydrophobicity between the 
enzyme in the free form and that bound to compound 6, as determined from the changes 
in ANSA fluorescence curve slopes (Figure 2.8c). The change in the accessible 
hydrophobic surface is accompanied by a shift in the protein equilibrium between the 
dimeric and monomeric state toward the monomeric state, as demonstrated by the single 
elution peak in SEC (Figure 2.8d). This suggests that the dimerization is due to 
intermolecular interactions between the exposed hydrophobic surfaces of the protein. 
Additionally, the effect of complex formation on EGCII flexibility was tested by trypsin 
digestion at 25 and 37 °C. At 25 °C, the EGCII-6 complex is more resistant to proteolytic 
activity, compared to the protein free state, as shown by SDS-PAGE (Figure 2.9a). At 
37 °C, the protein is still digested into two bands. However, these two bands persist during 
the incubation time (Figure 2.9c), contrary to what was observed for the free protein. 
This latter peptic profile resembles that seen in the free state at 25 °C. The peptic 
fragments were analyzed by Western blotting with an anti-His tag antibody against the 
C-terminal histidine tag of EGCII. The blot confirms that the lower band contains the
C-terminal fragment of the protein (Figure 2.9b). The same peptic pattern is observed
when the protein is labeled with activity-based probe 9. The lower band is the part of the
protein that contains covalently bound ABP 9, presumably to the nucleophile Glu351
(Figure 2.9d). To investigate the EGCII-6 complex peptic fragment, the trypsin-cleaved
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and uncleaved EGCII samples were analyzed by SEC. Their chromatograms show the 
same elution volume for a single peak, and also single bands are observed via native gel 
electrophoresis (Figure 2.9e,f). These observations support the conclusion that after 
digestion the two protein fragments stick together forming a strong noncovalent complex. 
On SDS-PAGE, two bands were observed due to the dissociation of the complex under 
the denaturing conditions (Figure 2.9f). Therefore, it could be speculated that the 
hydrophobic interaction between the two nicked fragments is the main force that keeps 
the complex together. This hydrophobic interaction is likely enhanced by the aliphatic 
tail of the irreversible inhibitors. On the basis of these observations, it can be concluded 
that in its complexed state EGCII experiences pronounced conformational changes, as 
seen from its 1H-15N HSQC-TROSY spectrum and the measured accessible hydrophobic 
solvent. Additionally, an increase in trypsin resistance was observed, although the trypsin 
cleavage site remains accessible. This conformation of the protein may represent a closed 
and rigid state that could be stabilized by the hydrophobic interaction between the 
aliphatic tail of the irreversible inhibitor and the hydrophobic part of the substrate binding 
site. 
Figure 2.8. Effects of compound 6 on EGCII structure and thermal stability. (a) Thermal denaturation at pH 
5.5 monitored by CD spectroscopy with a heating rate of 1 °C/min. The fitted apparent Tm values of the 
EGCII free state (black) and the EGCII-6 complex (red) were 43 and 55 °C, respectively. (b) 15N-1H TROSY 
spectra of [15N]-Leu-labeled EGCII in the free (black) and bound (red) states. (c) Relative solvent-accessible 
hydrophobic surface of EGCII free (black) and bound (red) states, determined by ANSA fluorescence. The lines 
represent a linear fit through the origin with the indicated fitted slopes. (d) Size exclusion chromatograms of 
EGCII free (black) and covalently bound (red) states. 
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Figure 2.9. Rigidification of EGCII by compound 6. EGCII-6 complex peptic fragment pattern at 25 °C (a) 
and 37 °C (c) on 10% SDS−PAGE. (b) Anti- histidine tag Western blot membrane of digested EGCII in its free 
state and bound to compound 6 or ABP 9. (d) Fluorescence image (Cy3) of the anti- histidine tag blot showing 
the fluorescence of ABP. (e) Size exclusion chromatograms of trypsin-treated (red) and untreated (blue) EGCII-
6 complex. The elution volumes of the peaks are indicated. (f) Untreated EGCII-6 complex and EGCII-6 
treated with trypsin analyzed under native and denaturing electrophoresis conditions. 
Correlation between EGCII stabilization and the lipophilic potential of 
cyclophellitols 
A series of cyclophellitol aziridines N-alkylated or N-acylated with different lipophilic 
moieties (Figure 2.10a) were screened and the effects on EGCII melting temperature 
monitored by CD. Compounds 1 and 2 have no effect on the EGCII apparent Tm, in 
contrast to compounds 4-8, for which an increase in the apparent Tm was observed with 
a maximal shift of 14.5 °C obtained with compound 8, containing an adamantane moiety 
(Figure 2.10b). A correlation between the molecular lipophilic potential of the 
compounds and the increase in EGCII melting temperature is observed. This correlation 
can be explained by the more compact and rigid conformation adopted by the protein 
upon the interaction with the cyclophellitol aliphatic tags. Next, the solvent-accessible 
hydrophobic surfaces (SAHSs) of EGCII-cyclophellitol/cyclophellitol aziridine 
complexes were measured by ANSA (Figure 2.10c), and a decrease in EGCII SAHS 
was observed with an increase in inactivator lipophilicity. To highlight this correlation, 
the SAHS of the complexes is plotted against the theoretical “log P” of the compounds 
(Figure 2.10d). The plot suggests that with an increasing tag hydrophobicity, the protein 
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adopts a more closed and compact conformation. An exception is observed for compound 
3, which could be due to its bulky aromatic ring that may cause steric hindrance in the 
narrow hydrophobic channel of the substrate binding pocket. On the basis of these results, 
it is concluded that the shape and length of the aliphatic tail, and therefore its molecular 
lipophilic potential, are key factors for rigidification and stabilization of EGCII. 
Figure 2.10. EGCII-cyclophellitol-aziridine derivative complexes. (a) Molecular lipophilic potential of 
cyclophellitol-aziridine derivatives as visualized using MLP Tools, a PyMOL plugin60. (b) Fits of thermal 
denaturation curves of the different EGCII compound complexes, monitored by circular dichroism at pH 5.5 
(the colors agree with those in panels c and d, and experimental data points were omitted for the sake of clarity). 
(c) Effect of the tested compounds on the relative EGCII solvent-accessible hydrophobic surface monitored by
ANSA fluorescence. (d) Correlation between the calculated log P of the different tested compounds and the
relative solvent-accessible hydrophobic surface of EGCII compound complexes. The free EGCII solvent-
accessible hydrophobic surface was set to 100%. 
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Discussion 
The interaction of a ligand binding protein with its cognate substrate usually induces 
changes in the protein thermal stability, resulting in a shift of the observed melting 
temperature (Tm). This phenomenon is widely exploited as a tool to identify potential 
binders for scientific and medicinal applications24,25. For instance, this approach found 
successful application in the identification of target inhibitors in drug screening and for 
decrypting unknown protein functions. As an illustrative example, ligand-induced protein 
stabilization was used to identify inhibitors against human serine/threonine kinases. It 
was found that compounds that enhanced protein thermostability have a higher 
inhibition activity26. Another example is the elucidation of a protein function of an 
essential gene from Streptococcus pneumoniae using a thermofluor screening assay27. A library 
of 3000 compounds was screened against the unknown functional protein, and two hits 
were found to increase the protein thermal stability by 25 and 5 °C. The shifts of the 
protein melting temperature correlated with the ligand dissociation constant (Kd values of 
≈50 pM and ≈2.5 μM, respectively). The protein was identified as a nucleoside 
diphospho-keto-sugar aminotransferase27. Ligand-induced protein stabilization can also 
be attained by changes of the protein conformational flexibility28-30. By studying the 
interaction between ANSA derivatives and BSA, Celej and co-workers found that binding 
of ligand to the protein induces an increase in protein conformational rigidity that 
correlates with thermostability30. Rigidification upon ligand binding is used to screen for 
small compounds that assist protein refolding and prevent their aggregation31 or for 
specific active site binders that stabilize the folded state of a protein and improve its 
functionality32. The latter compounds are called pharmacological chaperones and have 
potential application in drug discovery for rescuing protein activity in several misfolding 
diseases33-36. As a representative example, a deficiency of GBA activity represents the 
etiology of Gaucher disease, the most common lysosomal storage disorder37. This 
deficiency can be due to various point mutations, destabilizing the protein fold and 
disrupting cellular tracking. It has been reported that active site binders restore to some 
extent the activity of lysosomal retaining β-glucosidase GBA mutants by stabilizing the 
folded conformation of the protein. For instance, IFG increased GBA thermal stability at 
neutral pH by 8.7 °C and improved protein traffcking of the N370S GBA mutant, 
resulting in an increase in GBA cellular levels in Gaucher patient tissues, including 
brain38. Additionally, oral administration of IFG increased GBA L444P mutant activity 
in mice up to 5-fold7. Several lipophilic IFG derivatives proved to have a higher affinity 
and chaperoning activity toward GBA mutants39-42. In connection to these findings, 
irreversible inhibitor cyclophellitol and its aziridine derivatives were also found to be 
effective mechanism-based ligands against retaining β-glucosidases43-45; therefore, they 
were used to study the kinetics and structural basis of β-glucosidase inhibition46. In the 
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work presented here, on the basis of the similarity of the structural topology between β-
glucosidases GBA and EGCII as well as of their target of catalysis, the β-glucosidic linkage 
in glucosylceramide, it was speculated that cyclophellitol derivatives binding covalently 
to the catalytic nucleophile of GBA might also react with EGCII. The observation that 
EGCII is indeed irreversibly inhibited by cyclophellitol derivatives opened new 
possibilities for research on the enzyme. The factors influencing the conformational 
stability of EGCII were investigated with several biophysical and biochemical techniques, 
with emphasis on the effect of occupancy of the active site by cyclophellitols. This 
investigation led to a number of findings warranting further discussion. The 
thermostability study of EGCII by circular dichroism indicated that the protein has an 
apparent midpoint of the unfolding transition of 42 °C with an irreversible unfolding 
process, forming an aggregate as a final state. The isothermal denaturation of EGCII at 
37 °C, which represents its optimal catalytic temperature, shows that the protein has a 
short half-life of 10 min, unlike what was observed at 25 °C where the protein shows a 
remarkable kinetic stability. These findings differ from those reported by Ito and co-
workers. They found that the protein has a thermal stability of 60 min at 37 °C at the 
same pH1. An explanation for this discrepancy is presently not available; the buffer 
conditions were not reported, so they may have deviated from the ones used here. The 
noted thermolability of EGCII could stem from its 3D structure containing several flexible 
regions without a well-packed hydrophobic core19. Analysis of EGCII flexibility in 
solution by proteolysis shows that the protein is susceptible to trypsin and has a major 
cleavage site localized in an a-helix in the crystal structure. It has been reported that 
protease cleavage sites for a variety of proteins of known 3D structure never occur in a-
helices, but largely in loops47. Therefore, it is speculated that this region in solution is 
either highly flexible or locally disordered. In the presence of detergents, this cleavage site 
becomes inaccessible to the trypsin and adopts a more structured conformation, as 
observed in the crystal structure of the protein. This local conformational flexibility, in 
combination with the high positive charge in this region, could play a crucial role in 
membrane association of EGCII, required to exert its enzymatic activity toward 
glycosphingolipids. The fact that EGCII processes a wide range of substrates24, which 
requires a high flexibility and plasticity of the substrate binding site, may also explain its 
flexible behavior in solution. Protein flexibility may also be important in protein-protein 
complex formation. EGCII has an activator of 69 kDa that increases the catalytic activity 
of the enzyme against gangliosides in the absence of detergents under in vitro conditions48. 
It could be that protein flexibility is necessary for protein-activator complex formation via 
an induced-fit mechanism. EGCII has a typical TIM (triose-phosphate isomerase) barrel 
folding pattern with a (b/a)8 N-terminal domain and a b-sheet C-terminal domain27. The 
function of the b-sheet domain is unclear, even though it is highly conserved in different 
families of retaining β-glucosidases. The attempt to express only the catalytic domain to 
no avail, and all of the produced protein was found in inclusion bodies. This observation, 
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combined with the high flexibility of the catalytic domain, supports the hypothesis that 
this domain not only is necessary for the stability of the catalytic domain but also may 
play a crucial role as an internal chaperone to guide the folding of the catalytic domain. 
The dramatic stabilization and rigidification of EGCII upon complex formation with the 
irreversible inhibitors are caused by the hydrophobic interaction with their aliphatic tail. 
A correlation between the molecular lipophilic potential of the tested compounds and the 
decrease in the solvent-accessible hydrophobic surface was observed. When 
accommodated into the enzyme binding pocket, the hydrophobic moieties of the 
compound appear to function as a “hydrophobic zipper”. This interaction makes the 
protein more rigid but with the preservation of the trypsin cleavage site. After cleavage, 
the two fragments were shown to stay together in a noncovalent complex, mediated by 
the hydrophobic interactions with the aliphatic tail of the irreversible inhibitor. A similar 
mechanism of binding pocket occupancy effects was observed for the complex between 
renin, an aspartic protease playing a key physiological role in the regulation of blood 
pressure, and a nonpeptidomimetic inhibitor, showing dramatic structural changes in 
renin. In this case, a movement of protein flexible loops of the binding pocket was 
observed and further changes in the protein around the bulky lipophilic substitutes of the 
inhibitors were seen. The lipophilic substitutes and hydrophobic side chains in renin act 
to form a new compact hydrophobic region within the protein49. A stabilization and 
rigidification effect was also observed in the case of the covalent modification of the b-(1-
4)-glycosidase Cex catalytic domain, from the soil bacterium Cellulomonas fimi, with the 
mechanism-based inhibitors 2,4-dinitrophenyl 2-deoxy-2- fluoro-β-cellobioside. The free 
state of the Cex catalytic domain was markedly stabilized upon formation of the 
glycosyl−enzyme intermediate with an increase in its Tm of 10.5 °C. This protein 
stabilization was accompanied by a distinct thermolysin proteolytic resistance, with no 
proteolysis of the glycosyl-enzyme complex occurring, even after incubation for 50 h at 
50 °C50. 
Conclusion 
In conclusion, EGCII was used as a research model to investigate the effects of occupancy 
of the active site by cyclophellitol analogues with variable lipophilic potential. The 
hydrophobic interaction plays a decisive role in the protein-inhibitor complex, promoting 
rigidification of the protein and conformational stability. In theory, 
endoglycoceramidases could be employed to treat a number of inherited 
glycosphingolipidoses caused by deficiency in a lysosomal exoglycosidase. Insight into 
factors influencing the conformational stability of endoglycoceramidases is one important 
prerequisite for their design as successful therapeutic agents. 
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Experimental procedures 
General synthesis 
All reagents and solvents were of commercial grade and used as received unless stated 
otherwise. Tetrahydrofuran and dichloromethane were stored over flamedried 3 Å 
molecular sieves. All reactions were performed under an inert atmosphere unless stated 
otherwise. Solvents used for flash chromatography were of pro analysis quality. Reactions 
were monitored by TLC analysis using aluminum sheets precoated with silica gel 60 with 
detection by UV absorption (254 nm) and by spraying with a solution of (NH4)6Mo7O24· 
H2O (25 g/L) and (NH4)4Ce(SO4)4·H2O (10 g/L) in 10% sulfuric acid, followed by 
charring at ∼150 °C or by spraying with 20% sulfuric acid in ethanol followed by charring 
at ∼150 °C. Column chromatography was performed using Screening Device silica gel 
in the indicated solvents. 1H-nuclear magnetic resonance (NMR), 13C NMR, COSY, and 
HSQC spectra were recorded on Bruker DMX-400 (400/100 MHz), Bruker AV-400 
(400/100 MHz), and Bruker AVIII-600 (600/150 MHz) spectrometers in the given 
solvent. Chemical shifts are reported as δ values in parts per million relative to the 
chloroform residual solvent peak, tetramethylsilane (TMS) as an internal standard, or the 
deuterated solvent signal for CD3OD. All given 13C spectra were proton-decoupled. 
High-resolution mass spectra were recorded with an LTQ Orbitrap instrument 
(ThermoFinnigan). LC/MS analysis was performed on an LCQ Adventage Max 
(ThermoFinnigan) ion trap spectrometer (ESI+) coupled to a Surveyor high-performance 
liquid chromatography (HPLC) system (ThermoFinnigan) equipped with a C18 column 
(Gemini, 4.6 mm ×50 mm, 3 μ m particle size, Phenomenex) using buffers A (H2O), B 
(acetonitrile in MeCN), and C (50mM NH4OAc). For reverse phase HPLC purifications, 
an Agilent Technologies 1200 series instrument equipped with a semi preparative Gemini 
C18 column (10 mm ×250 mm) was used. The applied buffers were 50 mM NH4 HCO3 
in H2 O (buffer A) and MeCN (buffer B). Compound 6 was synthesized according to a 
published report51. Compounds 1-5 and 7 and cyclophellitol-aziridine ABP 9 were 
prepared as described previously52. 
Synthesis of compound 8 
N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) (79 mg, 0.32 mmol) and 6-O- 
adamantanemethyl-6-hydroxyhexanoic acid X (85 mg, 0.32 mmol) were dissolved in
anhydrous DMF (0.32 mL) and stirred at room temperature for 2 h (Scheme 2.1). The
resulting dissolved mixed anhydride (160 μL) was added to cyclophellitol-aziridine 217 (35
mg, 0.2 mmol) in dry DMF (1.2 mL) at 0 °C and stirred for 30 min. At this time, an
additional batch of mixed anhydride (160 μL) was added. The resulting mixture was
stirred at 0 °C for 2 h. The reaction was quenched with MeOH (1 mL), and the mixture
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was concentrated in vacuo. Then the crude product was purified by semipreparative 
reverse HPLC [linear gradient from 38 to 47% B in A, 12 min; solutions used, H2O (A) 
and MeCN (B)], and the fractions were lyophilized yielding 8 as white powder (21 mg, 
0.05 mmol, 25% yield): 1H NMR (400 MHz, MeOD) δ 4.09 (d, J = 10.4, 4.4 Hz, 2H), 
3.72−3.66 (m, 2H), 3.414 (t, J = 6.4 Hz, 2H), 3.23 (dd, J = 10.0, 8.0 Hz, 1H), 3.10−3.02 
(m, 2H), 2.74 (d, J = 5.6 Hz, 1H), 2.55−2.51 (m, 2H), 2.01−1.95 (m, 4H), 1.77−1.66 (m, 
8H); 1.64−1.56 (m, 8H);13C NMR (100 MHz, MeOD) δ 188.5, 83.0, 79.1, 73.4, 72.2, 
69.4, 63.6, 45.3, 42.4, 41.1, 40.8, 38.3, 36.6, 35.2, 30.1, 29.9, 29.8, 22.9; LC/MS tR 7.87 
min (linear gradient from 10 to 90% B in 15 min); ESI-MS m/z 424.4 (M + H)+; HRMS 
calcd for C14H17NO4 (M + H+) 424.26936, found 424.26921.  
Scheme 2.1. Synthesis of Compound 8 
Production and purification of recombinant EGCII 
The gene encoding EGCII from Rhodococcus sp. strain M777 lacking the N-terminal signal 
peptide sequence was subcloned into pET21a using NdeI/NotI restriction sites, 
introducing a C-terminal His tag. Escherichia coli BL21(DE3) pLysS cells were transformed 
with the obtained vector and cultured at 37 °C in lysogency broth containing 50 μg/mL 
ampicillin and 30 μg/mL chloramphenicol. Gene expression was induced with 0.5 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG) when the culture reached an OD600 of ≈ 
0.6, and the incubation was continued overnight at 20 °C. The cells were harvested by 
centrifugation, resuspended in extraction buffer [20 mM Tris-HCl, 150 mM NaCl, and 
20 mM imidazole (pH 7.6)], and sonicated. The resulting EGCII 6-His supernatant was 
further purified by Ni(II) affnity chromatography to > 95%, as determined by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). All the purification steps 
were conducted at 4 °C. [15N]-Leucine isotope selective labeling of EGCII was started by 
culturing the transformed E. coli BL21(DE3) in a 50 mL culture in M9 medium overnight 
at 37 °C, supplemented with each amino acid (at 0.1 g/L) except leucine, as well as 125 
mg/L adenosine, 125 mg/L guanosine, 125 mg/L cytosine, 50 mg/L thymine, 50 mg/L 
uracil, 50 mg/L nicotinic acid, and 2 g/L succinic acid. The next day, 0.5 L of this 
medium was inoculated with the overnight preculture and incubated at 37 °C until the 
OD600 reached ≈ 0.6. Fifteen minutes before induction, a mixture of 0.5 g of each 
unlabeled amino acid except leucine and 50 mg of [15N]-Leucine were added to the 
culture53. Protein production was started by inducing gene expression with 0.5 mM 
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IPTG, and the culture was continued overnight at 20 °C. The purification procedure was 
as described above. 
NMR spectroscopy 
Two-dimensional 15N-1H TROSY54 spectra were recorded at 298 K on a Bruker Avance 
III HD 850 MHz spectrometer equipped with a TCI-Z-GRAD cryoprobe on a sample 
of 150-200 μM [15N]-Leu EGCII in McIlvaine’s buffer [110 mM Na2HPO4 and 40 mM 
citric acid (pH 5.5)] and 6% D2O. Data were processed with Topspin (Bruker Biospin) 
and analyzed using the Sparky software package55. 
EGCII activity assay and cyclophellitol complex formation  
The enzymatic activity of the purified enzyme was measured in the presence of the 
substrate 4-methylumbelliferyl-b-D-lactopyranoside (4MU-Lac) (Marker Gene 
Technologies, Inc.). The enzyme (153 nM) was incubated with different concentrations 
of 4MU-Lac for 1 h at 37 °C in McIlvaine’s (citrate/phosphate) buffer and 0.1% BSA. 
The reaction was quenched by adding 2.5 mL of a 0.3 M glycine solution (pH 10.6). The 
reaction rates were monitored by measuring the fluorescence of the released 4MU at its 
emission wavelength of 445 nm on an LS55 fluorimeter. For each enzymatic reaction, a 
blank was used, in the absence of EGCII, to measure the spontaneous hydrolysis of 4MU-
Lac, and this rate was subtracted from the enzymatically catalyzed reaction rate. For 
covalent complex formation, EGCII and the irreversible inhibitors were incubated at a 
ratio of 1:30 in McIlvaine’s buffer for 3 h at 25 °C. Thereafter, the samples were 
incubated for 1 h at 37 °C as a final step to promote complex formation and to discard 
aggregated protein. The samples were centrifuged for 30 min at 16000g, and the excess 
of inhibitor was removed by buffer exchange. The samples were kept at 4 °C for further 
experiments. 
Circular dichroism (CD) spectroscopy 
The far-UV region (200−280 nm) CD spectra were recorded in a 0.1 cm path length 
quartz cuvette in a Jasco 810 CD spectrometer using a 5 μM protein solution. The spectra 
were recorded using four scans with a bandwidth and a wavelength step of 1 nm. The 
obtained spectra were background corrected and smoothed using Jasco Spectra Manager. 
The unfolding transition point (Tm) was measured by following the dichroic signal decay 
at 222 nm, by applying heating rates from 1 to 5 °C/min, over a temperature gradient 
from 20 to 80 °C in McIlvaine’s buffer. The obtained CD ellipticity at each point (θt) was 
assumed to be the linear combination of the folded (θF) and unfolded (θU) ellipticity. At 
each point of the melting curve, the unfolded fraction was calculated using the formula fU 
= (θt-θF)/(θU-θF). The unfolding transition curves were plotted and fitted using GraphPad 
Prism, and the Tm was extracted from the obtained fits as the temperature for which fU = 
0.5. 
Limited proteolysis 
Proteolysis of free EGCII and EGCII complexes was conducted at 25 or 37 °C using a 
trypsin: EGCII ratio of 1:100 (by weight) in the absence and the presence of 1% Triton 
X-100 and lauryl glucoside. A time course analysis of the proteolytic events was
conducted using SDS-PAGE, and the peptic fragments were further analyzed by in-gel
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digestion LC-MS on a Thermo LTQ-orbitrap mass spectrometer following the described 
protocol56. To analyze the mass of the produced EGCII tryptic fragments, the proteolytic 
reaction was quenched by adding phenylmethanesulfonyl fluoride (PMSF) after 
incubation for 10 min and analyzed on a SYNAPT G2-Si mass spectrometer (Waters). 
EGCII solvent-accessible hydrophobic surface determination by 8-anilino-
1-naphthalenesulfonic acid (ANSA)
Protein surface hydrophobicity was determined using ANSA according to the method
described by Kato and Nakai57. A stock solution of 10 mM ANSA was prepared in
McIlvaine’s buffer. A variable amount of EGCII or EGCII-inactivator complex was
mixed with a 2 mM ANSA solution. The mixture was incubated for 30 min in the dark
at room temperature. The fluorescence was measured using an LS55 fluorimeter. The
excitation and emission slits were both 5 nm, and the excitation and emission wavelengths
were set at and 366 and 490 nm, respectively. The fluorescence of a blank solution was
subtracted from each protein sample. The slope of the net fluorescence intensity (percent)
plotted versus the protein concentration was calculated by linear regression analysis with
GraphPad Prism and used as an index of the protein surface hydrophobicity.
Size exclusion chromatography and multiangle laser light scattering 
Size exclusion chromatography in con- junction with multiangle laser light scattering 
(SEC-MALLS) was used to determine the absolute molecular mass of EGCII samples. 
EGCII (1 mg/mL) in 20 mM Tris-HCl (pH 7.6) or McIlvaine’s buffer was injected into 
the column. The refractive index and multiangle light scattering were measured 
simultaneously as the solute eluted from the size exclusion column. The concentration of 
the solute was determined from the refractive index, the excess Rayleigh scattering from 
the light scattering. These two parameters were entered into the Rayleigh-Gans- Debye 
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54. Pervushin, K., Riek, R., Wider, G., and Wüthrich, K. (1997) Attenuated T2 relaxation by mutual
cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR 
structures of very large biological macromolecules in solution. Proc. Natl. Acad. Sci. U. S. A. 94,
12366−12371. 
55. Goddard, T. D., and Kneller, D. G. (2007) SPARKY 3, University of California, San Francisco.
56. Shevchenko, A., Tomas, H., Havlis, J., Olsen, J. V., and Mann, M. (2007) In-gel digestion for mass
spectrometric characterization of proteins and proteomes. Nat. Protoc. 1, 2856−2860. 
57. Kato, A., and Nakai, S. (1980) Hydrophobicity determined by a fluorescence probe method and its
correlation with surface-properties of proteins. Biochim. Biophys. Acta, Protein Struct. 624, 13−20. 
58. Knobloch, J. E., and Shaklee, P. N. (1997) Absolute molecular weight distribution of low-molecular-weight
heparins by size-exclusion chromatography with multiangle laser light scattering detection. Anal.
Biochem. 245, 231−241. 
59. Ye, Y., and Godzik, A. (2003) Flexible structure alignment by chaining aligned fragment pairs allowing
twists. Bioinformatics 19, ii246− ii255. 
CHAPTER 2 
CHAPTER 2
- 56 - 
60. Oberhauser, N., Nurisso, A., and Carrupt, P.-A. (2014) MLP Tools: a PyMOL plugin for using the




- 57 - 
CHAPTER 3 




- 58 - 
Abstract 
lucocerebrosidase (GBA) is a lysosomal β-glucosidase that degrades 
glucosylceramide. Its deficiency results in Gaucher disease (GD). The 
effects of active site occupancy of GBA on its structural stability were 
examined. For this, cyclophellitol-derived activity-based probes (ABPs) that bind 
irreversibly to the catalytic nucleophile (E340) were used in conjunction with the potent 
reversible inhibitor isofagomine, for comparaison. It is demonstrated that cyclophellitol 
ABPs improve the stability of GBA in vitro, as revealed by thermodynamic 
measurements (Tm increase by 21 °C), and introduce resistance to tryptic digestion. 
The stabilizing effect of cell-permeable cyclophellitol ABPs is also observed in intact 
cultured cells containing wild-type GBA, N370S GBA (labile in lysosomes), and L444P 
GBA (exhibits impaired ER folding): all show marked increases in lysosomal forms of 
GBA molecules upon exposure to ABPs. The same stabilization effect is observed for 
endogenous GBA in the liver of wild-type mice injected with cyclophellitol ABPs. 
Stabilization effects similar to those observed with ABPs were also noted at high 
concentrations of the reversible inhibitor isofagomine. In conclusion, evidence is 
provided that the increase in cellular levels of GBA by ABPs and by the reversible 
inhibitor is in part caused by their ability to stabilize GBA folding, which increases the 
resistance of GBA against breakdown by lysosomal proteases. These effects are more 
pronounced in the case of the amphiphilic ABPs, presumably due to their high 
lipophilic potential, which may promote further structural compactness of GBA 
through hydrophobic interactions. This study provides further rationale for the design 
of chaperones for GBA to ameliorate Gaucher disease. 
This work was published as: Ben Bdira, F., et al., Stabilization of Glucocerebrosidase by Active Site 
Occupancy. ACS Chemical Biology, 2017. 12(7): p. 1830-1841. 
All of the cell biology studies were conducted by: Kallemeijn, W. W., Oussoren, S. V., Scheij, S., Bleijlevens, 
B., Florea, B. I., van Roomen, C. P. A. A., Ottenhoff, R., van Kooten, M. J. F. M., Walvoort, M. T. C., Witte, 
M. D., Boot, R. G. at the Department of Medical Biochemistry Academic Medical Center, University of
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Introduction 
 
ysosomal β-glucosidase glucocerebrosidase (GBA) cleaves glucosylceramide, an 
essential step in the turnover of cellular glycosphingolipids1,2. GBA is co-
translationally translocated into the ER, where it acquires four N-linked 
glycans3. After removal of its signal peptide, the 495-amino acids polypeptide completely 
folds and subsequently binds to the triple helical structure in the apical region of the 
integral membrane protein LIMP-2 (lysosome integral membrane protein 2, encoded by 
the Scarb2 gene), which contains trafficking information in its cytoplasmic tail4,5. 
Complexed to LIMP2, GBA is transported through the Golgi apparatus, where its N-
linked glycans are converted into complex-type structures6. The GBA−LIMP2 complex 
is routed to late endosomes/lysosomes, where GBA dissociates as a result of local acid 
pH5,7. GBA belongs to family 30 of glycoside hydrolase clan A (www.casy.org); its 
structural topology displays a typical (a/b)8TIM barrel fold that forms the catalytic 
domain, a β-sheets domain, and an immunoglobulin-like domain. The catalytic domain 
contains several loops located in the proximity of the enzyme’s active site8. These seem to 
adopt multiple conformations, indicating their structural flexibility and presumably 
reflecting their crucial role in the enzyme’s conformational stability and/or its substrate 
turnover9. Inspection of the GBA crystal structure in complex with N- 
nonyldeoxynojirimycin (NN-DNJ) (PDB code: 2V3E) shows that the binding site of the 
enzyme is formed by a hydrophilic glycon binding pocket, where the sugar ring of the 
inhibitor is accommodated, forming multiple hydrogen bonds with its surrounding 
residues. Also, an aglycon binding pocket is present, formed by a narrow hydrophobic 
channel in which the aliphatic tail of the inhibitor forms a cluster of hydrophobic 
interactions with residues Leu241, Phe246, Tyr313, Leu314, and Tyr244 (Figure 
3.2d)10. Deficiency of GBA results in Gaucher disease11. At present, more than 200 
mutations in the gba1 gene have been linked with GD, and next to truncations and splicing 
defects, several hundred amino acid substitutions in GBA have been shown to cause 
GD12. Substitutions in the GBA polypeptide chain distant from the catalytic site 
destabilized GBA’s structure, decreasing its half-life in the cell. For instance, the L444P 
substitution in GBA causes faulty folding of most of its molecules in the ER, followed by 
subsequent proteasomal degradation13. Homozygosity for L444P GBA nearly always 
leads to a severe neuronopathic course of GD, albeit with great individual variability in 
onset and progression11. Premature degradation may also occur in the case of GBA 
molecules with mutations in the catalytic domain. In fact, many of the documented 
mutations in GBA lead to defective folding and reduced transport to lysosomes14. An 
exception is the N370S GBA substitution, which is the most prevalent gba1 mutation 
among caucasian GD patients. This amino acid substitution is in a loop close to the 
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parameters such as affinity for substrates and inhibitors15-19. Notably, the intralysosomal 
stability of N370S GBA is also reduced15,16,19. The survival of wild-type GBA within 
lysosomes is already relatively short (t1/2 ~ 24−36 h), at least in cultured cells, where its 
intralysosomal proteolytic breakdown is supposedly mediated by cysteine proteases, as 
suggested by inhibition studies with leupeptin20. The major symptoms of GD are 
predominantly caused by the abnormal accumulation of glucosylceramide in lysosomes 
of tissue macrophages21,22. Lysosomal accumulation of glucosylceramide induces a 
multisystem disorder with various symptoms such as hepatosplenomegaly, cytopenia, and 
bone disease11. Severely affected GD patients also develop neurological symptoms, and 
GBA abnormalities have been recognized as a risk factor for developing a-
synucleinopathies23. Enzyme replacement therapy (i.e., chronic intravenous 
administration of macrophage-targeted recombinant human GBA24) markedly improves 
visceral symptomatology in GD patients, but the inability of the infused enzyme to pass 
the blood-brain barrier prohibits the prevention and correction of neurological 
manifestations25. An alternative treatment might be offered by so-called pharmacological 
chaperones that promote the folding and stability of (mutant) GBA through interacting 
with its catalytic site26-29. These, preferably brain-permeable, small compounds should 
promote the folding of (mutant) GBA in the endoplasmic reticulum, resulting in increased 
transport of GBA to the lysosome26-29. Additionally, pharmacological chaperones might 
also stabilize GBA intra-lysosomally15. Whether the latter is clinically beneficial is debated 
since pharmacological chaperones that interact with the active site of GBA will 
intrinsically also inhibit its enzymatic activity. Among pharmacological chaperone 
candidates, one of the best studied is the iminosugar isofagomine (IFG 1). IFG 1 increased 
the thermal stability of GBA at neutral pH by 8.7 °C and improved the trafficking of the 
N370S GBA mutant, resulting in an increase of cellular GBA levels in Gaucher patient 
tissues, including the brain30. Additionally, oral administration of IFG 1 increased GBA 
L444P mutant activity in mice up to 5-fold31. Nevertheless, IFG 1 has exhibited poor 
performance when tested in humans, which could be due to its high hydrophilicity. 
Therefore, several other lipophilic derivatives have been tested and shown to have a 
higher affinity and chaperoning activity toward GBA mutants. For example, the GBA 
inhibitors N-butyldeoxynojirimycin (NB-DNJ, Miglustat) and NN-DNJ have been 
applied to GD cells with relative success: NN-DNJ has been used to restore protein levels 
of the N370S GBA variant in fibroblasts and NN-DNJ has been shown to lead to a 
significant increase in the protein level of several GBA mutants in cells, with a moderate 
enhancement in their thermal stability in vitro17,32. The crystal structures of GBA bound 
to IFG 1, NB-DNJ, and NN-DNJ have provided insights into the interactions in GBA-
inhibitor complexs10,30. However, these crystalline states did not provide a clear 
correlation between the induced conformational changes in GBA upon complex 
formation and the mechanism by which the inhibitors stabilized GBA folding in solution. 
Therefore, it is aimed to elucidate this mechanism using reversible and irreversible 
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glycomimetic ligands with different lipophilic properties in vitro and to verify the findings 
in vivo. Moreover, it is aimed to address the question of whether the occupancy of the 
binding pocket of GBA promotes its protection against proteolytic degradation in 
lysosomes. In the present study, first the stabilizing effects of cyclophellitol-type activity-
based probes (ABPs; Figure 3.1a) were examined, which permanently bind to the E340 
catalytic nucleophile, on pure, recombinant GBA by utilizing its double-displacement 
mechanism (Figure 3.1b). The ABPs are β-glucose-configured cyclophellitols with a 
spacer possessing hydrophobic green or red fluorescent BODIPY moieties (MDW933 4 
and MDW941 5; Figure 3.1a) attached to C633,34. Also conduritol β-epoxide (CBE 2) 
was used as a small hydrophilic covalent inhibitor that is supposed to occupy only the 
glycon binding pocket of GBA. By trapping GBA in its intermediate state by forming an 
adduct complex with the aforementioned mechanism-based inhibitors, the contribution 
of the different moieties to the structural stabilization of GBA through binding site 
occupancy was dissected. The effect of 2-deoxy-2-fluoro-β-D-glucopyranosyl-N-
phenyltrifluoroacetimidate (fluoro 3; Figure 3.1a)35, which forms a transient glycosyl-
enzyme intermediate (Figure 3.1c), on GBA was also examined. For comparison, the 
effect of the potent reversible competitive GBA inhibitor IFG 1, which has an in vitro IC50 
of ~30 nM at pH 5.2 and 5 nM at pH 7.027 was studied. The various investigations are 
described herein, and their implications are discussed.  
Figure 3.1. Inhibitors and reaction mechanism. (a) Structural formulas of competitive, reversible inhibitor 
isofagomine (IFG 1), irreversible inhibitors conduritol β-epoxide (CBE 2), semi-irreversible inhibitor-2-deoxy-
2-fluoro-β-D-glucopyranosyl-N-phenyltrifluoroacetimidate33 (fluoro3), cyclophellitol β-epoxide type ABP 4
(MDW933, green fluorescent), and β-epoxide-type ABP 5 (MDW941, red fluorescent)35. (b) Irreversible binding
mechanism of β-epoxide-type ABPs to the nucleophile of GBA via its double-displacement mechanism. (c)
Hydrolysis of fluoro 3 and temporary trapping of the glycosylated nucleophile adducts of GBA.
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Results 
Structural Stability and Flexibility of GBA: Impact of pH and 
Temperature
During its life cycle, GBA is exposed to a broad range of pH values: from neutral pH in 
the ER to an increasingly acidic pH in endosomes and lysosomes (pH 6.5 to >pH 4.5-
5.0). Therefore, the effect of both acidic and neutral pH on the structural stability of 
purified recombinant GBA (rGBA, imiglucerase) was first investigated, by monitoring its 
thermal unfolding using circular dichroism. The dependence of the secondary structure 
of rGBA on temperature was recorded by monitoring the emission rGBA at a helical 
ellipticity wavelength (222 nm) while gradually heating it from 30 to 80°C (1 °C/min; see 
Figure 3.2a). The melting curve obtained for rGBA at pH 7.4 shows an apparent Tm 
value of 57 °C, and its melting temperature at pH 5.2 increased by 4 °C to an apparent 
Tm value of 61 °C. The increase in Tm at acidic pH is in agreement with previously 
reported measurements using differential scanning calorimetry (DSC)15,32. Next, the effect 
of neutral and acidic pH on the activity of rGBA was investigated in a time-dependent 
manner at 37 °C. For this purpose, rGBA was first incubated for different lengths of time 
at 37 °C in 150 mM McIlvaine’s buffer at a pH of 5.2 or 7.4. The residual activity of 
rGBA was measured with the 4MU-β-D-Glc substrate in 150 mM McIlvaine buffer at 
pH 5.2 (Figure 3.2b). The data indicate that the activity of rGBA is preserved under 
acidic conditions, whereas at pH 7.4, its activity is lost in a time dependent manner, with 
a half-life of 30 min. The noted loss in rGBA activity at pH 7.4 could be due to a loss of 
the enzyme’s native fold, apparently due to an irreversible process since the remaining 
activity was measured at pH 5.2. To substantiate this explanation, a limited proteolysis 
reaction using trypsin was performed to probe the effects of pH on the rigidity of rGBA. 
Here, rGBA was digested with trypsin in 150 mM McIlvaine buffer at pH 5.2 or 7.4, and 
the tryptic events were analyzed every 10 min by SDS-PAGE (Figure 3.2c). At pH 5.2, 
rGBA shows resistance to tryptic digestion over the course of 90 min, whereas at pH 7.4, 
rGBA is more sensitive to trypsin digestion, with about 40% degraded within 60 min. 
The activity of trypsin at pH 5.2 and 7.4 on endoglucosylceramidase (EGCII) was 
checked and found it to be similar (Figure 3.3). Of note, a tryptic fragment of 
approximately 34 kDa appears during proteolysis that persists over the course of the 
experiment, which may point to a structured and rigid domain of rGBA (Figure 3.2c, 
arrow). Mass spectrometry was used to tentatively identify the trypsin cleavage site in 
GBA. The results suggest that the cleavage site position could be after lysine 233 (UniProt: 
P04062) within the polypeptide sequence VNGK_GSL, located in a loop close to the 
active site (Tables A2.1 and A2.2). In addition, this cleavage site seems to be more 
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accessible to trypsin digestion at neutral pH and more protected at acidic pH (Figure 
3.2d). 
Figure 3.2. pH affects the structure of rGBA. (a) rGBA melting curve at pH 5.2 (closed squares) and pH 7.4 
(open circles) as determined by circular dichroism. (b) Time-dependent decay of rGBA activity at pH 5.2 (closed 
squares) and pH 7.4 (open circles), as determined by hydrolysis of 4MU-β-D-Glc substrate at pH 5.2. Data are 
averages of duplicate values ± SD. (c) Coomassie brilliant blue staining of the time-dependent tryptic digestion 
of rGBA with a trypsin/rGBA ratio of 1/10 (w/w) at pH 5.2 and 7.4 (top and bottom, respectively). The 35 
kDa tryptic fragment is highlighted by an arrow. (d) Trypsin cleavage site at lysine 233 (pink spheres) present 
on the flexible outer loop (red) shown on the crystal structure of GBA in complex with NN-DNJ (PDB code: 
2V3E), with NN-DNJ shown using a ball and stick model. Amino acid residues of the glycon binding pocket of 
GBA are shown in blue, and residues of the aglycon site are shown in yellow. A detail view of the rendered 
structure is shown to the right.
Figure 3.3. Coomassie brilliant blue staining of time-dependent, tryptic digestion of endoglycoceramidase 
EGCII with an optimum trypsin/EGCII ratio of 1/100 (w/w) at pH 5.2 and 7.4 (left, right, respectively). 
CHAPTER 3
CHAPTER 3
- 64 - 
Thermal Stability of rGBA: Impact of Glycomimetic Ligands 
The effects of the competitive inhibitor IFG 1, the semi-irreversible inhibitor fluoro 3, 
and the irreversible inhibitors CBE 2 and lipophilic ABPs 4/5 on the thermal stability of 
rGBA were investigated at pH 5.2, mimicking lysosomal conditions. For this purpose, 
rGBA was incubated with saturating concentrations of inhibitors for 1 h at 37 °C and 
then gradually heated while monitoring tryptophan fluorescence36,38, which decays as a 
result of tertiary structure unfolding. As depicted in Figure 3.4a, IFG 1 increased the 
Tm of rGBA (55.2 °C) by +5.6 °C, irreversible inhibitor 2, by +14.1°C, 3, by +12.9 °C, 
and ABPs 4 and 5, by +21.0 and +21.7 °C, respectively. Another analysis of biophysical 
stability was performed by circular dichroism37. rGBA without inhibitors was compared 
to the enzyme saturated with 2 and β-epoxide 4 (Figure 3.4b). The calculated melting 
temperatures of rGBA preparations follow a similar trend as that observed using 
tryptophan fluorescence decay. Again, β-epoxide 4 is found to exert the most prominent 
stabilization of rGBA. 
Glycomimetic Ligands Influence the Intrinsic Fluorescence of GBA 
The 12 tryptophan residues present in GBA were exploited to probe the effects of ligand 
binding on the general folding of GBA. Notably, Trp178 and Trp381 are in close 
proximity to the substrate binding pocket, and residue Trp348 (loop2) and Trp393 (loop3) 
reside on the protein surface; the other Trp residues are buried in the hydrophobic core 
of the protein8. rGBA emission spectra were acquired by exciting tryptophan residues at 
295 nm and recording the emission by scanning from 300 to 450 nm in the presence or 
absence of various irreversible inhibitors (Figure 3.3c). In its free form, rGBA exhibits a 
maximum emission of 336.5 nm (similar to a previously reported value38). A slight 2 nm 
blue shift in the spectrum was observed upon complex formation with CBE 2, with a 
maximum emission at 334.5 nm, reflective of a more hydrophobic environment of the 
tryptophan residues within the complex state (Figure 3.3d). rGBA exhibits a slightly 
larger blue shift when bound to ABPs 4 and 5, with emission maxima of 333 nm. These 
data suggest that CBE 2 and ABPs 4/5 cause changes in the folding of rGBA, with the 
stronger effects of the latter ABPs presumably being promoted by their lipophilic tails. 
Serendipitously, the blue shifts induced by ABP 4 and 5 were concomitant with 
fluorescence quenching. As ABPs 4 and 5 contain a BODIPY fluorescence moiety (green 
and red fluorescent, respectively), it was speculated that part of the intrinsic GBA 
tryptophan emitted fluorescence is transferred to these fluorophores through an intrinsic 
FRET (iFRET) mechanism39. To test this, the fluorescence spectra of ABP 4 and ABP 5-
labeled rGBA were acquired by exciting at 295 nm and extending the scanning range to 
700 nm. Indeed, two peaks appear (515 and 610 nm) at maximum emission, which 
represent the maximum emission for both ABP- incorporated BODIPYs (Figure 3.3d). 
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This iFRET mechanism is also supported by the overlap between the emission spectra of 
rGBA and ABPs (Figure 3.5). 
Glycomimetic Ligands Variably Rigidify the Structure of GBA 
Protein stabilization by ligands is generally paired with protein rigidification due to new 
hydrogen bonds formation or due to the formation of new clusters of hydrophobic 
interactions40. From the data presented above, it is speculated that there is a correlation 
between the ligand-induced conformational changes in GBA and its thermodynamic 
stabilization. Next it was investigated whether interactions with (ir)reversible inhibitors 
stabilize GBA by rigidification in vitro; the effect of these inhibitors on the ability of trypsin 
to digest rGBA was analyzed. As depicted in Figure 3.4e,f, only ~10% of rGBA in its 
free form remains after 90 min of incubation, and two major fragments are formed (~35 
and ~40 kDa), which remain mostly intact over the course of the experiment. The trypsin 
cleavage site of the 35 kDa fragment was previously identified to be after Lys233 (Tables 
A2.1 and A2.2). The presence of hydrophilic compounds IFG 1 or CBE 2 increased the 
resistance of rGBA against tryptic digestion, with 50% of rGBA remaining intact, and 
cleavage site of rGBA in its free state by trypsin was preserved (Figure 3.4 e,f). Fluoro 
3 and ABPs 4 and 5 exert prominent effects on the sensitivity of rGBA to tryptic digestion 
(Figure 3.4 e,f) such that within 90 min no degradation was observed. These ABPs have 
long hydrophobic tails of 15-18 Å, giving them a high lipophilic potential. After binding 
to the nucleophile of GBA, the ABPs’ hydrophobic tails further rigidify GBA through 
hydrophobic interactions that shield its hydrophobic core and lock into place the flexible 
loop that contains the trypsin cleavage site. Altogether, these observations match the 
incremental increases in the melting temperature of rGBA between CBE 2 and ABPs 4 
and 5 (Figure 3.4a,b). Of note, amphiphilic inhibitors 4 and 5 also show the lowest IC50 
values regarding the inhibition of GBA’s enzymatic activity, reflecting a correlation 
between their stabilization effects and their high binding affinity for the catalytic pocket 
(Table 3.1). 
Table 3.1. Apparent IC50 of Inhibitors
a
compound apparent IC50 (nM) 
IFG 1 31.4 at pH 5.2; 5.8 at pH 7.2 
CBE 2 9497 ± 42.8 
fluoro 3 5458 ± 130 
ABP 4 1.24 ± 0.04 
ABP 5 1.94 ± 0.08 
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Figure 3.4. rGBA conformational changes monitored by intrinsic fluorescence and tryptic digestion. (a) 
Melting temperature (Tm) determined by tryptophan fluorescence of rGBA in the absence (control) or presence 
of saturating concentrations of inhibitors IFG 1, CBE 2, fluoro 3, or β-epoxide ABPs 4 and 5. Statistical analysis 
of n = 3 experiments, two-way ANOVA (***, p < 0.001). (b) Tm determined by circular dichroism of rGBA in 
the absence or presence of saturating concentrations of inhibitors 2 and 4. Statistical analysis of n=2, two-way 
ANOVA (***, p < 0.001). (c) rGBA fluorescence spectra at λEX 295 nm in the absence of additives (black dashed 
line) with a maximum λEM of 335 nm, in complex with CBE 2 (yellow) with a maximum λEM of 333 nm, with 
ABP 4 (green) with a maximum λEM of 332 nm, and with ABP 5 (red) with a maximum λEM of 331 nm. (d) 
rGBA fluorescence spectra showing fluorescence quenching by ABP 5 (red) with the appearance of an emission 
peak at 610 nm and ABP 4 (green) with the emergence of an emission peak at 515 nm. All measurements were 
done in 10 mM phosphate buffer, 150 mM NaCl, pH 7.4. (e) Time-resolved analysis of the tryptic digestion of 
rGBA in complex with IFG 1, CBE 2, fluoro 3, ABP 4, or ABP 5. (f) Quantification of rGBA band densitometry 
during tryptic digestion in the absence (black dashed line) and presence of ABP 5 (red), ABP 4 (green), fluoro 3 
(magenta), CBE 2 (yellow), or IFG 1 (cyan). Duplicate quantifications ± SD. 
Figure 3.5: Absorption spectra of free ABPs 4 and 5 versus the emission spectrum of unlabeled rGBA. (a) 
Overlay of unlabeled rGBA emission spectrum (blue) excited at 295 nm and ABP 5 absorption spectrum (red 
dashed line) with a maximum absorption at 304 and 560 nm. Overlap between the spectra is highlighted in 
grey. (b) Overlay of unlabeled rGBA emission spectrum (blue) with ABP 4 absorption spectrum (green dashed 
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Lipophilic ABPs 4 and 5 Stabilize GBA in Macrophages and Living Mice 
As ABPs 4 and 5 exerted the strongest effect on the stability of rGBA in vitro, their 
influence on the enzyme in situ was assessed. Hence, human monocyte-derived 
macrophages were cultured with 100 nM ABP 5, completely labeling all active GBA 
molecules (in situ IC50 ~10 nM). After a continuous pulse for up to 192 h (8 days), in situ 
ABP 5-labeled GBA was detected by fluorescence scanning (Figure 3.6a). ABP 5 labeled 
various molecular weight forms of GBA in the range 58-66 kDa, stemming from 
modifications in the enzyme’s N-linked glycans41. Earlier investigations revealed that the 
58 kDa form of GBA is formed inside lysosomes as a result of N-linked glycans being 
trimmed by local glycsidases41. As seen in Figure 3.6a, the mature 58 kDa form of GBA 
accumulates when the enzyme is labeled with 5. This finding suggests that ABP labeling 
stabilizes GBA against proteolytic degradation in lysosomes and does not prohibit N-
glycan modifications by lysosomal glycosidases. 
To further examine the stabilizing effect of ABPs on GBA in situ, the fate of exogenous 
unlabeled rGBA and the same enzyme prelabeled with ABP 4 following uptake by human 
monocyte-derived macrophages (Figure 3.6b) was analyzed. The ABP 4-labeled 
enzyme was stable after uptake for at least 48 h, in sharp contrast with the rapid 
breakdown of unlabeled rGBA (Figure 3.6b). The in situ stabilizing effect was also 
visualized and verified through fluorescence microscopic analyses, showing stable ABP 
4−rGBA in monocyte-derived macrophages 48 h after uptake compared to cells loaded 
with rGBA (Figure 3.6c). Next, mice were infused intravenously with 1 nanomole of 
ABP 4, which subsequently labeled endogenous GBA in various tissues34,35,54. In the livers 
of treated animals, sacrificed 6 weeks post ABP administration, 4-labeled GBA could still 
be detected (Figure 3.6d). The amount was around ~35% of that in the livers of animals 
that were sacrificed 24 h after infusion of an identical dose of ABP 4 (Figure 3.6d, with 
quantification in e). This suggests again that ABP labeling markedly stabilizes GBA in 
vivo, since the half-life of unlabeled GBA is reported to be around 32-48 h18,20.  
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Figure 3.6. In situ labeling of GBA with cyclophellitol ABPs 4 and 5. (a) Continuous labeling of human 
monocyte-derived macrophage GBA with ABP 5 (top) and Coomassie brilliant blue (CBB) staining of protein 
input (bottom). (b) Chase of ABP 4 (pre-) labeled rGBA (imiglucerase) taken up by CBE 2 pretreated human 
monocyte-derived macrophages (top) and CBB staining (bottom). (c) Fluorescence micrographs of macrophages 
in (b): control (top) and cells treated with unlabeled rGBA (middle) and ABP 4-labeled rGBA (bottom) after 0 
and 48 h (left and right, respectively). Unlabeled rGBA was detected by labeling for 30 min with 10 nM ABP 4 
prior to fixation. Scale bar represents 25 μm. (d) Chase of murine hepatic (endogenous) GBA of animals treated 
either with vehicle, ABP 4 for 15 days (7 injections), or a single dose 6 weeks prior to sacrifice (top) and CBB 
staining (bottom). (e) Densitometry of ABP 4-emitted fluorescence from (d), normalized using CBB, with no 
treatment (open circles) or treated with repeated doses of ABP 4 (closed diamonds) or a single dose (closed 
squares); data are the mean of duplicate quantifications ± SEM. All gels contain 50 fmol of equimolar ABP 4- 
and 5-labeled ~59 kDa imiglucerase (asterisk) as a positive control.
Lipophilic ABPs 4 and 5 Increase GBA in Fibroblasts by Protection 
against Lysosomal Proteolysis 
To assess whether the accumulation of ABP 4-labeled 58 kDa GBA stems from a reduced 
susceptibility to lysosomal proteases, confluent human control fibroblasts were treated for 
3, 5, 7, 9, or 12 days with the cysteine-cathepsin inhibitor leupeptin18. After harvesting 
the cells, GBA in the lysates of control cells and leupeptin-exposed cells was labeled with 
excess ABP 4 in vitro. As shown in Figure 3.7a, the amount of green fluorescent 4-labeled 
GBA in untreated control cells increased slightly with culture time (top row). The 
incubation of the cells with Leupeptin caused a prominent accumulation of ~58 kDa 
active GBA over time (second row)18. Next, cells were incubated with red fluorescent ABP 
5. The inhibitor treatment induced a prominent time-dependent accumulation of ABP-
labeled GBA (third row, Figure 3.7a). The increase in in situ ABP 5-labeled GBA was
slightly further enhanced in cells co-incubated with leupeptin (fourth row), suggesting that
5-labeled GBA is still prone to some degree of proteolysis within lysosomes (Figure 3.7a).
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The quantification of ABP-labeled GBA is shown in Figure 3.7b, indicating that the in 
situ stabilization of GBA by leupeptin and ABP 5 at least partially overlap. 
Lipophilic ABPs 4 and 5 Increase Mutant GBA Molecules in GD 
Fibroblasts  
In fibroblasts from a homozygous N370S GBA Gaucher patient and a homozygous 
L444P GBA Gaucher patient, similar stabilizing effects of ABP on the enzyme were 
observed (Figure 3.7c). Both fibroblast cell lines contained a lower amount of active 
GBA compared to the control fibroblasts. Incubation of the cells with leupeptin and ABP 
5 resulted in the stabilization of GBA, which was more prominent (6-8-fold) compared to 
that seen for GBA in wild- type cells (about 3-fold) (compare Figure 3.7, panels b and 
d). Exposure of both Gaucher fibroblast cell lines to the combination of ABP 5 and 
leupeptin further increased the stabilizing effect, which again partially overlapped 
(Figure 3.7d). Total GBA protein in cell lysates was also visualized by western blotting 
using the GBA-specific 8E455 antibody (Figure 3.7e,g, with corresponding 
quantification in Figure 3.7f,h). Again, a prominent stabilization of ~58 kDa GBA was 
noted with ABP 5 and/or leupeptin in the case of wild-type cells and N370S GBA 
Gaucher fibroblasts (Figure 3.7, panels f and h, respectively). Unfortunately, 
comparable analysis of L444P GBA Gaucher fibroblasts was not reliable due to their very 
low quantities of GBA protein. Overall, these findings suggest that the stabilizing effect of 
ABP 5 is partially caused by protection against breakdown by lysosomal proteases. This 
effect is specific since the lysosomal glycosidases processing GBA to its 58 kDa form do 
not appear to be inhibited. The reversible inhibitor IFG 1 and semi-irreversible inhibitor 
3 were found to augment GBA in fibroblasts to a lesser extent. Confluent wild-type and 
homozygous N370S GBA fibroblasts were treated for 12 days with 0-100 μM 1. After 
harvesting, cell lysates were labeled with excess green ABP 4 to visualize residual active 
GBA molecules (Figure 3.8a,b). A stabilizing effect of IFG 1 became evident only at 
concentrations greater than 10 μM, being maximal at 100 μM (the highest concentration 
tested). Western blot analysis of the same experiment rendered a similar result (Figure 
3.8c,d). The semi-irreversible inhibitor 3 comparably augmented GBA in wild-type and 
N370S/N370S GD fibroblasts (Figure 3.9a,b). The findings from treating fibroblasts 
with 3 were confirmed by western blot analysis (Figure 3.9c,d). 
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Figure 3.7. In situ stabilization of GBA by ABP 5 and leupeptin. Wild-type GBA fibroblasts were incubated 
with leupeptin, ABP 5 (red), or both for the indicated lengths of time. (a) GBA levels in untreated fibroblasts 
(top row) and cells incubated with leupeptin (second row), visualized in vitro with ABP 4 (green). Labeling of 
GBA in cells in situ with ABP 5 (red, third row) and in combination with leupeptin (bottom row). Equal green 
and red fluorescence yields a yellow overlay; fluorescence was calibrated with 50 fmol of equimolar green ABP 
4- and red ABP 5-labeled imiglucerase present in each SDS-PAGE gel (asterisk). (b) Quantification of ABP-
emitted fluorescence from in vitro ABP 4-labeled controls (open black circles), cells treated with leupeptin only
(blue triangles), cells treated with in situ ABP 5-labeled GBA (red squares), and cells treated with a combination
of ABP 5-labeled GBA and leupeptin (purple diamonds). Data are the mean of n = 2 ± SD. (c) GBA levels in
N370S/N370S fibroblasts treated in the same manner as wild-type GBA fibroblasts in panel a, vide supra. (d)
Quantifications of ABP fluorescence in N370S/N370S fibroblasts. (e) Detection of total GBA protein in wild-
type fibroblasts (green) by western immunoblotting of gels depicted in panel a (molecular weight ladder is in
red). (f) Quantification of total GBA protein from in vitro ABP 4-labeled controls (open black circles), cells
treated with leupeptin only (blue triangles), cells treated with in situ ABP 5-labeled GBA (red squares), and cells
treated with a combination of ABP 5-labeled GBA and leupeptin (purple diamonds). Data are the mean of n =
2 ± SD. (g) Total GBA protein in N370S/N370S fibroblasts treated in the same manner as wild-type GBA
fibroblasts in panel a, vide supra. (h) Quantifications of ABP fluorescence in N370S/N370S fibroblasts. All data
are expressed as average of n = 2 ± SD.
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Figure 3.8: In situ GBA stabilization by IFG 1. Wild-type GBA (open columns) and N370S GBA (closed 
columns) fibroblasts were grown for 12 days in the absence or presence of incubated with leupeptin, red 
fluorescent ABP 5, both, or 0.001–100 μM IFG 1. (a) Gel depicts in situ labeling of active GBA wild type (top) 
and N370S variant (bottom) by ABP 5 in the presence and absence of IFG 1 and/or leupeptin. (b) 
Quantification of ABP-emitted fluorescence from in vitro ABP 4-labeled controls, leupeptin and IFG 1-treated 
cells, compared to fluorescence of in situ ABP 5-labeled GBA. (c) Total GBA protein in wild type (top) and 
N370S variant (bottom) fibroblasts lysates visualized by Western blot using GBA-specific antibody 8E4 and it 
densitometry quantification (d) in the presence and absence of IFG 1, leupeptin and/or ABP 5. All data 
expressed as average of n = 2, ± SD. 
Figure 3.9: In situ GBA stabilization by fluoro 3. Wild-type GBA (open columns) and N370S GBA 
(closed columns) fibroblasts were grown for 12 days in the absence or presence of incubated with leupeptin, 
green fluorescent ABP 4, both, or 0.001–100 μM fluoro 3. (a) Gel depicts in situ labeling of active GBA wild 
type (top) and N370S variant (bottom) by ABP 4 in the presence and absence of fluoro 3 and/or leupeptin. (b) 
GBA activity towards artificial substrate in lysates shown in a. (c) Total GBA protein in wild type (top) and 
N370S variant (bottom) fibroblasts lysates visualized by Western blot using GBA-specific antibody 8E4 and it 
densitometry quantification (d) in the presence and absence of fluoro 3, leupeptin and/or ABP 4. All data 
expressed as average of n = 2, ± SD. 
CHAPTER 3
CHAPTER 3
- 72 - 
Discussion 
In recent years, attention has been paid to the design and synthesis of chemical 
chaperones for GBA. Reviews by Benito et al.28 and Jung et al.29 cover some of the classes 
of glycomimetics currently under investigation as GBA chaperones. Many of these are 
reversible competitive, or mixed-type, inhibitors of GBA. The most well-studied chemical 
chaperone so far has been IFG 1, which was the subject of several preclinical studies as 
well as a clinical study that did not fully meet expectations. Ambroxol42-45, a weak, mixed-
type inhibitor of GBA, has been found to augment the enzyme in cultured GD patient 
cells, and following oral administration to patients, an impressive reduction in spleen and 
liver volumes was observed. The beneficial effects of chemical chaperones on GBA in 
cultured cells are generally attributed to improved chaperone-assisted folding of GBA in 
the endoplasmic reticulum. The present investigation suggests an additional beneficial 
mode of action of inhibitors, i.e., the contribution of hydrophobic interactions in the GBA 
aglycon binding pocket to its structural stability and protection against intralysosomal 
proteolytic degradation. 
The evidence for this notion stems from in vitro and in vivo experiments testing GBA 
stabilization by inhibitors. Thermodynamic measurements with pure recombinant GBA 
suggested that all tested inhibitors stabilized the enzyme to a degree that correlates with 
the strength of the inhibition. A modest stabilization of GBA was observed for small 
hydrophilic compounds IFG 1 and conduritol β-epoxide 2. The lipophilic fluoro 3 and 
β-epoxides 4/5 equipped with hydrophobic fluorophores cause a more dramatic increase 
in the melting temperature of rGBA up by 21 °C. Upon complex formation with CBE 2, 
GBA presents a slight shift toward the blue region of its fluorescence spectra, an indication 
of a conformational change, possibly resulting from orientation adjustments of its indole 
groups toward a more hydrophobic environment. A higher shift toward the blue region 
was observed when the protein was in complex with lipophilic ABPs 4 and 5. Presumably, 
their lipophilic tails cause further conformational changes in which the indole groups of 
a tryptophan experience extra hydrophobicity. Of note, equipping cyclophellitol and 
cyclophellitol-aziridine with hydrophobic fluorophore tags markedly increases their 
affnity for GBA33,34. Along the same line, Vocadlo and co-workers developed an elegant 
fluorescence-quenched substrate for GBA by exploiting the fact that GBA accommodates 
the hydrophobic ceramide moiety of glucosylceramide, as it is known that GBA could 
tolerate a hydrophobic modification in the 6-position of glucose46. The designed high-
affinity fluorescence-quenched substrate harbors a fluorophore attached at C6 of glucose 
and the hydrophobic quencher attached to the anomeric site; to a certain extent, it mimics 
fluoro 3 and ABPs 4 and 5. This successful substrate design indicates again that the 
catalytic pocket of GBA accommodates substrates possessing a hydrophobic modification. 
At present, no crystal structure of GBA has been solved in the presence of the fluoro 3 or 
ABPs 4 and 5. However, the crystal structure of GBA in complex with a lipophilic ligand 
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(NN-DNJ, PDB code: 2V3E) shows that GBA loops 1 and 2 become structured and 
undergo interactions with the aliphatic tails of NN-DNJ10. Similarly, upon complex 
formation with 3, 4, and 5, GBA becomes extremely protected against tryptic digestion, 
providing strong evidence of its structural rigidification, presumably by the formation of 
clusters of hydrophobic interactions between the tails of the ABPs and the flexible loops 
in the entrance of the catalytic site of GBA. Therefore, it is presumed that the observed 
differences of the stabilization mechanisms between the tested compounds are mainly due 
to differences in their lipophilic potential. The predominant trypsin cleavage site in GBA’s 
free state is located in a loop (residues 223-241, UniProt: P04062) close to the active site. 
In solution, this loop appears to be accessible for trypsin digestion by adopting a flexible 
conformation that fits within the protease catalytic site. Protease cleavage sites almost 
never occur in rigid secondary structures; they occur largely in flexible loops.47 
Interestingly, within this protein region, 16 mutations have been reported. These have 
been described to dramatically decrease GBA stability and activity, leading to severe GD 
symptoms. For instance, the L224F substitution decreases GBA activity to 4% and 
markedly increases its susceptibility to proteolytic degradation48. Mutation V230E 
dramatically affects GBA activity, leading to type 1 GD disease49. Along this line, the 
G232E mutation was identified in GD patients as well as patients suffering from 
Parkinson’s disease, with the mutation markedly reducing GBA activity (~7%) and 
causing severe type 2 GD50. Moreover, substitution of G234E in GBA’s sequence has 
severe effects on the stability and catalytic activity of the enzyme51. The position of the 
latter mutation overlaps with what it is described here as a major trypsin cleavage site. 
On the basis of those observations, this particular region is plausibly essential for 
maintaining the correct fold of GBA’s catalytic domain. Upon complex formation with 
lipophilic ABPs, this site becomes protected against proteolytic degradation. Recently 
similar stabilization mechanism for another retaining β-glucosidase, 
endoglycoceramidase II (EGCII) from Rhodococcus sp52 was noticed. The stability of 
EGCII was found to be improved by the formation of covalent complexes with 
cyclophellitols substituted with hydrophobic moieties. The tested compounds induced a 
more compact conformation of the flexible protein structure, revealed by an increased 
EGCII melting temperature, resistance against tryptic digestion, changes in its NMR 
spectrum, and a decrease of its exposed hydrophobic surface to the solvent, as determined 
by 8-anilino-1-naphthalenesulfonic acid fluorescence. Stabilization of the conformation 
of EGCII was correlated with the shape and hydrophobicity of the cyclophellitols 
substituents. The structural comparison between GBA and EGCII showed a remarkable 
overlap of their glycon and aglycon binding pockets52. Therefore, the EGCII study 
supports the proposed stabilization mechanism of inhibitors on the structure of GBA. 
Following the observed in vitro stabilization of GBA by inhibitors, This study was extended 
to living cells and mice. It is consistently noted that exposing cells (monocyte-derived 
macrophages and skin fibroblasts) and mice to cyclophellitol ABP 4 or 5 resulted in the 
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accumulation of GBA with a molecular weight of approximately 58 kDa, suggestive of 
lysosomal localization. Co-incubation of fibroblasts with ABPs and leupeptin, a broad 
lysosomal cysteine protease inhibitor known to inhibit the proteolytic breakdown of GBA, 
indicated that the stabilizing effect could indeed be partly ascribed to reduced lysosomal 
breakdown. Of note, the beneficial action of catalytic pocket occupancy by amphiphilic 
inhibitors on the stability and proteolytic resistance of GBA was also observed for N370S 
and L444P, two common mutations in GD. Clearly, irreversible covalent inhibitors 4 and 
5 are of no use in the treatment of GD. However, they are valuable tools to establish the 
contribution of hydrophobic interactions to GBA stabilization and to selectively label the 
active form of GBA within living cells and laboratory animals. Fluoroglucosides, designed 
by Withers and co-workers53, in theory may be more attractive as chaperones since they 
initially covalently bind to the catalytic nucleophile of a retaining glycosidase but are 
ultimately released. Therapeutic application of such compounds in patients will, however, 
offer the major challenge of dosing the inhibitor adequately to reach concomitant 
beneficial effects in all tissues: under-dosing in a tissue will be without effect and 
overdosing will cause undesired loss of degradative capacity in addition to GBA activity 
inhibition. It should also be mentioned that the natural substrate glucosylceramide may 
assist in the stabilization of GBA in lysosomes. In that case, intralysosomal GBA levels 
would be higher during high substrate flux, and the prolonged absence of substrate would 
promote the degradation of the enzyme. It will be of interest to examine whether a 
reduction of glycosphingolipids in cells by inhibition of glucosylceramide synthase activity 
is associated with increased lysosomal turnover of GBA.  
In conclusion, GBA is significantly stabilized by the dual occupancy of its glycon and 
aglycon binding pockets by amphiphilic inhibitors, likely in part by promoting a global 
structural compactness of the enzyme associated with reduced susceptibility for 
proteolytic cleavage by lysosomal proteases. The findings of this study reveal new insights 
into the mechanism of stabilization by pharmacological chaperones that could be further 
exploited in the design of new compounds to rescue GBA proteostasis in GD patients. 
Material and Methods 
General Methods 
Isofagomine 1, fluoro 3, and ABPs 4 and 5 were synthesized as described previously34,35,54. 
Chemicals were obtained from Sigma-Aldrich if not otherwise indicated. Recombinant 
GBA (rGBA, imiglucerase) was obtained from Genzyme (Cambridge, MA, USA). 
Gaucher patients were diagnosed on the basis of reduced GBA activity and 
demonstration of an abnormal genotype. Fibroblasts were obtained with consent from 
donors. Cell lines were cultured in Ham’s F12/DMEM (Invitrogen) supplemented with 
10% (v/v) FBS. Monoclonal anti-human GBA antibody 8E4 was produced from 
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Cerezyme Purification 
rGBA (imiglucerase) was supplied as a sterile white lyophilized powder in the presence of 
mannitol and polysorbate 80 NF as stabilizer substances. Thorough purification of rGBA 
from its additives was conducted by affinity chromatography using a Concanavalin A-
Sepharose column, eluting with a 30-min gradient of 0-1 M mannoside in 150 mM 
McIlvaine buffer (citric acid-Na2HPO4, pH 5.2). Next, an additional purification step was 
performed on pooled fractions using size-exclusion chromatography (Superdex 75), and 
elution occurred either with 150 mM McIlvaine buffer (citric acid-Na2HPO4, pH 5.2) or 
with 20 mM Tris-HCl, pH 7.4, supplemented with 150 mM NaCl. rGBA was 
concentrated using Amicon Ultra-4 centrifugal filter devices (30 kDa cutoff) and kept at 
4 °C for further experiments. 
Limited Proteolysis 
Tryptic digestion of purified rGBA with or without reversible or irreversible inhibitors 
was performed at 37 °C either in 150 mM McIlvaine’s buffer (pH 5.2 or 7.4) or in 20 mM 
Tris-HCl, pH 7.4, supplemented with 150 mM NaCl, using a trypsin/rGBA ratio of 1/10 
(w/w) as the optimum conditions for proteolysis. Digestions were stopped with cracking 
buffer (50 mM Tris-HCl, pH 6.8, supplemented with 1% (w/v) SDS, 25% (v/v) glycerol, 
1% (v/v) β-mercaptoethanol, and 0.05% (w/v) bromophenol blue), immediately followed 
by heating for 10 min at 100 °C. The tryptic digestion products (1.5-5 μg) were separated 
by SDS-PAGE and analyzed by Coomassie staining or, where stated, by fluorescence 
scanning (see below). To check the effect of acidic and neutral pH on trypsin activity, we 
used EGCII as a control. The same proteolysis conditions (see above) were applied with 
an optimum trypsin/EGCII ratio of 1/ 100 (w/w). 
Tryptophan Fluorescence 
rGBA (50 μM) was preincubated with 1 mM IFG 1 or fluoro 3, 10 mM conduritol β-
epoxide 2, or 100 μM cyclophellitol ABP 4 or 5 in 150 mM McIlvaine’s buffer (citric 
acid−Na2HPO4, pH 5.2, supplemented with 0.2% (w/v) sodium taurocholate and 0.1% 
(v/v) Triton X-100) for 3 h at 37 °C. Fluorescence decay curves were obtained by diluting 
the rGBA-inhibitor complex to 1 μM in Nanopure H2O, followed by determination of 
tryptophane fluorescence (λEX 295 nm, slit width 5 nm; λEM 345 nm, slit width 5 nm) while 
the sample temperature was increased at a rate of 1.5 °C per minute. Sample temperature 
was controlled via a PTP-1 Fluorescence Peltier system (PerkinElmer). We defined the 
inflection point of the temperature-induced decrease in tryptophan fluorescence intensity 
as the melting temperature (Tm). This value was determined by taking the minimum value 
of the first-derivative of the slope, at which the negative slope is maximal, using GraphPad 
Prism 5.1. Tryptophan emission fluorescence spectra were mapped using λEX 295 nm (slit 
width 5 nm) and scanning emission at λEM 300−470 (slit width 5 nm; Cary Eclipse 
fluorescence spectrophotometer, Agilent Technologies). Samples were composed of 5 μM 
purified rGBA with or without 2, 4, or 5 in 10 mM potassium phosphate buffer (K2HPO4-
KH2PO4, pH 7.4) supplemented with 150 mM NaCl. Spectral backgrounds were 
corrected and smoothed using Cary Eclipse fluorescence spectrophotometer software. To 
obtain the different protein-inhibitor complexes, purified rGBA was preincubated with 
inhibitors in excess for 3 h at 37 °C in 150 mM McIlvaine buffer. After labeling, excess 
irreversible inhibitor was removed via buffer exchange into 10 mM potassium phosphate 
buffer using Centriprep filter devices (30 kDa cutoff). 
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Circular Dichroism 
Spectra were recorded on a Chirascan CD spectrometer (Applied Photophysics). Far-UV 
CD spectra were recorded from 180 to 300 nm in a 1 mm path length quartz cuvette 
(Hellma) at 20 °C at a concentration of ca. 10 μM. Spectra were collected for 0.5 s per 
data point at a 0.5 nm step size (spectral bandwidth was 1 nm) and were corrected for 
background signals. A Peltier element was used to control the sample temperature and 
allow the temperature to be ramped at 1 °C per minute. The intensity of the CD signal 
was monitored at various wavelengths (204, 215, and 235nm). The unfolding transition 
point (Tm) of free purified rGBA at different pH values (5.2 or 7.4) was measured by 
following the ellipticity signal decay at 222 nm by applying a heating rate of 1 °C per 
minute over a temperature gradient from 30 to 80 °C in 10 mM potassium phosphate 
buffer (K2HPO4-KH2PO4, pH 5.2 or 7.4), supplemented with 150 mM NaCl. The 
melting curves were fitted, and the Tm’s were calculated using GraphPad Prism 5.1. 
Enzyme Activity Assays 
The residual β-glucosidase activity associated with GBA was assayed at 37 °C by 
incubating samples with 3.75 mM 4-methylumbelliferyl-β-D-glucopyranoside (4MU-β-
D-Glc) as substrate in 150 mM McIlvaine buffer, pH 5.2, supplemented with 0.1% (w/v)
BSA, 0.2% (w/v) sodium taurocholate, and 0.1% (v/v) Triton X-100.56 The half-
maximal inhibitory concentrations (IC50) of compounds 1-5 were measured as published
previously54. The time-dependent decay of rGBA activity was assessed by incubating
rGBA for 0-60 min at 37 °C, and at various time points, the residual rGBA activity was
assessed by adding substrate. Assays were stopped with excess NaOH−glycine (pH 10.3),
and fluorescence was measured with a LS30/LS55 fluorimeter (PerkinElmer) using λEX 
366 nm and λEM 445 nm.
Isolation and Maturation of Macrophages. 
Buffy coats were diluted into PBS supplemented with 0.1% (w/v) BSA and heparin, 
subsequently layered on top of a Lymphoprep gradient (Stemcell Technologies), and 
centrifuged at 1000g for 15 min at room temperature (RT). After washing the peripheral 
blood mononuclear cell pellets with PBS supplemented with 0.1% (w/v) BSA, cells were 
centrifuged at 750g for 10 min at RT and rinsed, and this was repeated at 500g for 5 min. 
Hereafter, the pellet was washed with aforementioned PBS and centrifuged at 250g for 
10 min at RT. Then, monocytes were separated on a Percoll gradient. The resulting pellet 
was resuspended in 2.5 mL of 60% (w/v) SIP, layered with 5 mL of 45% (w/v) SIP and 
2.0 mL of 34% (w/v) SIP, and centrifuged at 1750 g for 45 min at RT. The upper 
interface containing monocytes was washed thrice with the aforementioned PBS, 
centrifuged at 500g for 10 min, and then centrifuged twice at 500g for 5 min. The cell 
fraction was then resuspended in RPMI medium supplemented with 1% (w/v) human 
serum; the monocytes were counted with tryphan blue staining, and106 monocytes were 
seeded per well. After 1 h at 37 °C in a 5% (v/v) CO2 atmosphere, non-adherant 
nonmonocyte cells were washed away with the aforementioned PBS and the adherent 
monocytes were cultured in RPMI medium supplemented with 10% (v/v) human serum 
for 7 days prior to experiment initiation. 
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Continuous β-Epoxide ABP 5 Pulse in Human Monocyte-Derived 
Macrophages 
Human monocyte-derived macrophages were switched to X-VIVO 15 medium (Lonza) 
lacking human serum and continuously pulsed with 100 nM β-epoxide ABP 5. After 0-
192 h (8 days), cells were washed extensively with PBS and lysed by scraping them in 25 
mM potassium phosphate buffer (pH 6.5, supplemented with 0.1% (v/v) Triton X-100 
and protease inhibitor cocktail (Roche). Protein concentrations were determined, and 10 
μg of total protein (20 μL) was denatured with 5× Laemmli buffer (50% (v/v) 1 M Tris-
HCl, pH 6.8, 50% (v/v) glycerol, 10% (w/v) DTT, 10% (w/v) SDS, 0.01% (w/v) 
bromophenol blue), boiled for 4 min at 100 °C, and separated by electrophoresis on a 
7.5% (w/v) SDS-PAGE gel running continuously at 90 V.34,35.54-56 Wet slab gels were 
scanned for fluorescence using a Typhoon variable mode imager (Amersham Biosciences) 
using λEX 488 nm and λEM 520 nm (band pass filter 40 nm) for green fluorescent fluoro 
ABP 3 and β-epoxide ABP 4 and λEX 532 nm and λEM 610 nM (band pass filter 30 nm) 
for red fluorescent β-epoxide ABP 5. ABP-emitted fluorescence was quantified using 
ImageJ software (NIH, Bethesda, USA) and verified in-gel by the presence of 50 fmol of 
equimolar green β-epoxide ABP 4- and red ABP 5-labeled imiglucerase. After 
fluorescence scanning, SDS-PAGE gels were fixed (50/40/10 MeOH/H2O/HAc) for 1 
h, stained for total protein (50/40/10 with 1% (w/v) CBB-G250), and destained 
(45/45/10). Coomassie brilliant blue-stained gels were scanned on a flatbed scanner. 
Determination of in Situ IC50. 
Confluent human skin control fibroblasts with wild-type GBA were incubated with 0-100 
μM IFG 1, 0-10 μM fluoro ABP 3, or 0-100 nM β-epoxide ABP 4 for 2 h at 37 °C, and 
GBA-associated β-glucosidase activity was subsequently determined by incubating them 
in the presence or absence of 250 μM fluorescein-di-β-D-glucopyranoside (FDG) for 1 h 
at 37 °C. Next, cells were suspended by trypsinization, fixed in 3% (w/v) p-formaldehyde, 
and analyzed by FACS using the FL1 channel (λEX 488 nm) of a FACSCalibur (BD 
Biosciences). In the case of reversible inhibitor 1, all procedures, including washing with 
PBS, occurred in the presence of 1 at the concentration employed during the in situ 
incubation. 
Pulse-Chase of Exogenous GBA 
rGBA (imiglucerase, 50 μM) was incubated with(out) 100 μM ABP 4 for 1 h in 150 mM 
McIlvaine buffer, pH 5.2, supplemented with 0.2% (w/v) sodium taurocholate and 0.1% 
(v/v) Triton X-100, at 37 °C and cleaned three times over a 30 kDa cutoff filter with PBS. 
Mature human monocyte-derived macrophages were incubated with 300 μM 2 for 2 h; 
cells were the washed extensively with PBS, incubated with 100 nM rGBA (control) or 4-
labeled rGBA with for 30 min at 37 °C, and again washed extensively; the medium was 
then refreshed. After 0-48 h, cells were again washed extensively with PBS and lysed by 
scraping in 25 mM potassium phosphate buffer (pH 6.5, supplemented with 0.1% (v/v) 
Triton X-100 and protease inhibitor cocktail (Roche). Protein concentrations were 
determined in the lysates, and of the control rGBA-treated cells, 10 μg of total protein 
was labeled in vitro with 1μM β-epoxide ABP 4 in McIlvaine buffer, pH 5.2, and with 
supplements, for 1 h at 37 °C. Finally, samples were denatured, and 4-labeled proteins 
were visualized by fluorescence scanning of the SDS-PAGE slab gels. ABP-emitted 
fluorescence was quantified using ImageJ software (NIH, Bethesda, USA), vide supra. 
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Pulse-Chase of GBA in Living Animals. 
The appropriate ethics committee for animal experiments approved all experimental 
procedures. C57BL/6J mice were obtained from Charles River (Wilmington, MA, USA) 
and fed a commercially available lab diet (CRM(E), Special Diet Services, UK). Two 
male C57BL/6J mice were injected intravenously via the tail vein with a single dose of 
100 μL of PBS, four were injected with 100 μL of PBS containing 100 pmol of ABP 4 (~2 
μg kg-1) 6 weeks prior to sacrifice, and four mice received the same dose every 48 h for 15 
days prior to sacrifice. At the termination of the experiment, the mice were anesthetized 
with FFM mix (25/25/50 fentanyl citrate/midazolam/H2O) and then perfused via the 
heart into the aortic root with PBS, flowing at 3.0 mL min-1, using a syringe pump 
(Harvard apparatus, Holliston, MA, USA). The liver was collected and directly frozen in 
liquid nitrogen. Homogenates were made in 25 mM potassium phosphate buffer, pH 6.5, 
supplemented with 0.1% (v/v) Triton X-100, and ABP 4-labeled GBA in 10 μg of total 
protein was analyzed via SDS-PAGE. After fluorescence scanning, SDS-PAGE gels were 
fixed and stained with CBB, vide supra. 
Pulse-Chase of Normal and Gaucher Patient Skin Fibroblasts 
Confluent human skin fibroblasts homozygous for wild-type, N370S, or L444P GBA were 
cultured with medium supplemented with 100 nM ABP 5, 100 μM leupeptin, or both 
components. Medium was completely refreshed every fortnight, and after 0-12 days, cells 
were lysed by scraping in 25 mM potassium phosphate buffer (pH 6.5, supplemented with 
0.1% (v/v) Triton X-100 and protease inhibitor cocktail (Roche). After determination of 
the protein concentration, 10 μg of total protein was incubated with 100 nM ABP 4 (if 
fibroblasts were not treated by β-epoxide ABP 5 in situ) dissolved in 150 mM McIlvaine 
buffer (pH 5.2, supplemented with 0.2% (w/v) sodium taurocholate, 0.1% (v/v) Triton 
X-100, and protease inhibitor cocktail (Roche) for 1 h at 37 °C. Finally, samples were
analyzed by SDS- PAGE on two gels: one for fluorescence scanning followed by CBB 
staining and one for western blotting; this was accomplished by transferring the protein
in the gel to a membrane for 1 h at 12 V, followed by blocking the membrane with 2%
(w/v) BSA in TBST buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% (v/v) Tween-
20), incubating the membrane with a 1:1000 diluted primary mouse α-human GBA
monoclonal antibody (8E4, 2% (w/v) BSA in TBST), washing with TBST for 20 min
(repeated 6 times), incubating with a 1:10000 diluted secondary rabbit α-mouse IRD680
antibody (Cell Signaling, 2% (w/v) BSA in TBST), subsequent washing with TBST for
20 min (repeated 6 times), and reading the signal on an Odyssey infrared scanner (LI-
COR). Fluorescence emitted by either ABP-labeled proteins or antibodies was quantified
using ImageJ software (NIH, Bethesda, MD, USA), vide supra.
In Situ Treatment with IFG 1 or Fluoro 3. 
Confluent human skin fibroblasts homozygous for wild-type, N370S, or L444P GBA were 
incubated for 12 days with 100 nM ABP 5, 100 μM leupeptin, or both or with 0.001-100 
μM IFG 1 or fluoro 3. Medium was completely refreshed every fortnight, and samples 
were treated as described earlier, vide supra. 
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Abstract 
 
H11 xylanases are a family of b-glycosidases involved in the degradation of 
hemicellulose, one of the major components of renewable biomass. This 
family of enzymes has attracted increased attention due to their potential 
industrial applications, especially in biofuel production. To explore the conformational 
landscape and the dynamics of GH11 xylanases during catalysis, Bacillus circulans (BCX) 
xylanase was used as a model. By combining paramagnetic NMR spectroscopy with Carr-
Purcell-Meiboom-Gill relaxation dispersion (CPMG RD) techniques, the millisecond 
dynamics and conformational changes of BCX in each step of its catalytic reaction were 
studied. To study the Michaelis-Menten complex a catalytically inactive variant of BCX 
was used in the presence of xylohexaose (X6); the glycosyl-enzyme intermediate was 
trapped using a novel epoxide compound, epoxy-Xylobiose (epoxyX2) that forms a stable 
adduct with the nucleophilic residue. The last step of the reaction, the product release, 
was studied in the presence of xylobiose (X2). In the free state, the protein adopts a ground 
state that resembles its crystal conformation showing millisecond dynamics in its “fingers” 
and “thumb” regions. Substrate binding to BCX follows an induced fit mechanism as 
revealed from the NMR titration data. The exchange rate between the open bound and 
the closed bound protein conformations is in the range of its substrate turnover rate, 
suggesting a role for such movement in the enzymatic reaction. Both of the enzyme bound 
states conformations are different from the one of the free state, as revealed by PCS data. 
Structural differences are located within the b-strands and the thumb that sculpture the 
enzyme binding cleft. X6 binding induces a global enhancement of the protein 
millisecond dynamics for the same regions that experience conformational changes. Such 
millisecond dynamics enhancement might reflect the role played by the protein motion 
in substrate positioning and sugar rings distortion.  
In the covalent glycosyl-enzyme complex dynamics in the millisecond timescale is similar 
to that of the free enzyme. Nevertheless, covalent complex formation causes significant 
conformational changes located in the thumb and in the vicinity of the catalytic residues, 
as revealed by chemical shift perturbations and PCSs. In the product enzyme complex, 
the protein experiences subtle conformational changes compared to its free state, yet 
significant changes of its dynamic behaviour are observed. It is hypothesised that the 
protein motion in its product complex is playing a role in product dissociation from the 
catalytic site. 
The protein ground states in the Michaelis-Menten and in the product complexes sample 
excited states that share a similar conformation with the glycosyl-enzyme complex ground 
state, which is suggested by the correlations between the chemical shift changes derived 
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In summary, BCX samples at least five ground states during catalysis and the rate limiting 
step of the reaction is possibly due to the high energy barrier that separates the adopted 
conformations in the Michaelis-Menten complex. The protein grounds states are 
connected by an excited state that resembles the intermediate state conformation.  
 To be submitted for publication 
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Introduction 
hemical reactions in living organisms occur at an ominously higher rate than 
their spontaneous counterparts as a result of a decrease of the transition state 
energy of the reaction by highly sophisticated catalysts called enzymes. In the 
past decades, understanding enzyme function has been revolutionized by 
determining snapshots of their 3D structures at an atomic resolution using X-ray 
crystallography, paving the way for describing their structure/function relationships. 
Despite this great triumph, the obtained static structures cannot always explain the elusive 
catalytic function of enzymes. Later on, it became evident that proteins in general, 
including enzymes, are dynamic entities that sample a large ensemble of conformations 
around an average structure. The time scale of these structural fluctuations in 
combination to their amplitudes and directions have proven to be the missing piece of the 
puzzle necessary to achieve a better understanding of enzyme function. The 
conformational space that can be explored by a protein is referred to its “energy 
landscape” in which its native conformation populates a low-energy state called “ground 
states”, which is in a continuous exchange with higher energy conformations called 
“excited states”1, 2. The exchange kinetics between the protein conformers is dictated by 
the amplitude of the energy barrier that separates the different states. Excited states that 
are separated by a high energy barrier, interconvert on the microsecond to millisecond 
time scale or longer. Those “excited states” have been associated with enzyme molecular 
function, including ligand binding3, 4 and catalysis 5, 6.  
NMR spectroscopy and X-ray crystallography are the techniques of choice to determine 
the protein ground state structures. However, each technique has its limitations and 
challenges, for instance structure calculation by NMR spectroscopy remains a laborious 
method limited by the protein size and the quality of its NMR spectra. X-ray 
crystallography does not always capture the in-solution conformation of the ground state, 
due to crystal packing artefacts. Moreover, in the presence of their ligands, enzymes can 
experience conformational changes in solution that may not be visible in the crystalline 
state. Recently, paramagnetic NMR spectroscopy has emerged as an approach that 
bridges both techniques by providing structural restraints in solution that can be used to 
validate protein conformations in the crystalline state7. For instance, pseudocontact shifts 
(PCSs) provide long range restraints. They are caused by magnetic susceptibility 
anisotropy of a paramagnetic metal ion, described by a tensor, the Δχ-tensor7. PCSs have 
been used in crystal structure refinement8 and also exploited to determine the structure 
of a short-lived enzyme intermediate state9. These advanced applications of PCSs in the 
field of structural biology benefit from rigid lanthanide tags such as CLaNP-510. On the 
other hand, the characterisation of the excited state conformers and the understanding of 
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to their short lifetime and their lowly populated fraction compared to the ground state. 
By virtue of the recent development of NMR spectroscopy techniques it is possible now 
to probe those “invisible” states and characterize their thermodynamics and kinetics 
properties. One of the most successful techniques is the Carr-Purcell-Meiboom-Gill 
relaxation dispersion (CPMG RD)11, 12. It has been applied to dissect the energy landscape 
of enzymes during catalysis in combination with lower resolution techniques13-15. 
However, the most successful RD studies profited from the availability of enzyme 
conformations of consecutive steps of catalysis captured in the crystalline state, a situation 
that is not accessible for most enzymes13, 15.  
One of the prominent enzyme classes in nature are glycosyl hydrolases (GHs), which are 
classified in more than 140 families in Cazy the database16. GH11 xylanases are GHs able 
to hydrolyse the endo b-1-4-glycosidic link of xlyan polymers, the main components of 
hemicellulose and the second most abundant renewable biomass material17. This family 
of enzymes attracted an increasing attention in the last decades due to their potential 
applications in industry and, especially, in biofuel production18. Therefore, the quest to 
find the optimum conditions for their large-scale industrial applications has boosted 
research to understand their structure/function relationship. GH11 xylanases have a 
characteristic fold, a b-jelly roll fold with a highly conserved amino acid sequence for the 
residues lining the binding site. The superposition of more than forty available crystal 
structures from different organisms revealed a remarkable conservation of the b-jelly roll 
domain topology as indicated by the small Ca atom RMSD (<1.5 Å)19. The overall shape 
of the GH11 fold is often compared to a right-hand fist. It includes  b-strands A which 
are nearly planar and distorted at the end to form a “hand palm” and “fingers”, and b-
strands B perpendicular to b-strands A, sculpting the binding cleft and including the 
“thumb” region. The two sides of the cleft are connected by a long loop called the “cord”. 
The fold includes a single a-helix, sitting under the b-strands B structure (Figure 4.1a). 
The topographical properties of the catalytic cleft of GH11 xylanases are highly 
conserved with an approximate depth of 9 Å, a width of 4 Å and length of 25 Å. The 
position of the catalytic dyad in the middle of catalytic cleft is in agreement with their 
endo catalytic mechanism. The thumb region displays a well-structured classical hairpin, 
containing a type I b-turn with six internal hydrogen bonds. Among GH11 members the 
primary structure of this loop is conserved, suggesting a key role for function20. One of 
the best characterized GH11 xylanases member is the endo b-1-4 xylanase from Bacillus 
circulans (BCX). This enzyme has been extensively studied by X-ray crystallography21 and 
NMR spectroscopy22 due to its low molecular weight (20 kDa, like other GH11 members) 
and its apparently rigid and globular structure. The binding cleft of BCX has at least 
three (-) subsites (glycon binding site) and three (+) subsites (aglycon binding sites) 
according to the nomenclature of Davies et al.23. The glycosidic bond hydrolysis of xylan 
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polymer takes place between the -1/+1 subsites with a substrate binding in at least the -
2/-1 and +1 subsites in accordance with the protein endo catalytic mechanism.  
BCX, like other GH11 members, employs the “Koshland” double displacement 
mechanism with a catalytic nucleophile and acid/base for catalysis24. After substrate 
binding within the enzyme binding cleft (ES complex), a nucleophilic attack by the 
catalytic amino acid to the anomeric carbon of the glycosidic substrate occurs. 
Concomitantly, a proton transfer from the acid/base residue followed by departure of the 
leaving group from the aglycon site takes place during the first catalytic phase, from which 
an enzyme-glycoside covalent intermediate results (EI complex). In the next phase, an 
activated water molecule acts as a nucleophile with the assistance of the general acid/base 
to deglycosylate the catalytic residue through an oxocarbenium ion transition state. The 
final step is the product release from the enzymatic pocket (EP complex) (Figure 4.1b). 
The chemistry behind this hydrolysis function is widely accepted. Although several 
studies, mainly based on molecular dynamics calculations25-27 have provided some 
insights, a complete understanding of the conformational changes and dynamics of BCX 
during catalysis is still lacking. For instance, molecular dynamics simulations have 
suggested the opening of the thumb loop to induce the product dissociation25-28. The only 
evidence of a full opening of the thumb was observed in the case of a xylanase mutant 
from B. subtilis in the crystalline state29. A recently published study of GH11 xylanase 
millisecond time scale dynamics using the CPMG RD technique showed that the protein 
in its free form experiences a millisecond motion for multiple residues localized within the 
binding site30. In the presence of its substrate (ES), an enhancement of the millisecond 
(ms) time scale motion was observed30. This study has provided the first evidence of such 
dynamics behaviour in GH11 family enzymes. A thorough MD investigation on GH11 
family enzymes was undertaken in XYNII from Trichoderma reesei. 31. By combining the 
different crystal structures of the enzyme, it was proposed that the protein samples three 
sequential substates during its catalytic reaction. First, the protein adopts an open state to 
accommodate the substrate in the cleft. Substrate binding induces a closed conformation 
necessary for positioning the substrate into the correct configuration for glycosidic bond 
hydrolysis. The last state is a loose structure from which the product is released. The study 
provided a first model for the enzyme catalytic cycle based on the available crystal 
structures, which still needs to be validated with in solution studies.  
In the present work, paramagnetic NMR and CPMG RD techniques were combined to 
characterize GH11 xylanases in each step of their catalytic cycle using BCX as a model. 
First, the in-solution average conformations of the enzyme in its Efree as well as ES, EI 
and EP forms were studied by PCSs. To characterize the ES complex, a silenced version 
of the enzyme was generated by substituting the E78 nucleophile with a glutamine in the 
presence of xylohexose (X6). The EI complex was trapped by a novel compound epoxy-
xylobiose (epoxyX2) that mimics closely the intermediate state of the reaction and forms 
a covalent adduct complex with the enzyme. The EP ground state conformation was 
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studied in the presence of xylobiose (X2) that appears to bind only to the -1/-2 subsites, 
thus emulating the last step of the reaction. The dynamic behaviour of each complex, 
separately, was also studied using CPMG RD, aiming to uncover the link between the 
ground and excited states. The implications for BCX catalytic function are discussed.  
Figure 4.1. GH11 fold and catalytic mechanism. (a) b-jelly roll fold of Bacillus circulans xylanase with b-strands 
numbering. Glycon and aglycon binding sites of BCX binding cleft are indicated in arrows. The catalytic dyad 
in the middle of the binding cleft are shown in sticks. (b) General retaining b-glycosidases mechanism. 
Results 
BCX free state (Efree) in solution conformation 
To investigate BCX conformational state in solution with an atomic resolution, 
pseudocontatct shifts (PCSs) were used. BCX PCSs were obtained by preparing 
diamagnetic and paramagnetic NMR samples through the attachment of Lu-CLaNP-5 
and Yb-CLaNP-5 to 15N labelled BCX T109C/T111C double mutant, respectively. The 
choice of the double mutations positions was based on the rigidity of the region and its 
exposure to the surface, as suggested by the protein crystal structure32. Positions for which 
the distance between the Cα atoms was between 8 to 10 Å, in accordance with the 
standard for CLaNP512 were selected, to warrant correct attachment of the lanthanide 
tag to the protein. A few double cysteines mutants at different positions were generated 
and tested for expression yield and stability and the optimal one was identified to be 
T109C/T111C (Figure 4.2).  
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The backbone nuclei of the diamagnetic and paramagnetic spectra were assigned using 
the wild type assignment24. By calculating the chemical shift differences between the 
paramagnetic and diamagnetic spectra 127 PCSs were obtained (Figure 4.3a). The 
experimental PCSs were used to determine the position of the lanthanoid ion and the size 
and the orientation of the Δχ tensor. The data was fitted to BCX crystal structure (PDB 
ID: 2bvv or 1bcx)32 and the lanthanoid position was ~ 8 Å from the Ca atoms of both 
cysteines, which is in agreement the previously reported distances10. The magnitudes of 
the axial and rhombic parts of the tensor were determined to be 8.3 ± 0.1 × 10−32 m3 and 
2.1 ± 0.1 × 10−32 m3, respectively. A correlation between the experimental and the 
predicted PCSs from BCX crystal structure was observed with a low Q factor value equal 
to 0.021 including all data (Figure 4.3b). Exceptions are residues G139, W58 and T44 
which show slight deviations from predicted values. Overall, the PCSs are consistent with 
prior studies that revealed BCX is indeed globular and compact, mainly due the extensive 
hydrogen bonds network between its backbone amide groups21, 22. The compact 
conformation of BCX is also supported by study of the pico-nanosecond dynamics33. The 
protein exhibits restricted motion on the probed time scale. Nevertheless, these 
observations do not exclude the possibility of a slower protein motion, on the millisecond 
time scale. 
Figure 4.2. Locations of engineered Cys residue for CLaNP-5 attachment and the lanthanoid position on the 
BCX surface, depicted on the crystal structure (PDB ID:2bvv). BCX is shown in black Ca trace, cysteines in 
grey sticks and the lanthanoid in black sphere. The distances between the cysteines side chains and the 
lanthanoid are indicated. 
Efree dynamics 
To follow the millisecond time scale dynamics of BCX a relaxation dispersion TROSY-
CPMG experiment at 293 K was performed. Forty-three residues show relaxation 
dispersion profiles (Rex > 1 s-1) clustered within the fingers, thumb and palm regions and 
in loops connecting  b-strands 6 and 7 and the ones connecting b-strand 12 to the a-helix 
(Figure 4.3c, d). A global two-site exchange fit of 27 residues with Rex ³ 1.8 s-1 yields an 
exchange rate (kex) between the ground and excited states of 2.5 (±0.09) × 103 s-1 with an 
excited fraction (pB) equal to 0.78 %, suggesting a lowly populated excited state with local 
ms time scale dynamics (Figure 4.4a).  
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Figure 4.3. BCX free state conformation and dynamics in solution. (a) Overlay between BCX free state 
diamagnetic (BCX T09C/T111C-CLaNP-5-Lu3+, blue) and paramagnetic (BCX T09C/T111C-CLaNP-5-
Yb3+, red) spectra. Three PCSs are highlighted with green arrows. (b) Plot of the observed vs. calculated PCSs 
after fitting to the BCX crystal structure (PDB ID:2bvv)32. Blue circles indicate PCSs of with high correlation 
factor (PCS deviation < 0.02) and red circles indicate PCSs of outliers (PCS deviation > 0.02). The dashed line 
represents a perfect correlation. (c) Plot of Rex vs. residue numbers of BCX free state. Residues with Rex ≥ 1 s-1 
are shown in blue bars. The error bars represent the estimated error based on a duplicate measurement of 
different nCPMG frequencies. (d) Amides with 1 s-1 ≤ Re x≤8.5 s-1 shown in spheres on the BCX crystal structure 
(PDB ID: 2bvv) and coloured with a white/blue gradient. Residues with Rex ≤ 1s-1 are shown in grey cartoon. 
Figure 4.4: Global fit of CPMG RD data to a two-state chemical exchange model acquired on two static fields 
(red at 600 MHz and blue at 850 MHz) for (a) Efree; (b) (ES)open; (c) EI; (d) EP. Six residues with the best global 
fit profiles are shown for each state. Residue names are indicated. 
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BCX substrate complex (ES) 
Michaelis-Menten binding 
The first step of any enzymatic reaction is the formation of the Michaelis-Menten 
complex between the enzyme and its cognate substrate. GH11 xylanases binding sites are 
formed by multiple subsites that accommodate at least six sugar units of xylan polymer. 
The subsites are named -1/-2/-3 and +1/+2/+3 for the glycon and the aglycon binding 
cavities, respectively. BCX is able to hydrolyse the glycosidic link (between -1/+1 subsites) 
of at least three xylose units, where two of them have to be accommodated within the -
1/-2 subsites and the remaining one in the +1 subsite. 
To avoid substrate hydrolysis while investigating the Michaelis-Menten complex of BCX, 
the nucleophile residue E78 was substituted by a Q. 1H-15N heteronuclear single quantum 
correlation spectroscopy (HSQC) was used to monitor the titration of the inactive enzyme 
with xylohexaose (X6). The single amino acid substitution did not induce major changes 
of the protein HSQC spectrum, so the mutant assignment was performed using the wild 
peak list and curated by PCSs. Twelve titration points were acquired by increasing X6 
concentration from 0 to 20 mM. Throughout the titration, significant line broadening 
(Figure 4.5a) in conjunction to diverse chemical exchange regimes of the side-chain and 
backbone amides were observed. Line broadening reflects an increase of the global 
tumbling time, which could be due to the changes of the buffer viscosity or due to weak 
self-association induced by X6. Similar observations were made when titrating the 
enzyme with X434. 
Residues N54, A55, N141 and W185 exhibited a fast exchange behaviour (kex >> Dw) 
with progressive chemical changes and significant Ddavg (up to 0.4 ppm) (Figure 4.6.a,c). 
Those residues are located in the “knuckles” of the hand-like protein previously identified 
as a secondary binding site (SBS) of the substrate (Figure 4.6d)34. Peak shape analysis of 
the SBS residues revealed a Kd= 2.8 (±0.01) mM and a koff= 5.7 (±0.12) × 103 s-1. At 3.5 
mM of X6 concentration, several secondary peaks start to appear in a slow exchange 
regime (kex < Dw) some of them appear in the vicinity of the amides primary peaks 
(Figure 4.6b). Among those secondary peaks, 32 were identified to be located within the 
enzyme binding cleft (primary binding site) and others scattered over the protein 
backbone. For instance, residues N8, G12 and K40 of the fingers and residues D119, 
G120, Y166 and V168 located within the thumb loop and its surrounding at the -1/ -2 
/-3 subsites which exhibit clear splitting of their peaks. Moreover, residues of the +1/+2 
subsites, such as Y65 and V81, experience the same phenomena. Variability in the 
linewidth of the secondary peaks was observed (Figure 4.5b). By performing a peak 
shape analysis of the titration data and fitting 16 backbone amides with a secondary peak 
to the “induced fit binding model”, a correlation between the predicted versus the 
experimental peaks positions was obtained (Figure 4.6b). The kd of the binding process 
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is equal to 1.9 (±0.015) mM and the koff= 1.3 (±0.03) × 103 s-1. The fit suggests that the 
ligand binds to the protein through an induced fit mechanism where the ES complex is 
in equilibrium between two conformations (Efree+S®(ES)openÛ(ES)closed) with a kopen and 
kclosed equal to 11 and 9 s-1, respectively. Additionally, residues distal from the enzyme 
binding cleft exhibit also chemical perturbations in the intermediate exchange regime 
(kex»Dw) such as A152 and S155 of the a-helix with respective Ddavg = 0.3 and 0.18 ppm. 
The calculation of the average chemical shift perturbations (Ddavg) between the backbone 
amides of the (ES)open and Efree confirmed the location of the amides with secondary peaks 
in the enzyme binding cleft (Figure 4.6c,e). The most important Ddavg are for residues 
located within the thumb and the finger regions. Residues of the a-helix such as A152 
and S155 experience also large Ddavg in the (ES)open state despite their remote position 
from the primary and secondary binding sites which might suggests changes of the a-
helix conformation upon ligand binding. 
Figure 4.5: BCX E78Q NMR titration with X6 and its ms relaxation. (a) General line broadening of the BCX 
E78Q upon titration with X6. The ratios between R2 values, predicted from the 2D peak shape analysis with 
TITAN, in the absence and the presence of 20 mM X6 from amides peaks that do not shift during titration. 
NH indicate side chain amides. N.a indicate non-assigned backbone amides. (b) the ratios between the (ES)open 
and (ES)closed R2 values of the backbone amides in the slow exchange regime (kex << Dw). (c) Overlay between 
the Rex values of the BCX WT (blue) and the BCX E78Q (black).  
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Figure 4.6. BCX E78Q titration with X6 (ES complex). (a) Experimental versus simulated chemical shift 
perturbations of backbone and side chain amides (NH) in the fast exchange regime (kex >> Dw) that belong to 
the secondary binding site. The simulation was performed using TITAN35 software and the binding kinetics 
parameters are indicated. (b) Experimental chemical shift perturbations of BCX E78Q backbone amides with 
slow chemical regime (kex < Dw) versus their simulated chemical shift perturbations using an induced fit binding 
model. The kinetic parameters are indicated with a scheme of the enzyme-substrate interaction. (c) Ddavg 
between the (ES)open and the Efree plotted versus residue numbers. Ddavg of the secondary binding site amides are 
shown in red bars. (d) Amide groups of the secondary binding sites with Ddavg > 0.05 ppm mapped on the BCX 
crystal structure (PDB ID: 1bcx)21 in spheres and sticks and coloured by the amplitude of the Ddavg using a 
blue/red colour gradient. Residues for which no data were obtained are coloured in green and the ones with 
Ddavg< 0.05 ppm in black. (e) Amide groups of the binding cleft with Ddavg> 0.05 ppm, including amides with a 
secondary peak, mapped on the BCX crystal structure (PDB ID: 1bcx) in spheres and coloured by the amplitude 
of the calculated Ddavg using a blue/red colour gradient. Residues for which no data was obtained are coloured 
in green and the ones with Ddavg < 0.05 ppm in grey. 
ES conformations 
To interrogate the conformational changes of BCX in the ES complex an X6 titration of 
the protein was performed using diamagnetic and paramagnetic NMR samples (1H-15N 
BCX E78Q T109C/T111C tagged with CLaNP5). Similar chemical exchange regimes 
during titration were observed as for BCX E78Q. The chemical shift differences between 
the paramagnetic and diamagnetic NMR spectra of the protein in the presence of 20 mM 
X6 were calculated and 105 PCSs were obtained for the (ES)open. Ten PCSs were also 
calculated for (ES)closed. Fitting of the PCS data vs. the crystal structure of the free protein 
yielded small variations between the tensors obtained for the Efree and (ES)open states 
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(Figure 4.7), suggesting that the lanthanoid moves slightly or the tensor reorients. As the 
structure of the (ES)open state is not available, it was decided that the PCSs were best 
compared using the structure of the free enzyme and the tensor obtained for that state. 
Thus, observed PCSs of the (ES)open were compared to the PCSs predicted from BCX 
crystal structure (PDB ID:2bvv) using the tensor parameters of the Efree state. Eighty-seven 
PCSs show a good fit with the protein crystal and multiple outliers were observed 
(Q=0.115), which suggests conformational differences between the Efree and (ES)open states 
(Figure 4.8a). When mapped on the protein structure, the amides outliers are seen to be 
located within the thumb, the a-helix and the finger regions (Figure 4.8b).  
The PCSs differences (DPCSs) between the (ES)open and Efree were calculated and plotted 
vs. residue numbers (Figure 4.9.c). It reveals that at least five regions of the protein 
backbone experience significant changes of their conformation (|DPCS| > 0.02 ppm) 
upon substrate binding and they are approximately clusters between W9-N20 and T33-
N35 in the fingers; Y65-Y69 in the middle of hand palm close, to the nucleophile catalytic 
residue E78; A115-S117 in the thumb and A165-G173 in the hand palm, which 
accommodates the acid/base catalytic residue. When mapped on the protein crystal 
structure, those regions are spanned all over the protein b-jelly roll fold including the 
fingers, the thumb, the cord, the a-helix and the palm-hand (Figure 4.9d). This suggest 
that upon substrate association, the protein experiences a global conformational change. 
Additionally, by comparing the 10 experimental PCSs of the (ES)open and with their 
counterparts in the (ES)closed, three of them show weak structural correlation between the 
two states (Figure 4.8c). Those residues include D119 located on the tip of the thump 
loop and I107 and V168 positioned deep in the binding cleft (Figure 4.8d). Thus, 
(ES)open and (ES)closed conformations might be also different at least within the thumb and 
hand palm regions.  
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Figure 4.7: Efree, (ES)open, EI and EP tensors parameters and precision. One hundred Δχ tensors generated 
from jackknife analysis within Numbat for Efree (cyan), (ES)open (purple), EI (red) and EP (green) placed at the 
center of a sphere. The locations where the X, Y, and Z components pierce the sphere are indicated. The 
surface of the sphere is shown as a Sanson-Flamsteed equivalent projection with gridlines at every 20° (vertical) 
and 10° (horizontal).  
Figure 4.8. ES conformational states in solution probed by PCSs. (a) Plot of the (ES)open observed vs. 
calculated PCSs after fitting to the BCX crystal structure (PDB ID:2bvv). Blue circles indicate PCSs with high 
correlation (PCS deviation < 0.02) and red circles indicate PCSs of outliers (PCS deviation > 0.02). The dashed 
line represents a perfect correlation. (b) (ES)open observed PCSs mapped on the BCX crystal structure (PDB 
ID:2bvv) shown in spheres. Blue spheres indicate amide residues with high correlation to the back calculated 
PCSs and red spheres represent outliers. Residues with no observed PCSs are shown in grey cartoon. (c) Plot of 
observed PCSs of the (ES)open vs. the (ES)closed states. The dashed line represents a perfect correlation. (d) Amides 
for which the (ES)closed PCS could be measured mapped on the BCX crystal structure (PDB ID:2bvv). The black 
spheres indicate the position of the lanthanide (Yb3+). 
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ES millisecond dynamics 
To investigate the dynamics of BCX in the ES complex, its ms time scale motions were 
probed. Previous study has shown a local change of a BCX protein homologue backbone 
dynamics when substituting the nucleophile with Ala30. In the present study, the 
substitution E78 by Q did not cause significant changes of the protein dynamics behaviour 
(Figure 4.5c). Thereafter, a TROSY-CPMG experiment of BCX E78Q in the presence 
of 20 mM X6 (> 90% saturation of the primary binding site) was acquired. By analysing 
the relaxation dispersion profiles of the backbone amides of the (ES)open, a remarkable 
enhancement of the chemical exchange was observed, as can be concluded from a 
comparison of Rex values between the (ES)open and Efree states (Figure 4.9a). Multiple 
protein regions experience such exchanges located mainly between W6-D11; N31-T43; 
N54-T72; M169-S176 of the fingers and between residues I77-V81 of the hand palm, 
including residue Q78 and T111-S130, covering the thumb region. All of these regions 
are spanning the binding cleft of the enzyme, including both the glycon (-1/-2/-3 subsites) 
and the aglycon (+1/+2/+3 subsites) sites (Figure 4.9b). A two-site exchange global fit 
of 30 dispersion profiles (Rex > 2 s-1) yielded a kex = 741 (±9) s-1 and an excited state 
fraction pB= 9.2 (± 0.2) % (Figure 4.4b). The residues with enhanced Rex are located in 
regions that experience conformational changes in the (ES)open compared to Efree, as is 
revealed by the paramagnetic NMR study. For instance, the observed dynamics 
enhancement in the thumb regions is concomitant with pronounced DPCSs between the 
(ES)open to the Efree states. The same observation is for the fingers, hand palm and the a-
helix (Figure 4.9d).  
The binding of the substrate may enhance the exchange effects already observed for Efree 
by lowering the free energy of the excited state, thus increasing its population. This is in 
line with the observations for the EP state (vide infra). Exchange effects could also be caused 
by the association and dissociation of the substrate and the underlying chemical shift 
perturbations of the Efree and (ES)open states, however at 20 mM X6, the kex for the 
primary and secondary binding sites are 1.3 and 5.7 .104 s-1, respectively. Such fast 
binding and dissociation will affect the RD curves negligibly. It should be noted that the 
PCSs are an average of all conformations that exchange faster than determined by the 
size of PCSs expressed in rad s-1. So, in principle, the observed DPCSs could represent 
the weighted average of the PCSs in the (ES)open ground and excited states. We believe 
that this cannot explain all the DPCSs because the excited state is populated for 9%, 
suggesting that the PCSs for 100% excited state would differ up to 2 ppm from the ground 
state. Such large differences seem unrealistic. 
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Figure 4.9. (ES)open millisecond time scale dynamics. (a) Overlay of the Rex values of (ES)open (red circles) 
and BCX free states plotted versus the residue numbers. BCX regions that experience Rex enhancements are 
highlighted with grey shade bell. (b) (ES)open complex Rex values (> 1 s-1) mapped on the BCX crystal structure 
(PDB ID: 1bcx). Backbone amides with moderate Rex enhancement are shown in small spheres. Residues with 
a large enhancement are labelled and shown in big spheres. The residues are coloured based on their Rex values 
by a blue/yellow/red gradient. (c) |DPCSs| between BCX free state and (ES)open states plotted versus the residue 
numbers to show the correlation between dynamics behaviour and PCSs changes in the (ES)open state. Outliers 
form the PCSs fit to the BCX crystal structure are shown in red bars. Protein regions with |DPCSs| > 0.02 
ppm are highlighted with a grey shade bell. (d) |DPCSs| mapped on the BCX crystal structure. Residues with 
|DPCSs| > 0.02 are shown in spheres and coloured in yellow/green gradient indicating the strength of the 
|DPCSs|. Residues with |DPCSs| < 0.02 ppm are shown in grey cartoon and residues with non-determined 
|DPCSs| coloured in cyan. The black spheres indicate the position of the lanthanoid (Yb3+).
BCX intermediate state (EI) conformation 
Previously, the BCX intermediate state was trapped using a fluorinated substrate 2,4-
dinitrophenyl-2-deoxy-2-fluoro-b-xylobioside (DNP-2FXb)32,33. The fluoride at the C2 
position of the compound destabilizes the oxocarbenium transition state of the reaction, 
thus slowing the deglycosylation step and the good 2,4-dinitrophenolate leaving group 
warrants fast glycosylation of the enzyme. Therefore, the enzyme is trapped into its 
glycosylated form with a complex half-life of ~ 6 h at 40°C (Figure 4.10a). Here, an 
epoxide-xylobiose (epoxyX2) mechanism based inactivator was used to covalently trap 
the enzyme in its EI state. The inactivation mechanism involves the attack of the ligand 
epoxide active center by the enzyme nucleophile, resulting in ring opening and the 
formation of a covalent bond between the enzyme nucleophile and the inhibitor, which 
perfectly emulates EI state of the natural substrate hydrolysis reaction. The process is 
facilitated by protonation of the inactivator reactive center by the general acid/base 
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residue (Figure 4.10b). To generate the covalent complex, BCX was incubated with 
epoxyX2 at 1:20 ratio at 30°C. The reduction of BCX enzymatic activity was monitored 
over time using 4MU-xylobiose. After 4h of incubation no residual activity remained and 
the complex formation was identified by mass spectrometry after discarding the excess 
ligand by buffer exchange (Figure 4.11a). The complex was stable for months at room 
temperature. To investigate the binding site of the ligand within the protein binding cleft, 
a 15N uniformly labelled sample of the EI was prepared for HSQC spectrum acquisition. 
By overlaying the EI with the protein free state spectrum Efree significant chemical shift 
perturbations were observed suggesting changes of the chemical environment of the 
backbone amides, either due to ligand binding or due to conformational changes 
experienced by the protein upon covalent complex formation (Figure 4.11b). 
Due to these substantial chemical shift differences, it was difficult to accurately assign the 
EI spectrum only from the free enzyme peak list, so a 15N 13C double labelled EI sample 
was prepared and used for triple resonance experiments for backbone assignment. In the 
EI spectrum three residues were missing, presumably due to peak broadening, including 
E78, which is supposed to covalently bind to the C1 of the ligand, G70 and S117, which 
are in contact with the -1 subsite xylobiose sugar unit, according to BCX-2FXb crystal 
structure (PDB ID: 1bcx)32. The Ddavg between the Efree and EI states are plotted as 
function of the residue numbers in Figure 4.12a. Several clusters of amides show 
pronounced chemical shift perturbations between 0.1 and 0.6 ppm. Mapping the Ddavg 
on the protein crystal structure (Figure 4.12b) revealed that all of the observed 
perturbations are located within the protein binding site cleft, in the fingers and the thumb 
regions. The most significantly shifted residues are Y79, Y80 and V81, in the vicinity of 
the catalytic nucleophile E78 and also residues G173, Y174 and Q175, close to the 
catalytic acid/base E172. These observations point toward a correct covalent 
modification of the protein E78 nucleophile by the ligand and its correct positioning 
within the enzyme binding site. Although the ligand is supposed to only occupy the -1/ -
2 subsites of the enzyme binding cleft, chemical shift perturbations were also observed in 
the +1/ +2 subsites. The distal chemical shift perturbations suggest changes in the protein 
conformation upon EI complex formation. To establish the presence of conformational 
changes in BCX upon formation of the EI state, diamagnetic and paramagnetic 
uniformly 15N labelled samples of the EI complex were prepared using the procedure 
described above and 122 PCSs were obtained. To be consistent with the analysis of the 
(ES)open state, the observed PCSs of the EI were compared to the PCSs predicted from 
BCX crystal structure (PDB ID:1bcx) using the tensor parameters of the Efree. Multiple 
outliers were observed suggesting that the crystal structure is not a good representation of 
the epoxyX2 structure in solution (Figure 4.12e). Most of the backbone amides PCSs, 
especially the ones in the fingers regions, are well correlated with the back-calculated 
PCSs from the protein crystal structure. Eighteen outliers were observed, mainly located 
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within the thumb region (Figure 4.12f). This suggests a different conformation of the 
thumb region in the EI solution state compared to its crystalline state.  
The differences between the observed PCSs of the EI complex and Efree state (|DPCSs|) 
indicate also structural changes between the two states of the enzyme in solution (Figure 
4.12c). The major |DPCSs| (³ 0.02 ppm) are located within the enzyme binding cleft, 
the thumb and the finger regions, in addition to the C-terminal side of the a-helix (Figure 
4.12d). For instance, residues G70, W71 and T72 and D119 show remarkable DPCSs. 
T72 is next to R73 which is connected to the tip the thumb region through a salt-bridge 
interaction with residue D119, therefore, it is plausible that any conformational changes 
experienced by the thumb results in effects on R73 and surrounding residues. Thus, these 
observations suggest that the thumb in the EI state adopts a different conformation than 
in the free state. W9 shows a DPCS of 0.07 which could stem from its different 
conformational when forming a CH-p stacking interaction with the ligand sugar ring at 
the -2 subsite, as revealed from the BCX-2FXb crystal structure32. The other residues are 
in close proximity to E78, which forms a covalent bond with the ligand. Residues T171 
and Y174 located in the fingers regions of the +1/ +2 subsites also seem to experience 
structural changes in the EI state, being close to E172 acid/base residue. Correlations 
between DPCSs and Ddavg are observed suggesting the simultaneous contributions of 
ligand binding and its induced conformational changes on the protein structure into the 
significant differences between the EI and the Efree HSQCs spectra (Figure 4.12a,c).  
Figure 4.10. EI covalent complex formation by the DNP-2FXb (a) and the epoxyX2 (b). 
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Figure 4.11. BCX-epoxyX2 complex formation. (a) Residual BCX activity monitored over course of 
incubation at 30 °C in the presence of 1:20 (BCX: epoxyX2) ratio. Error bars indicate ±SD of a duplicate. (b) 
1H-15N HSQC spectra overlay of the Efree and EI states.  
Figure 4.12. The BCX-epoxyX2 complex (EI). (a) Ddavg plotted versus BCX residue numbers. Residues 
that have direct interactions with the ligand (according to BCX crystal structure PDB ID: 1bcx) are shown in 
red bars. The positions of the E78/E172 catalytic dyad are market with asterisks. (b) Amino acid residues with 
Ddavg > 0.05 ppm mapped on the BCX crystal structure (PDB ID: 1bcx) and coloured with a blue/red gradient. 
Residues with Ddavg < 0.05 are shown in grey cartoon and the ones with non-determined Ddavg in green cartoon. 
(c) |DPCSs| plotted versus the residue numbers. Outliers of the PCSs fit to the BCX crystal structure are shown
in red bars. The positions of the catalytic dyad are marked with asterisks. Protein regions with |DPCSs| > 0.02
ppm are highlighted with a grey shade bell. (d) |DPCSs| mapped on the BCX crystal structure. Residues with
|DPCS| > 0.02 are shown in spheres and coloured by a yellow/green gradient based on |DPCSs| strength.
Residues with |DPCSs| < 0.02 are shown in grey cartoon and the ones with non-observed |DPCSs| in cyan
cartoon. The black sphere indicates the position of the lanthanide (Yb3+). (e) Plot of the observed EI PCSs vs.
calculated PCSs after fitting to the BCX crystal structure (PDB ID:1bcx) using Efree tensor parameters. Blue
circles indicate PCSs with a deviation < 0.02 and red circles indicate PCSs of outliers (PCS deviation > 0.02). 
(f) EI observed PCSs mapped on the BCX crystal structure. Blue spheres indicate residues with the good
correlation between experimental and predicted PCSs and red spheres indicate the outliers. Amides with non-
observed PCSs are shown in grey cartoon.
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EI dynamics 
The previous study of the EI dynamics was performed for the ns to ps time scale, revealing 
no major changes of the dynamics on the probed time scales compared to its free state33. 
Here, the ms time scale chemical exchange of EI was probed by performing a CPMG 
RD experiment. Thirty-one residues show dispersion profiles (Rex ³ 1 s-1), and these are 
located within the fingers region at the -1/ -2 subsites of the binding cleft in the proximity 
of the acid/base catalytic residue and the E78 nucleophile covalently bound to the ligand 
(Figure 4.13a,b). No chemical exchange was observed in the thumb region. The global 
fit of 15 residues with a Rex ³ 1.8 s-1 revealed a kex =2.05 (± 0.08) × 103 s-1 and an excited 
state fraction pB of 0.6% (Figure 4.4c). A few residues show dynamic enhancement 
compared to the Efree as can be seen from the Rex comparison between the two states 
(Figure 4.13a). The most pronounced changes are for residues I77, R112, T123 and 
T124, which are located in the vicinity of E78 and for residue G173, located next to E172, 
the acid base in the -1 subsites. A lesser Rex increase is observed for residues W9, D11, 
G13 and G14, located in the -2 subsites in direct contact with the non-reducing end sugar 
ring of the ligand (Figure 4.13c). Concomitantly, residues T72, R73 and S74, located 
in a loop that connects the tip of the thumb to b-strands 6 and 7, show a reduction of 
their chemical exchanges, presumably as a result of the decrease of the thumb motion by 
ligand binding. Those residues also experience local conformational changes as 
concluded from their DPCSs (see above). As a conclusion, in the EI state the protein does 
not experience global dynamics changes, but it seems to assume local conformational 
changes, mainly located inthe fingers and the thumb at the aglycon binding site, where 
the ligand is covalently bound. However, few local chemical exchange enhancements 
were observed for residues surrounding the nucleophile and acid/base catalytic dyad 
presumably as a result of the covalent ligand binding. A slight reduction of the thumb and 
its surrounding loops in the ms time scale motion is noticed compared to Efree in solution 
(Figure 4.13c). The ms dynamics and PCSs studies suggest a different EI in solution 
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Figure 4.13. EI millisecond time scale dynamics. (a) Overlay between the Rex values of the EI complex 
state (red circles) and Efree state plotted against the residue numbers. Regions that show differences of Rex 
between the two states are highlighted with a grey shade bells. (b) EI complex Rex values (> 1 s-1) mapped in 
spheres on the BCX crystal structure (PDB ID: 1bcx) and coloured in a white/blue gradient. Residues with Rex 
< 1 s-1 are shown in grey cartoon. E172 and E78 are shown in sticks and coloured in green and red, respectively. 
(c) Residues that show an Rex enhancement or reduction in the EI state are mapped on BCX crystal structure
(PDB ID:1bcx) and shown in pink and blue spheres, respectively. The catalytic dyad E78 and E172 are displayed
in stick and coloured in red and green, respectively. Residues in the proximity of the catalytic dyad are indicated
in asterisks. The DNP-2FXb ligand of BCX crystal structure is displayed in sticks32. 
BCX product (EP) complex conformation 
The last step of xylanases enzymatic reaction is the product release from the -1/-2 /-3 
subsites of the enzyme binding cleft. The binding mode of the product X2 in BCX cleft 
was monitored by an NMR titration using 1.3 mM, 13 mM, 65 mM and 130 mM ligand 
concentrations. The observed Ddavg are in the fast exchange regime, exhibiting progressive 
chemical shift changes. In contrast to the ES state, neither line broadening nor the 
appearance of secondary peaks was observed at high substrate concentration. Residues 
in the vicinity of the nucleophile and acid/base catalytic dyad at the -1/-2 subsites show 
significant Ddavg, (Figure 4.14a). However, residues of the +1/+2 subsites do not show 
any chemical shift changes, which suggests differences in the binding affinity between the 
glycon and aglycon subsites. Substantial chemical shift changes (> 0.1 ppm) were 
observed for residues of the thumb regions, for instance S117 and D119 and for residues 
T69 and V37 located near the E78 and E172 catalytic dyad, respectively (Figure 4.14b). 
In addition, residues V168 and M169 positioned deep in the middle of the hand palm, 
approximately 10 Å distant from the catalytic dyad experience also significant Ddavg.  
The peak shape analysis of the HSQC spectra confirmed the absence of large peak 
broadening and revealed a dissociation constant of 10 mM and a koff= 3.1(± 0.2) × 103 s-
1. Next, the local conformational changes of BCX upon ligand association were
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investigated. Using the procedure described above, the changes in PCSs in every titration 
point were followed. The observed PCSs of the EP were compared to the PCSs predicted 
from BCX crystal structure (PDB ID:2bvv) using the tensor parameters of the Efree state 
in line with the analysis of the PCSs of the other states. The majority of the 125 PCSs 
correlate well with the predicted ones (Q = 0.077) with a few outliers located in the thumb 
loop (A115, S117, D119 and R122) (Figure 4.14c,d). The |DPCSs| between the free 
and EP states are plotted in Figure 4.15C. |DPCSs| showed dependence on ligand 
concentration and the subtle structural changes upon ligand binding occur in the thumb 
and the a-helix (Figure 4.15c,d). 
Figure 4.14. The EP complex. (a) Ddavg plotted against BCX residues numbers. Positions of the E78/E172 
catalytic dyad are indicated with asterisks. (b) Residues with Ddavg > 0.05 ppm are mapped on the BCX crystal 
structure (PDB ID:2bvv) in spheres and coloured with a blue/red gradient using the maximum Ddavg value 
observed in the EI state as a colour gradient threshold for comparison. The colour gradient position of the 
maximum Ddavg (0.2 ppm) in the EP state is indicated by triangles. Amide residues with Ddavg <0.05 ppm are 
displayed in grey cartoon and the amides with non-determined Ddavg in green cartoon. (c) Observed PCSs vs. 
calculated of the EP state after fitting to the BCX crystal structure (PDB ID:2bvv). Blue circles indicate good 
correlation between the observed PCSs and the back-calculated ones. Red circles indicate outliers (>0.02). (d) 
EP observed PCSs mapped on the BCX crystal structure. Blue spheres indicate the positions of residues with 
good correlation between their observed PCSs and calculated PCSs. Red spheres indicated the structural 
positions of the outliers. Only residues of the protein thumb regions are named.  
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EP dynamics on the millisecond time scale 
The paramagnetic NMR analysis suggests that in the EP state the protein adopts a slightly 
different conformation compared to the free form. However, in the presence of 130 mM 
X2 the protein exhibits a remarkable enhancement of exchange (Rex up to 31 s-1) in 
regions located within and on both sides of the binding cleft. The Rex of the Efree and EP 
states are plotted in Figure 4.15a for comparison. The most significantly affected regions 
are clustered approximately between residues N32-F36 (7 s-1 £ Rex £ 31 s-1), forming a 
loop that connects b-strands 3 and 4 in the -1 subsite of the fingers; between residues Y69-
Y80 (7 s-1 £ Rex £ 21 s-1) in b-strands 7 and 8 of the palm, including the nucleophile E78; 
between R112-Q127 (1.5 s-1 £ Rex £ 31 s-1) that forms the thumb loop and between T171-
S176 that accommodates the acid/base E172 (Figure 4.15b). Other residues remote 
from the active site (S140-T143, positioned on the non-catalytic side of the palm) 
experience smaller exchange effects. A global two-site exchange fit of 36 residues (Rex ³ 
1.8 s-1) yielded a kex = 1.53 (±18) × 103 s-1 and an excited state population of 4% (Figure 
4.4). The peaks shape analysis of BCX titration with 130 mM X2 (> 92% saturation) 
revealed a dissociation rate constant koff = 3.1 (±0.2) × 103 s-1 (see above). At 92% 
saturation, kex can be calculated to be 3.9 × 104 s-1, which is outside the range of CPMG 
RD time window. Therefore, its is assumed that the observed enhancement of the protein 
amide chemical exchange is dominated by structural fluctuations in the EP state rather 
than ligand dissociation. Interestingly, residues like G70 and R112 in the vicinity of E78 
and residues N35 and S117 of the fingers and the thumb loop, respectively, show a 
distinctive increase of their dispersion profiles compared to the free state. N35 and S117 
resides on the top of both side of the binding cleft, separated by ~12 Å distance (Figure 
4.15b). The tremendous enhancement of their Rex might reflect their involvement in the 
structural fluctuation of the binding cleft width while the ligand is associated to the 
protein. Additionally, regions that experience changes of their dynamics properties are 
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Figure 4.15. EP millisecond time scale dynamics. (a) Overlay between the Rex values of EP complex 
state (red circles) and the BCX free state plotted against the residue numbers. BCX regions that experience Rex 
enhancements are highlighted with grey rectangles. (b) EP complex Rex values (> 1 s-1) mapped on the BCX 
crystal structure (PDB ID: 1bcx). Residues with moderate Rex enhancement are shown in small spheres. 
Residues with a remarkable enhancement are shown in big spheres. The residues are coloured based on their 
Rex values by a blue/yellow/red gradient. (c) |DPCSs| between the EP and Efree states plotted against the 
residue numbers. |DPCSs| in the presence of 13 mM X2 are displayed in blue bars; the ones in the presence 
of 65 mM X2 are displayed in green bars and the ones in the presence of 130 mM X2 are in red bars. Protein 
regions that show ligand dependency of their |DPCSs| are highlighted in grey shade bell. (d) Amino acid 
residues with |DPCSs| > 0.02 ppm are shown in spheres on the BCX crystal structure (PDB ID: 2bvv) and 
coloured with a yellow/green gradient. Residues with |DPCSs| < 0.02 are displayed in grey cartoon and the 
ones with non-determined |DPCSs| are shown in cyan cartoon. The black sphere indicates the position of the 
lanthanide (Yb3+). 
Discussion 
BCX substrate binding modes and conformational landscape during 
catalysis 
To investigate BCX substrate binding mechanism and follow its conformational changes 
during catalysis 1H-15N HSQC NMR titrations and PCSs were used. Together, these 
approaches provided detailed information about the substrate binding site location and 
the binding kinetics in conjunction with indications of conformational changes during the 
enzyme catalytic pathway.  
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The fit of the experimental PCSs for free BCX to the protein crystal structure (PDB 
ID:2bvv)32 revealed a good agreement between the solution and crystalline ground states. 
Second, the binding kinetics of BCX to a substrate (X6, ES complex) was examined by 
NMR titration. For this purpose, the E78 nucleophile of the enzyme was substituted for 
Q, abolishing catalytic activity. During the course of titration, a complex chemical shift 
perturbation pattern of the backbone amide groups was observed concomitant with 
general line broadening. This effect was attributed to an increased viscosity caused by the 
xylose oligosaccharides. Viscosity determine the rotational diffusion time and thus 
relaxation rates of the protein. Similar observations were made in previous reports34. 
Chemical shifts changes in the fast exchange regime were noticed for the amides that 
form the secondary binding site34. Interestingly, at a X6 concentration at which BCX is 
partially saturated, new secondary peaks emerged for multiple backbone amides located 
within the binding cleft and its surrounding, indicating the existence of two ES bound 
states. The line shape analysis of the peaks showing this behaviour is suggests an “induced 
fit” binding mechanism. Therefore, it is hypothesised that in the ES state the substrate 
first binds to the protein in an open form (ES)open inducing a global closure of its binding 
cleft (ES)closed. The exchange rate of this process is 20 s-1, which coincides with the 
hydrolysis rate of BCX artificial substrate PNP-X2, therefore the open and close motion 
of the protein binding cleft might play a role in substrate turnover36.  
To interrogate the different conformations of the ES state, the PCSs of the (ES)open and 
(ES)closed complexes were measured. The PCSs fit of (ES)open to the BCX crystal structure 
(PDB ID: 2bvv) shows multiple outliers located within the binding cleft especially for 
residues that form the thumb, fingers and the a-helix and including also residues in the 
middle of the hand-palm. The PCSs differences between the free and the (ES)open revealed 
further conformational changes of the protein on both sides of the catalytic cleft, including 
residues that form the b-strands A and B. Thus, it was concluded that the (ES)open 
conformation is different from the one observed in the free protein. Those pronounce 
conformational changes of the protein structure might be consequence of simultaneous 
binding of the substrate in the aglycon and glycon subsites because such large effects are 
not observed when titrating with X2 (see below). Additionally, the few PCSs measured 
for residues that exhibit a resonance in the (ES)closed state included three amides that do 
not correlate well with their PCSs in the (ES)open state. Those amino acid residues were 
located in the thumb and deep in the hand palm. Therefore, it is concluded that substrate 
binding in the ES state follows an induced fit mechanism, which provoke two-bound 
states, none of them resemble the free state conformation of the protein. Previous studies 
on GH11 xylanases titration with oligosaccharides did not report the same observations30,
34. The structure obtained by co-crystallization of a silenced variant of GH11 xylanase
from Trichoderma reesei with X6 shows a movement of the thumb region toward the ligand
(2 Å compared to the free protein) enabling the formation of close interactions with xylose
subunits at the -1/-2/-3 subsites37. This thumb motion might occur in the BCX ES
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complex in solution, although it is assumed that these local conformational changes in the 
thumb may not explain the observed global conformational changes of the binding cleft 
in the (ES)open state, as suggested by PCSs.  
The next step was to characterize the enzyme in the intermediate state of the reaction 
(EI) by using an epoxy-xylobiose (epoxyX2) compound, which forms an adduct to the 
enzyme. CSPs were not only observed for residues at the -1/-2, subsites, including the 
thumb and the fingers, but also for distal residues in the aglycon pocket, suggesting the 
occurrence of a conformational change upon adduct formation. The EI PCSs fits to the 
EI crystal structure (PDB ID:1bcx) revealed multiple outliers for amides located mostly 
in the thumb region an indication for a different conformation in solution.  
The map of |DPCSs| between the EI and Efree states showed that residues involved in 
direct interactions with the ligand experience the most significant conformational 
changes. Therefore, both the thumb and residues at the -1/-2 subsites seem to adopt a 
new conformation when the protein is covalently bound to the ligand. 
In the EI complex an outward displacement of thumb was observed in XynII crystallized 
with epoxyalkyl xylobiosides 38 and also a 1.1 Å thumb displacement was observed in the 
BCX crystal structure when bound to the 2FXb compared to its free form32. Nevertheless, 
the fit of the EI PCSs to the BCX intermediate-state structure did not show a good 
correlation, suggesting that the EI adopts a conformation in solution that differs from the 
one in the crystal. 
The last step of the reaction is the product release from the glycon pocket. Studying the 
chemical shift perturbations upon protein titration with X2 revealed a ligand binding in 
the fast exchange regime with koff = 3.1 (±0.2) × 103 s-1. No minor peaks were observed 
at high product concertation, contrary to the titration with X6. The ligand seems to 
occupy only the -1/-2 subsites not the +1/+2 subsites. This suggests a difference in the 
binding sites affinities between the glycon and aglycon sites towards the product. These 
differences in affinity might be an adopted mechanism by the enzyme to facilitate the 
dissociation of the leaving group from the aglycon site. The paramagnetic NMR 
experiments on the EP complex revealed that the EP complex structure exhibits only 
small deviations from the Efree crystalline state, localized in the glycon site, in the thumb 
(-1/-2 subsite) and the a-helix.  
The EP complex has been trapped by co-crystallizing a GH11 xylanase from Trichoderma 
reesei with X6 due to the substantial reduction of its catalytic activity by single point 
mutation. The only significant conformational changes of the protein in the EP complex 
were observed in the thumb region where the atoms move closer to the product compared 
to their position in the ligand free structure of the mutant37. 
Therefore, based on crystallography studies of GH11 xylanases in complex with covalent 
and non-covalent ligands, the thumb region of the b-jelly roll fold might experience two 
types of movement: a movement that brings the thumb closer to the substrate in the case 
of non-covalent ligands, while in the EI complex the thumb experiences a backward 
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movement, which seems to assist the accommodation of the covalent ligands into the -1/-
2 subsites. It is speculated that the modulation of the thumb region conformations by the 
covalent and the non-covalent forms might play a role in positioning the substrate into 
the correct configuration to facilitate the glycosidic link hydrolysis and also to assist the 
product release from binding cleft in the final step of the catalytic reaction. 
This study of BCX covalently and non-covalently bound to its ligands revealed 
conformational changes not only of the thumb region but also within the a-helix and its 
binding cleft. The conformational changes depend also on the length of the bound 
substrate and on the occupancy of the protein glycon and aglycon sites. 
BCX dynamics during catalysis  
After studying the different average conformations of the protein in each step of its 
catalytic cycle, it was aimed to follow the ms time scale motions to investigate if there is 
an interconnection through their sampled excited states. The enzyme in the free state 
shows small chemical exchange effects for residues located mainly within the finger and 
the thumb regions. A two-site exchange model fit of the dispersion data revealed a kex= 
2.5 × 103 s-1 and a population of the excited state pB of 0.7%. The global rate of xylanase 
B2 (XlnB2) from Streptomyces lividans conformational exchange is equal to kex = 1.2 × 103 
s-1 for several residues in the fingers, yet no chemical exchange was observed in the 
thumb30.  
Next, the dynamics behaviour of the enzyme in the (ES)open state was examined by using 
a silenced version of the enzyme in the presence of X6 as a substrate. A global ms time 
motion enhancement was observed with a prominent increase of the Rex (up to 50 s-1). 
Amino acid residues that sculpture the binding cleft in addition to residues remote from 
the binding site experienced exchange. 
Residues with enhanced Rex exchange were also identified to experience conformational 
changes in the (ES)open upon ligand binding. The calculated kex of the substrate binding 
in the binding cleft and secondary binding site are 1.3 and 5.7 × 104 s-1 respectively, which 
falls outside the time scale window of the CPMG RD experiment. Therefore, the 
contributions of the dissociation process to the RD are considered negligible and the 
observed ms motion enhancement seems to be dominated by the intrinsic structural 
fluctuations of the protein in the (ES)open state. 
The enhancement of the ms time scale dynamics was also observed in the case of XlnB2 
in the presence of xylopentaose with an increase in its global kex from 1.2 × 103 s-1 to 3 × 
103 s-1. Residues of the fingers region, hand palm and thumb showed significant 
conformational exchanges leading to the conclusion that the substrate triggers the ms 
motion of the protein especially in the thumb, which was observed to be rigid in the free 
state30. However, in BCX, substrate binding reduces the kex from 2.5 × 103 s-1 in the free 
state to 740 s-1 in the (ES)open complex. The explanation for the different substrate effects 
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between the two homologues (40% primary sequence identity) of GH11 xylanases is 
unclear.  
The EI complex experiences subtle dynamics changes compared to the free protein with 
kex= 2 (±0.08) × 103 s-1 and pB= 0.6 %, when fitted to a global two-site exchange model. 
Nonetheless, local chemical exchange enhancement of residues in the vicinity of the 
catalytic dyad were observed, concomitant with a reduction of the thumb region 
dynamics and its surrounding loops, presumably due to the covalent ligand binding. 
The last step of the reaction is the product dissociation from the enzyme binding site. By 
following the dynamic of the EP state, a pronounced enhancement of the ms time scale 
chemical exchange was observed although to a lesser degree than in the ES complex. 
Significant Rex increases were noticed for amides of the thumb and the fingers at the -1/-
2 subsites. The global fit of the dispersion profile to a two-site exchange model revealed a 
kex=1.5 × 103 s-1 and 4% of the protein in the excited state. The observed increase of the 
protein dynamics is not related to Ddavg caused by ligand binding (kex= 3.9 × 104 s-1).  
All of the mentioned observations indicate a diversity in the protein dynamics behaviour 
in each step of the catalytic cycle, which depends on the substrate mode of binding 
(covalent or non-covalent) and also on its length (number of sugars units). To unravel the 
conformational connections between the BCX ground states, a comparison between the 
DdN and the DwN from the global CPMG RD data fits was performed. No correlations 
between the DwN values of the Efree and EI excited states with the DdN of the (ES)open and 
the EP were observed, suggesting that those excited states are not interconnected (Figure 
4.16a,b). A correlation was observed, however, between DwN values of (ES)open excited 
state and the DdN of the EI ground state (Figure 4.17a). For instance, residues N114, 
F125, T126, Q127 and Y128, clustered in the thumb region, show a remarkable 
correlation with a R2=0.8 (Figure 4.17c). Additionally, Y79, located next to E78 that 
form a covalent bond with the ligand in the EI state, show also a strong correlation. These 
observations suggest that the conformation of the thumb and residues proximal to the 
nucleophile in the (ES)open excited state resemble the adopted conformation in the EI 
ground state. Similarly, a correlation between the EP excited and EI ground states is 
observed, for residues I77, Y79 and Y80 in close proximity of the E78 nucleophile in 
conjunction to N114 and T126 of the thumb region (Figure 4.17b,d). This suggests that 
also the EP complex visits the EI conformation. Based on these observations, it is 
proposed that the (ES)open and EP ground states are connected through an excited state 
conformation in which the thumb and the proximal residues of the nucleophile adopt a 
conformation that resembles the one observed in the EI ground state.  
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Figure 4.16. Correlation between the Dw from global residues fits of the CPMG RD data with the DdN of the 
NMR titration data. (a) The Dw of the Efree excited state plotted against the DdN of the (ES)open, EI and EP 
ground states. (b) The Dw of the EI excited state plotted against the DdN of the (ES)open and EP ground states. 
Excited states are indicated in red and marked with asterisks and ground states in blue. 
Figure 4.17. Correlation between excited states and the EI ground state. (a, b) Correlation of Dw of the 
(ES)open excited state (a) and the EP excited state (b) with the DdN of EI state. Good correlations are shown in 
blue circles and the poor ones in black dots. The correlation factor (R2) is indicated using the same colour code. 
(c, d) Backbone amides that show a good correlation for (ES)open (c) and EP (D) excited state chemical shifts 
with EI ground state chemical shifts are mapped on the BCX crystal structure (PDB ID:2bvv) in blue spheres. 
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Conclusions 
The aim of this study was to follow the conformational changes and dynamics of GH11 
xylanase during their catalytic pathway, using BCX as a model. The titration and 
paramagnetic NMR experiments identified different binding modes of the enzymes to its 
substrate and product, which seems to be concomitant with changes of the protein 
conformation. The conformational changes are dependent on the mode of the ligand 
interactions (non-covalent versus covalent) and also on the glycon and aglycon binding 
sites occupancy.  
MD simulations by Muilu et al. on XYNII from Trichoderma reesei, captured in different 
crystalline states, suggested that the protein samples three sequential substates during its 
catalytic reaction. First, the protein adopts an open state to accommodate the substrate 
in the cleft. Substrate binding induces a closed conformation necessary for positioning the 
substrate into the correct configuration for glycosidic bond hydrolysis. The last state is a 
loose structure from which the product is released31. The results of MD simulations are 
in agreement with the present study in the solution state. Nevertheless, BCX seems to 
display more diverse conformational and dynamics behaviour during its catalytic 
pathway. Therefore, a new model is proposed for the GH11 xylanase conformational 
landscape changes and the contribution of dynamics to catalysis.  
PCSs analysis showed that the protein adopts at least five distinctive average structures 
where approximately five regions, including the fingers, the hand palm, the thumb, the 
cord and the a-helix contribute to this conformer diversity. The protein in the free state 
(Efree) is in an open structure. The NMR titration of BCX with substrate point toward an 
induced fit binding mechanism, suggesting that the protein indeed experiences 
conformational changes necessary for the formation of the Michaelis complex. Based on 
the chemical shifts and the PCSs, it was concluded that the two ES bound states 
conformations differ from each other as well as from that of the free state. The induced 
state seems to be similar to the (ES)closed state, yet is formed slowly, indicating a high 
activation barrier for its formation. It may be the dual occupancy of the glycon and the 
aglycon sites that induces this rearrangement. The slow conversion could limit catalysis, 
as the rate of formation is of a similar size as the turnover rate. The observed ms 
enhancement of the (ES)open motion in residues that sculpture the binding cleft, including 
the thumb and the fingers, could be an indication of structural fluctuations necessary for 
substrate positioning, deformation or even sliding, a process that was observed in other 
biomass degrading enzymes like cellulases39. Through the (ES)closed state, the glycosylation 
step occurs and the protein is locked into a closed conformation (EI)closed* that differs from 
the Efree, (ES)open and (ES)closed ground state conformations. The covalent bond formation 
restricts the protein dynamics in the thumb region concomitant with an observed 
enhancement of the ms motion for residues surrounding the nucleophile. Those subtle 
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dynamics enhancement may play a role in the hydrolysis of the glycosidic bond of the 
glycosyl-enzyme by the activated water molecule. Through the EI ground state, the 
deglycosylation takes place and the protein adopts a loose conformation (EP)loose. The 
remarkable enhancement of the ms protein motion between the EP and the EI ground 
states (between loose and closed conformations) may play a role in triggering the product 
release from the glycon site of the enzyme binding cleft (Figure 4.18). In the (ES)open and 
EP state the protein samples an excited state conformation similar to the EI ground state. 
The amplitude and directions of those conformational changes remain unknown. The 
calculation of the structure of the EI complex using NMR spectroscopy is on-going. 
Solving the EI structure may assist the modelling of the protein conformations in the EP 
and ES states based on their experimental PCSs and by using the EI NOEs as additional 
structural restraints. 
In this study, the aim was to shed light on the possible contributions of the conformational 
dynamics of GH11 xylanases to their paradigmatic hydrolysis mechanism.  
Figure 4.18. Conformational landscape of BCX during catalysis. The different schematic shapes and colours 
indicate different protein conformations and dynamic behaviour. Dashed arrows indicate non-probed 
conformational exchange between the different states.  
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Material and Methods 
Mutagenesis 
BCX E78Q, BCX T109C/T111C and BCX E78Q T109/T111C mutants were 
prepared by site-directed mutagenesis using Quik-Change protocol. The presence of the 
mutations was confirmed by sequencing. 
BCX overexpression and NMR samples preparation 
The gene of BCX with a sequence optimized for expression in E. coli was purchased from 
life technologies, including a N-terminus 6-His-Tag followed by a TEV protease 
recognition site. The gene was subcoloned into plasmid pET28a using NcoI/XhoI 
restriction sites. E. coli BL21DE Rosetta cells were transformed with the obtained vector 
and cultured in 2 ml lysogency broth media containing 100 µg/mL kanamycin for 6 hours 
at 37°C. 100 µl of the miniprep culture were used to inoculate 50 mL minimum medium 
supplemented with 15N labeled ammonium chloride (15NH4Cl) or in combination with 
13C-glucose. The next day, 0.5 L of the same medium was inoculated with the overnight 
preinoculation culture and incubated for 8 hours at 37°C with shaking until the OD600 
reached 0.6. BCX gene expression was induced with 0.5 mM IPTG and the culture was 
incubated overnight at 20°C with shaking. The cells were harvested by centrifugation and 
the pellet was resuspended in an extraction buffer (50 mM phosphate buffer solution 
(PBS), 40 mM imidazole, pH 7.5) and sonicated. The resulting 6His-BCX supernatant 
was purified by Ni(II) affinity chromatography. Subsequently, the eluted BCX fractions 
were collected and the protein was brought into a solution of 50 mM PBS using PD10 
column. The 6-His-BCX protein was incubated with TEV protease overnight at 4°C. 
Next, the cleaved 6-His-Tag and the TEV protease were separated from BCX using Ni(II) 
affinity chromatography. The unbound protein fraction, that included BCX, was 
collected and buffer exchanged to 25 mM sodium acetate buffer pH= 5.8 using PD10 
column. The protein was concentrated using Amicon® Ultra-Centrifugal Filters with 10 
kDa cutoff and its purity was checked by SDS page. The BCX concentration was 
determined by UV absorbance using the theoretical extinction coefficient of 84,3 M-1 cm-
1.  
EI covalent complex formation 
The epoxyX2 was synthesized by Schroder S.P. et al.40. The protein was incubated with 
20 times molar equivalent of BCX sample at 30 °C. The reduction of the enzyme activity 
was monitored over the course of incubation using 4MU-xylobiose as a substrate 
(Megazyme). The reaction rates were monitored by measuring the fluorescence of the 
released 4MU at its emission wavelength of 445 nm on a Cary Eclipse Fluorescence 
Spectrophotometer (Agilent). After an overnight incubation, the excess of epoxyX2 was 
removed using PD10 column and complex formation was checked by electrospray mass 
spectrometry (Waters). The same procedure was applied to prepare a 15N 13C BCX-
epoxyX2 sample (for assignment), 15N BCX-epoxyX2 sample (for 15N CPMG RD) and 
15N BCX T109C/T111C-LaNP-5-(Lu3+/Yb3+)-epoxyX2 samples for PCSs calculations. 
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NMR spectroscopy 
Sequential assignment of the BCX WT at 20 °C was performed by recording triple 
resonance HNCACB and CBCAcoNH spectra on a 15N 13C BCX NMR sample (0.6 
mM)22. The obtained peak list was used to assign the BCX E78Q, BCX T109C/111C 
and BCX E78Q T109C/111C mutants backbone amides. The assignments of these later 
were curated using PCSs. The same assignment procedure as for the BCX WT was 
applied for the assignment of the BCX-epoxyX2 (EI complex). The NMR spectra were 
acquired on Bruker Avance III (HD) 600 or 850 MHz spectrometers, equipped with TCI 
cryoprobes, processed by TopSpin 3.5 (Bruker Biospin) and analysed with Sparky 
Software41. 
NMR titration with oligosaccharides and peak shape analysis 
The NMR titration of 15N BCX E78Q (123 µM) with an increasing X6 concentration 
(123 µM-20 mM) was performed in 25 mM sodium acetate (pH=5.8) and 6% D2O at 20 
°C. The 1H-15N HSQC spectrum of every titration point was recorded and the average 
chemical shift perturbation values (∆davg) relative to the free protein were calculated 
according to the equation: 
An iterative least-squares procedure for 2D peak shape analysis of the HSQC titration 
spectra was performed using TITAN software35 and the titration data were fitted to either 
a two-state or an induced fit binding model. The fit yielded the Kd and koff values and also 
the R2 relaxation, in addition to the kopen and kclosed for the induced fit binding model.  
Paramagnetic NMR spectroscopy 
Uniformly labelled 15N BCX T109C/T111C was incubated with 10 mM DTT in 50 mM 
PBS (pH=7.2) and 150 mM NaCl for 1 h on ice to reduce the disulphide bridges between 
the protein dimers. DTT was removed by using a PD10 column. The protein was mixed 
with 10 molar equivalents of CLaNP-5-Lu3+ (diamagnetic sample) or CLaNP-5-Yb3+ 
(paramagnetic sample) and left stirring for 2 h at room temperature. The samples were 
concentrated to 0.5 mL using a 10 kDa Amicon® Ultra-Centrifugal Filter and injected 
into a Superdex G75 analytical gel filtration column to remove unreacted tag and protein 
dimers. To verify the labelling efficiency, the protein samples were analyzed on 15 % 
SDS-PAGE in the presence and absence of a reducing reagent (b-mercaptoethanol) and 
checked by acquiring 1H-15N HSQC spectra. weak peaks of untagged BCX were 
observed for both samples (<5% unlabeled). The obtained PCSs were fitted to the BCX 
crystal structures (PDB ID:2bvv or 1bcx) to optimize the location of the lathanoid and the 
tensor position and orientation using Numbat software42. The Q factor score of the 
experimental PCSs fit to the BCX crystal structure was calculated using the equation43. 
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A jackknife error analysis of the obtained tensors is part of the Numbat software and was 
used to enable Dc tensor comparison for different BCX states. The differences between 
the experimental PCSs of each BCX ligand-complex and the free protein were also 
calculated to monitor the conformational changes that occur upon ligand binding. 
NMR relaxation dispersion and CPMG data analysis 
15N CPMG RD data sets were recorded at 20 °C using a 15N TROSY-CPMG pulse 
scheme44. Data sets were recorded at field strengths of 11.7 T (600 MHz) and at 19.9 T 
(850 MHz). The constant time relaxation delay, tCPMG, was set to 50 ms. Dispersion 
profiles comprised ~ 20 different νCPMG frequencies, recorded in an interleaved manner, 
with values ranging from the minimum possible value (1/tCPMG) to a maximum of 1000 
Hz. Errors were estimated on the basis of repeat measurements at two or three different 
nCPMG frequencies. Each CPMG dataset required approximately 14 hours of 
measurement time. All experiments were performed on Bruker spectrometers equipped 
with a TCI-Z-GRAD triple resonance cryoprobe. The peak shape fit of the 3D-pseudo 
plans was performed using FuDa45 .The R2,eff (νCPMG) were obtained via the relation:  
Where I(νCPMG) and I0 are peak intensities with and without the 50 ms tCPMG, respectively. 
Values of the exchange parameters were extracted from a global fit of R2,eff (νCPMG) profiles 
to a two-site exchange model using CATIA 
(http://www.biochem.ucl.ac.uk/hansen/catia). The experimental Rex were calculated 
using the formula Rex= R2,eff (20 Hz) - R2,eff (1000 Hz) and plotted versus the residue numbers.  
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ue to their central physiological roles in living organisms, retaining b-
glycosidases have been the subject of tremendous research efforts to examine 
their structure/function relation using numerous biophysical and biochemical 
approaches. Since the proposition of the hydrolysis mechanism in the late 
fifties by Koshland1, the fundamental research on retaining b-glycosidases has been 
revolutionized by the discovery of multiple reversible and irreversible inhibitors2-5. One 
of the most successful class of inhibitors are mechanism based inactivators, which were 
extensively used to identify the nucleophilic catalytic residues and to comprehend the 
catalytic mechanism and substrate itinerary2, 6, 7. Subsequently, covalent inhibitors were 
used as warheads to synthesize chromogenic activity based probes (ABPs), which were 
widely used to selectively label and discover new retaining b-glycosidases in complex 
biological samples8, 9. For instance, Overkleeft and co-workers have developed 
ultrasensitive ABPs against human b-glucosidase (GBA)10. These ABPs were successfully 
utilized by Aerts and co-workers to deepen our understanding of the physiopathology 
underlying Gaucher disease11, 12. The organic synthesis and biological applications of 
these ABPs has become routine13. Nevertheless, their binding mechanism and influences 
on protein conformation and dynamics remained unexplored. Therefore, this work is 
aimed to establish a bridge between the two research disciplines, using ABP technology 
to understand functional dynamics and conformational stability of retaining b-
glycosidases in solution and in vivo. The research relied on standard biochemistry and 
advanced NMR spectroscopy research approaches.  
The deficiency of GBA activity in Gaucher patients14 leads to the accumulation 
of glucocerebrosides in lysosomes15 and GM3 gangliosides in plasma16. Such 
accumulations are the cause of the clinical manifestations of the disease17, 18. Continuous 
intravenous administration of exogenous GBA (rGBA) is, so far, the most efficient 
treatment for Gaucher disease19-24. It remains costly25 and non-affordable for many 
patients around the world, especially in countries with low health care quality. Thus, 
finding an inexpensive therapeutic alternative is imperative. 
The endo-glycosylceramidase II from Rohodococcus sp. is a bacterial homologue 
of GBA able to endo-hydrolyse the glycosidic link in complex glycosylceramidases. The 
enzyme was first discovered in 1980s by Ito et al. and found multiple applications in 
gangliosides analysis26. The crystal structure of EGCII was solved in 2007 by Strynadka 
and co-workers in the free and GM3 ganglioside-bound forms.27 In theory, this protein 
holds promise as a potential drug against Gaucher disease and other glycosphingolipidose 
disorders, via administration once in a lifetime for clearance of the accumulated 
gangliosides. Hence, ABPs were used to gain insight into factors that influence the 
conformational stability of EGCII as a preliminary step toward its design as a therapeutic 
agent. The study revealed that the protein is thermolabile and highly flexible in its free 
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interaction with the cell membrane to exert its function against its amphiphilic substrates. 
This hypothesis was supported by the highly exposed hydrophobic surface to the solvent 
probed by ANSA. Flexibility could also play a role in the interaction between EGCII and 
its activator, a protein partner that enhances its activity against gangliosides in the absence 
of detergents28. Upon complex formation with hydrophilic, activity-based inhibitors, a 
minor increase in thermostability and rigidity were observed, concomitant with a 
preserved high hydrophobic surface exposed to the solvent. However, the interactions 
with activity-based inhibitors with high lipophilic potential increased the protein 
thermostability and rigidity, and reduced its exposed hydrophobic surface. The 
stabilization of EGCII conformation correlates with the shape and hydrophobicity of the 
substituents of the ABPs. It was concluded that amphiphilic active site binders that mimic 
the natural substrate are superior stabilizers, compared to their small hydrophilic 
counterpart. By virtue of ABPs technology, the characteristics of the enzyme-inhibitors 
complex were investigated and helped to elucidate which parts of the inhibitors are 
important for efficient stabilization activity. This information could be further exploited 
in the design of more specific ABPs and inhibitors against other  b-glycosidases. EGCII 
thermolability and flexibility might hamper its therapeutic use, and, therefore, one 
strategy to overcome these disadvantages is to re-engineer the protein by including 
glycosylation sites on its surface29. This approach might enhance EGCII stability and also 
assist its uptake by macrophages receptors through those glycosylation sites20. 
Additionally, an endoglycoceramidase activity towards gangliosides has been reported for 
human cancer cells30, but the protein responsible for such activity has not been 
characterized yet. The development of endo-glycosidases activity-based probes (endo-
ABPs) could help in uncovering the enzyme behind the endo-hydrolysis of gangliosides in 
cancer cells and their role in cancer pathology. If the endoglycoceramidase is a marker 
for cancer cells phenotype, ultrasensitive endo-ABPs might be also be used for diagnosis 
purposes in the initial stage of cancer development.  
In addition to enzyme replacement therapy in Gaucher disease, new therapeutic 
approaches are under intense investigation, based on identifying small chemical 
molecules that rescue GBA proteostasis in Gaucher patients31-34. Those small molecules 
called “pharmacological chaperones” are supposed to stabilize GBA mutants fold in the 
ER compartment of the cells, thus escaping the quality control machinery in the ER 
compartment, so that they can reach their final lysosomal destination31, 35. Several GBA 
active site binders have validated this proof of principle in vivo and in vitro36-39. However, 
their stabilization mechanism on GBA and their effects on the enzyme conformation in 
solution remained unclear. Therefore, reversible, semi-reversible (time dependent) and 
irreversible (ABPs) inhibitors with different chemical characteristics were used to 
investigate the stabilization mechanism of those active site binders on GBA fold in vitro 
and in vivo. 
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The outcomes of the study revealed that small active site binders, which only occupy the 
glycon pocket of the active site, provoke minor changes of the biophysical properties of 
the protein. When interacting with amphiphilic ABPs, which are thought to occupy 
simultaneously the glycon and aglycon sites, a remarkable increase of the protein thermal 
stability was observed (up to 21ºC) in conjunction to its resistance against trypsin 
digestion, suggesting rigidification. Additionally, ABPs induced a shift of the GBA 
fluorescence spectrum toward the blue region, again suggesting a more compact 
conformation upon complex formation. Serendipitously, an iFRET mechanism between 
the BODIPY fluorescence reporter of the ABPs and the protein tryptophan residues was 
observed. This phenomenon could potentially be exploited as a method for cell imaging. 
By exciting the indole rings of GBA tryptophans and recording the BODIPY emission 
spectrum of the ABPs, the background signals originating from free ABPs might be 
bypassed and clearer images could be obtained40.  
The in vitro findings were validated in vivo by observing a correlation between the binding 
site occupancy of GBA by ABPs and the intracellular increase of the protein level.  
The studies on EGCII and GBA lead to the conclusion that both proteins share a similar 
stabilizing mechanism by active site binders. Therefore, evidence is provided about the 
increase in cellular levels of GBA by ABPs and reversible inhibitor is in part caused by 
their ability to stabilize GBA folding, which increases its resistance against breakdown by 
lysosomal proteases. Those finding provided extra information that could be considered 
when designing new pharmacological chaperones for Gaucher disease. 
Despite the devoted efforts to discover an optimal candidate for pharmacological 
chaperone treatment, none of the available compounds has reached the clinic. 
Isofagomine was the most successful compound but failed to pass the clinical trials, 
presumably due to its poor biodistribution, ascribed to its hydrophilicity41. Therefore, a 
hybrid therapy between pharmacological chaperones and enzyme administration 
represent a therapeutic alternative, which is under investigations. Continuous 
administration of rGBA to Gaucher patients is required because of the short half-life in 
the blood42. Providing a cocktail of rGBA and isofagomine might increase the half-life of 
the protein under physiological conditions, thus lowering the frequency of the enzyme 
transfusion and the cost of the treatment. However, this approach might require a high 
dose of isofagomine to warrant an effective rGBA stabilisation that could induce 
unwanted side-effects.  
An alternative in this hybrid therapy is the use of a fluorinated glucoside inhibitor, instead 
of isofagomine. This class of inhibitors is supposed to bind rGBA in a time dependent 
manner43, 44. The fluoride in the C2 position of the pyranose ring ensures slow dissociation 
of the enzyme-inhibitor complex, providing sufficient time for rGBA to reach its 
destination without being degraded in the blood circulation. The one to one ratio between 
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The use of GBA active site binders as pharmacological chaperones appears 
promising, however, their potential inhibition of the enzyme activity at high dose 
represents a potential problem. Therefore, attention should also be paid to allosteric 
pharmacological chaperone because they bind remote from the active site, avoiding such 
inhibitory effects. 
Like EGCII, GBA also has an activator called saposin C45. Saposin C is an 80-amino acid 
protein and its structure was determined by NMR spectroscopy and X-ray 
crystallography under different condition46-48. Saposin C binding to GBA induces 
significant changes of its fluorescence spectrum, suggesting changes in the GBA 
conformational state upon protein-protein complex formation49. Attempts to characterize 
the GBA-saposin C complex using X-ray crystallography was unsuccessful. The complex 
was modelled by molecular docking though50. Uncovering the saposin C binding site on 
GBA experimentally might give an idea about which structural location should be 
targeted to design allosteric pharmacological chaperones. The binding site could be 
studied by paramagnetic NMR spectroscopy. A new type of activity-based probes against 
GBA could be developed for this purpose, using epoxide as a warhead linked to 
lanthanoid paramagnetic NMR tag (PABP) instead of BODIPY. The covalent complex 
between GBA and the PABP might be used to obtain experimental restraints (PREs, PCSs 
and RDCs) of the GBA-Saposin C complex51-54. The experimental restraints can be used 
to direct the docking between the two proteins, providing realistic model of their 
complex55. Uncovering the saposin C binding site on GBA surface will assist the design 
of allosteric pharmacological chaperone. 
The characteristic shared between the different families of retaining b-
glycosidase is their conserved and well understood catalytic mechanism. This has 
somehow limited the research devoted to understand the contribution of the enzyme 
dynamics and conformational changes in the different steps of the catalytic reaction. In 
the present work, this question was addressed using BCX as a model. the choice was based 
on the suitable biophysical characteristics of BCX for NMR spectroscopy studies. 
Moreover, this protein has been extensively investigated by NMR spectroscopy and X-
ray crystallography in combination with other biochemistry techniques56-62.This 
knowledge provided a solid starting point that facilitated the task in exploring the 
conformational landscape and dynamics of this protein during its catalytic pathway. By 
incubating the protein with different non-covalent ligands and a covalent active based 
inhibitor, a novel compound that was specifically made for this study63, the enzyme-ligand 
complexes were systematically characterized in every step of the catalytic reaction using 
paramagnetic NMR spectroscopy and CPMG RD techniques. In its free state, the protein 
populates a ground state similar to its crystalline state as concluded from PCS data. The 
protein displays subtle millisecond dynamics in the thumb and fingers regions with an 
excited state population = 0.7%. The Michaels complex displays an induced fit 
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mechanism as shown by CSP analysis. This observation has not been reported before for 
a GH11 xylanase. Both states of the enzyme appear to have different conformations 
compared to the free protein, as concluded from the paramagnetic NMR data. The 
exchange rate between the initial and induced states is low, on the order of the turn-over 
rate of the enzyme, suggesting that the formation of the induced state may contributed to 
the rate limiting step of catalysis. In the ES state, the millisecond dynamics is strongly 
enhanced with a population of the excited state(s) of 9%. This finding is in accordance 
with a previous report on another GH11 xylanase family member. No major changes of 
the protein dynamics behaviour were observed in the case of the EI state compared to 
the free protein, despite the occurrence of conformational changes upon its covalent 
modification by epoxyX2. In the EP state the protein displays minor conformational 
changes upon ligand binding, again concomitant with enhancement of the millisecond 
dynamics, similar to the ES state. The ES and the EP ground states are connected via 
excited states to the EI ground state conformation. Based on those findings, a description 
of BCX conformational landscape and dynamics during catalysis is proposed, providing 
evidence for involvement of enzyme motions in the catalytic mechanism.  
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Appendix I 
Figure A1.1: EGCII and GBA primary sequences alignment using Needleman-Wunsch algorithm from 
EMBOSS Needle server (emboss.open-bio.org). Identical residues are highlighted on black background, 
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Figure A1.2. EGCII size exclusion chromatogram analyzed by Multi Angle Laser Light Scattering. 
Results 
Peak 1 Peak 2 
Volume (mL) 8.75-9.42 9.64-10.42 
Injection Mass (g) 1.0 10-4 1.0 10-4 
Calc. Mass (g) 3.82 10-5 2.47 10-5 
dn/dc (mL/g) 0.186 0.186 
Polydispersity (Mw/Mn) 1.003 +/- 0.033 1.002 +/- 0.086 
Molar Mass Moments (g/mol) 1.062 10+5 5.0 10+4 
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LC/MS spectra of compound 8 
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Appendix II 
Table A2.1: LC-MS identification of peptides in Band 1 
Start-End m/z (exp) z ppm Score Peptide sequence 
117-145 9.655.467 3 3 30 VKGFGGAMTDAAALNILALSPPAQNLLLK 
119-145 13.422.294 2 1 80 GFGGAMTDAAALNILALSPPAQNLLLK* 
146-159 8.244.048 2 1 81 SYFSEEGIGYNIIR 
160-170 6.417.996 2 0 53 VPMASCDFSIR 
195-202 3.305.582 3 -2 48 LKIPLIHR 
197-202 3.747.444 2 -2 48 IPLIHR 
203-225 8.551.525 3 1 22 ALQLAQRPVSLLASPWTSPTWLK 
234-250 6.386.585 3 0 36 GSLKGQPGDIYHQTWAR 
238-250 7.648.692 2 1 54 GQPGDIYHQTWAR 
251-263 5.442.807 3 1 44 YFVKFLDAYAEHK 
255-263 3.651.819 3 0 43 FLDAYAEHK 
264-296 12.509.374 3 -1 138 LQFWAVTAENEPSAGLLSGYPFQCLGFTPEHQR 
297-301 3.111.708 2 -2 22 DFIAR 
317-324 5.022.659 2 0 63 LLMLDDQR 
325-332 4.893.011 2 2 31 LLLPHWAK 
325-342 6.677.226 3 0 38 LLLPHWAKVVLTDPEAAK 
333-342 5.217.918 2 -2 10 VVLTDPEAAK 
333-360 7.816.724 4 0 37 VVLTDPEAAKYVHGIAVHWYLDFLAPAK 
343-360 10.505.557 2 -1 86 YVHGIAVHWYLDFLAPAK 
343-368 7.421.416 4 -1 28 YVHGIAVHWYLDFLAPAKATLGETHR 
369-385 9.364.572 2 2 85 LFPNTMLFASEACVGSK 
386-392 4.762.372 2 -1 39 FWEQSVR 
393-398 3.671.845 2 -1 40 LGSWDR 
399-434 13.853.512 3 1 116 GMQYSHSIITNLLYHVVGWTDWNLALNPEGGPNWVR* 
435-447 7.309.018 2 -2 89 NFVDSPIIVDITK 
435-452 7.057.049 3 0 24 NFVDSPIIVDITKDTFYK 
448-452 3.371.629 2 -1 15 DTFYK 
453-464 4.979.123 3 1 24 QPMFYHLGHFSK 
465-472 4.672.421 2 -2 15 FIPEGSQR 
473-480 4.012.456 2 1 51 VGLVASQK 
481-502 7.744.033 3 2 84 NDLDAVALMHPDGSAVVVVLNR* 
503-512 3.632.164 3 -1 16 SSKDVPLTIK 
506-512 3.932.421 2 0 14 DVPLTIK 
Table A2.2: LC-MS identification of peptides in Band 3 
Start-End m/z (exp) z ppm Score Peptide sequence 
234-250 6.386.578 3 -1 42 GSLKGQPGDIYHQTWAR 
238-250 7.648.693 2 1 64 GQPGDIYHQTWAR 
238-250 7.648.694 2 2 69 GQPGDIYHQTWAR 
251-263 5.442.804 3 0 45 YFVKFLDAYAEHK 
255-263 5.472.696 2 1 49 FLDAYAEHK 
264-296 12.509.392 3 1 92 LQFWAVTAENEPSAGLLSGYPFQCLGFTPEHQR 
302-316 5.446.115 3 -3 41 DLGPTLANSTHHNVR 
317-324 5.022.657 2 0 63 LLMLDDQR 
325-332 4.893.012 2 2 48 LLLPHWAK 
325-342 6.677.218 3 -1 56 LLLPHWAKVVLTDPEAAK 
343-360 10.505.557 2 -1 97 YVHGIAVHWYLDFLAPAK 
343-368 7.421.419 4 -1 56 YVHGIAVHWYLDFLAPAKATLGETHR 
369-385 9.364.542 2 -1 105 LFPNTMLFASEACVGSK 
386-392 4.762.373 2 -1 52 FWEQSVR 
399-434 13.800.196 3 1 117 GMQYSHSIITNLLYHVVGWTDWNLALNPEGGPNWVR 
435-447 7.309.021 2 -2 92 NFVDSPIIVDITK 
453-464 7.463.647 2 1 63 QPMFYHLGHFSK 
473-480 4.012.456 2 1 60 VGLVASQK 
473-502 7.726.692 4 -2 46 VGLVASQKNDLDAVALMHPDGSAVVVVLNR 
473-505 8.482.103 4 0 60 VGLVASQKNDLDAVALMHPDGSAVVVVLNRSSK 
481-502 11.611.033 2 3 90 NDLDAVALMHPDGSAVVVVLNR* 
G noting the N-terminus residue of Band 3; asterisk * (Asterisk) noting Methionine oxidation 
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ENGLISH SUMMARY 
-glycosidases play fundamental roles in maintaining the cellular homeostasis
in living organisms. In the last decades, this widespread enzyme family has
found multiple industrial applications. Given the importance of these
enzymes, characterization of the biophysical properties of b-glycosidases is a
necessity for deepening our understanding of their structure/function relationship. 
Chapter 1 is a general introduction describing the biophysical and structural 
characteristics of b-glycosidases that belong to the GH5, GH11 and GH30 families, as 
well as the commonly used inhibitors that modulate their activities.  
In humans, ganglioside catabolism comprises consecutive hydrolysis of the 
oligosaccharide moieties by different exo b-glycosidases. Deficiency in ganglioside 
processing enzymes leads to a range of metabolic disorders collectively classified as 
glycosphingolipidoses. In bacteria, ganglioside metabolism follows a different path, in 
which the entire oligosaccharide chain is removed from the ceramide moiety in a single 
step. One of the first enzymes identified to be able to perform this reaction is 
endoglycoceramidase II (EGCII) from Rhodococcus sp. In theory, this enzyme could be 
applied to treat human glycosphingolipidoses, and insight into factors that influence 
EGCII conformational stability is an important prerequisite for its application as a 
therapeutic agent. Chapter 2 describes the characterization of EGCII using activity-
based probes (ABPs) initially developed against the human b-glucocerebrosidase (GBA.) 
The protein is heat labile and its stability is markedly enhanced by formation of covalent 
complexes with ABPs based on cyclophellitol linked to hydrophobic substituents. This is 
evidenced by an increased melting temperature, resistance against tryptic digestion, 
changes in 15N-1H NMR spectra of the enzyme, and changes in the degree of exposed 
hydrophobic surface area, as determined by 8-anilino-1-naphthalenesulfonic acid 
fluorescence.  
Deficiency of GBA function leads to the accumulation of its glucocerebroside 
substrate in the lysosomal compartment of the cell, thus causing a syndrome called 
Gaucher disease. The application of small chemical compounds that rescue the activity 
of GBA mutants in Gaucher patients is under intense investigation. This new therapeutic 
approach represents a promising avenue for treatment of Gaucher patients with 
symptoms that also include neural manifestation of the disease. However, the effects of 
those compounds on the protein conformation in solution remain unclear. Therefore, 
Chapter 3 describes the utilization of a variety of active site binders to dissect their 
stabilization mechanisms on the GBA fold. Amphiphilic ABPs, which are supposed to 
simultaneously occupy the glycon and aglycon pockets of GBA binding site, exert superior 
stabilization effects presumably by promoting a further structural compactness of GBA 
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Despite the differences in folds and in substrate specificities between the b-
glycosidases, these enzymes share a common catalytic mechanism, in which two catalytic 
residues act in a synchronized manner on the glycosidic link, causing its hydrolysis. The 
chemistry that governs this mechanism became widely accepted, which somehow limited 
the study of the contribution of the conformational changes of the enzyme and the 
dynamics in the catalytic reaction. In chapter 4 this topic is addressed by following the 
dynamics of Bacillus circulans xylanase during its catalytic pathway using standard and 
advanced NMR spectroscopy techniques. In its resting state, the protein shows minor 
millisecond time scale dynamics. The Michaelis complex formation seems to follow an 
induced fit mechanism and the exchange between the two bound forms of the enzyme is 
revealed to be in the slow exchange regime. It is hypothesised that this step with a high 
activation barrier is a change in the protein conformation that is necessary for substrate 
positioning and distortion, which could represent a rate limiting step of the reaction. In 
the covalent intermediate state of the reaction, the protein preserves its free state 
dynamics behaviour although it assumes a different conformational state. A drastic 
enhancement of the millisecond motion of the protein in the last step of the catalytic 
reaction (product dissociation) suggests a role of such dynamics in assisting the product 
dissociation from the enzyme binding site. The study provided evidence for the 
involvement of b-glycosidases motions in their paradigmatic hydrolysis mechanism. 
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-glycosidasen spelen een fundamentele rol bij het handhaven van de cellulaire
homeostase in levende organismen. Bovendien heeft deze wijdverspreide
groep van enzymen de afgelopen decennia meerdere industriële toepassingen
gevonden. Het belang van deze enzymfamilie maakt het karakteriseren van de biofysische 
eigenschappen van b-glycosidases zeer relevant. Daarmee kunnen we een beter begrip 
krijgen van hun structuur/functie relatie. Hoofdstuk 1 is een algemene inleiding waarin 
de biofysische en structurele kenmerken van b-glycosidasen die tot de GH5, GH11 en 
GH30 families behoren, worden beschreven, alsmede de vaak gebruikte remmers die hun 
activiteiten moduleren. 
In de mens bestaat het katabolisme van gangliosiden uit de sequentiële hydrolyse van hun 
oligosaccharidegroep door verschillende exo b-glycosidasen. Het ontbreken van de 
activiteit van één van de ganglioside verwerkende enzymen vormt de oorzaak van een 
reeks metabole aandoeningen die collectief worden geclassificeerd als 
glycosfingolipidosen. In bacteriën volgt het metabolisme van gangliosiden een ander pad, 
waarbij de gehele oligosaccharideketen in een enkele stap van het ceramidedeel wordt 
verwijderd. Een van de eerst ontdekte enzymen die deze reactie kunnen uitvoeren, is 
endoglycoceramidase II (EGCII) van Rhodococcus sp. In theorie zou dit enzym kunnen 
worden toegepast om menselijke glycosfingolipidosen te behandelen. Inzicht in factoren 
die de stabiliteit van EGCII beïnvloeden, is een belangrijke voorwaarde voor eventuele 
toepassing ervan als therapeuticum. Hoofdstuk 2 beschrijft de karakterisering van 
EGCII met behulp van activity based probes (ABPs) die aanvankelijk waren ontwikkeld voor 
humaan gluocerobrosidase GBA. EGCII is warmtelabiel en de stabiliteit wordt 
aanzienlijk verbeterd door de vorming van covalente complexen met ABPs op basis van 
cyclofellitol, gesubstitueerd met hydrofobe groepen, zoals blijkt uit een verhoogde 
smelttemperatuur, resistentie tegen tryptische digestie, veranderingen in 15N-1H NMR-
spectra van het enzym en in de hoeveelheid hydrofoob eiwitoppervlak, zoals bepaald door 
8-anilino-1-naftaleensulfonzuurfluorescentie.
Een verlaagde of afwezige activiteit van GBA leidt bij de mens tot accumulatie van het
glucocerobosidesubstraat in het lysosomale compartiment van de cel, waardoor een
syndroom ontstaat dat de ziekte van Gaucher wordt genoemd. De toepassing van kleine
chemische verbindingen die de activiteit van GBA-mutanten bij Gaucherpantiënten
kunnen verhogen, wordt intensief onderzocht. Deze nieuwe therapeutische aanpak
vertegenwoordigt een veelbelovend vorm van behandeling van Gaucher-symptomen, in
het bijzonder voor de neurale manifestatie ervan. De effecten van die verbindingen op de
eiwitconformatie in oplossing zijn echter nog onduidelijk. Daarom beschrijft hoofdstuk
3 de karakterisatie van de effecten van een serie verbindingen op de stabiliteit van GBA.
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door de reversibele remmers ten dele wordt veroorzaakt door hun vermogen om de 
gevouwen vorm van GBA te stabiliseren, waardoor de weerstand tegen afbraak door 
lysosomale proteasen toeneemt. Deze effecten zijn het duidelijkst voor de amfifiele ABPs, 
vermoedelijk vanwege hun hoge lipofiele karakter, die compactheid van GBA kan 
bevorderen door middel van hydrofobe interacties. 
Ondanks de verschillen in vouwing en in substraatspecificiteiten tussen de b-glycosidasen, 
delen deze enzymen een gemeenschappelijk katalytisch mechanisme, waarbij twee 
katalytische residuen samenwerken om de glycosidische binding te hydrolyseren. Het 
mechanisme van deze reactie is algemeen geaccepteerd, wat op de een of andere manier 
de studie naar de rol van conformatieveranderingen en dynamiek van het enzym in de 
katalyse heeft beperkt. In hoofdstuk 4 wordt dit onderwerp bestudeerd door de 
dynamiek van Bacillus circulans xylanase te karakteriseren voor de opeenvolgende stappen 
van de katalyse, met behulp van standaard en geavanceerde NMR spectroscopische 
technieken. In de rusttoestand vertoont het enzym een geringe dynamiek op de 
milliseconde tijdschaal. De Michaelis-complexvorming lijkt een geïnduceerde fit-
mechanisme te volgen en de uitwisseling tussen de twee gebonden vormen van het enzym 
blijkt langzaam te zijn. Er wordt voorgesteld dat deze conformatieverandering met een 
hoge activeringsenergie nodig is voor substraatpositionering en –vervorming. Dit zou de 
snelheidsbeperkende stap van de reactie zou kunnen zijn. In de toestand van de covalente 
intermediair laat het enzym hetzelfde dynamisch gedrag zien als in de rusttoestand, 
hoewel het een andere conformatie heeft. Een drastische verhoging van de dynamiek op 
de millisecondetijdschaal van het enzym in de laatste stap van de reactie suggereert dat 
het enzym een actieve rol speelt bij de productdissociatie. Deze studie leverde het eerste 
bewijs voor dynamiek en conformationele veranderingen bij b-glycosidases en impliceert 
betrokkenheid van de enzymmatrix bij het paradigmatische hydrolysemechanisme. 
Hoofdstuk 5 bespreekt de nieuwe inzichten beschreven in dit proefschrift en schetst 
enkele toekomstperspectieven voor onderzoek en toepassing. 
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